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The Newborn Infant 
Classification of the Newborn Infant 
Newborn infants can be classified according to birth weight or gestational age.1 Gestational 
age is calculated from the first day of the last normal menstrual period to the date of birth and 
is expressed in completed weeks. Term neonates are born at or after 37 and before 42 
weeks’ gestation, preterm neonates are born after less than 37 weeks’ gestation, and post-
term neonates are born at or after 42 completed weeks of gestation. Low birth weight infants 
weigh less than 2500 g at birth. These infants are either (or both) born too early (preterm) or 
(and) have grown inadequately in the uterus. Very low birth weight infants weigh less than 
1500 g at birth and extremely low birth weight infants weigh less than 1000 g at birth.1 
The Apgar Scoring System 
The Apgar scoring system was originally designed by Virginia Apgar, an anaesthesiologist, in 
1953. The Apgar score is a useful aid for evaluating the condition of the newborn infant and 
is recorded routinely at 1, 5, and 10 minutes after birth. The condition of the newborn infant is 
expressed on a scale of 0 to 10. Five clinical signs (colour, heart rate, reflex irritability, mus-
cle tone, and respiratory effort) are evaluated and each given a score of 0, 1, or 2.1-3 The 
lower the Apgar score, the more depressed the baby is, hence necessitating more aggres-
sive resuscitating efforts.1,2 Generally, an Apgar score of 7 to 10 at 1 minute is considered 
normal, 4 to 6 is considered moderately depressed, and 0 to 3 is considered severely de-
pressed.1,2 The correlation of the 1-minute Apgar score with long-term neurological outcome 
has been poor.4 The 5-minute Apgar score is more predictive of long-term neurological out-
come and mortality. A newborn infant with a 5-minute Apgar score of less than 7 should be 
considered at risk.5   
 
Neonatal Sepsis 
Neonatal sepsis is a clinical syndrome characterized by systemic signs of infection and ac-
companied by bacteremia in the first month of life.2,3,6 Neonatal sepsis has always been one 
of the most important causes of neonatal mortality.1 The incidence of neonatal sepsis is ap-
proximately 1 to 10 per 1000 live births.3 This incidence is higher for premature infants1 and 
infants weighing less than 1500 g.3  
Immature Immune System 
Relative immaturity of the immune system is considered to be an important cause of in-
creased risk of infection during the neonatal period.6 Immunity includes specific and non-
specific defences.1 Specific immunity is mediated through lymphocytes. There are two types 
of lymphocytes: B cells and T cells. When stimulated, B cells produce immunoglobulin (Ig). 
Neonates have low levels of Igs, particularly IgM and IgA. When stimulated, T cells produce 
chemical messengers called lymphokines, such as interleukin and interferon, which have a 
role in amplifying the immune response. Neonatal lymphocytes have a reduced production of 
lymphokines. Phagocytes are the predominant non-specific immune cells. Phagocytes need 
opsonins to kill bacteria. In neonates, phagocytic as well as opsonic activity is impaired. Ex-
ogenous factors may also predispose the infant to infection. Infants exposed to very early 
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antibiotic use may be predisposed to infection. Drugs and hyperbilirubinaemia may reduce 
immune function and fat emulsions may impair phagocytic function.1  
Risk Factors 
There are many risk factors associated with neonatal infections.2,3 Prematurity and low birth 
weight are the most important risk factors for neonatal sepsis. Two other important risk fac-
tors are prolonged rupture of the membranes and maternal peripartum fever or infection. 
Infants who experienced fetal distress, obtained by traumatic delivery, or severely depressed 
at birth and requiring intubation and resuscitation, are at higher risk for infections. Male in-
fants, infants who are the first born of twins, infants of diabetic mothers, infants with a skin or 
mucosal defect, and infants with galactosemia, immune defects, or asplenia, are also at 
higher risk. Other factors are invasive procedures, such as invasive monitoring, endotracheal 
tubes, and indwelling central venous catheters, iron therapy, and improper hand hygiene of 
care givers and family members.2,3  
Origins 
Neonatal infections may be acquired in utero (congenital/intrauterine), intrapartum, or post-
natally.1 Two congenital infections can be distinguished: transplacental and ascending infec-
tions. Ascending infections can occur after rupture of the membranes.1 The feto-maternal 
membranes protect the developing fetus against the microbial flora of the maternal genital 
tract. With rupture of the membranes, bacteria from the maternal genital tract may ascend to 
reach the amniotic cavity and the fetus.3,6 Intrapartum infections occur during passage of the 
infant through the maternal birth canal. Postnatal infections can be acquired in the nursery 
(nosocomial).1 In the neonatal ward, the newborn may become infected via various pathways 
involving either human carriers or contaminated materials and equipment.6 Human sources 
in the hospital include personnel, family members, and other infants. The methods of human 
transmission may include: (1) droplets spread from the respiratory tract of adults or other 
newborn infants, (2) carriage of the micro-organism on the hands of hospital personnel, (3) 
suppurative lesions, (4) human milk, and (5) blood products. Contaminated solutions, cathe-
terization of the umbilical vein and artery, and parenteral feeding with lipid emulsions have 
been associated with neonatal sepsis.6  
Early-Onset and Late-Onset Infections 
Neonatal infections occur in the first few days of life (early-onset infections) or later on (late-
onset infections).3,4,6 Early-onset infections are caused by bacteria acquired from the mater-
nal genital tract in utero or during delivery. Group B streptococci, Escherichia coli, and other 
Gram-negative rods, and Listeria monocytogenes are the predominant organisms in early-
onset infections.4 Bacteria responsible for late-onset infections include those acquired from 
the maternal genital tract as well as bacteria acquired after birth in the nursery from human 
contacts or from contaminated equipment or materials. Therefore, horizontal transmission 
plays a significant role in late-onset infections.3,4,6 Some of the late-onset infections are 
caused by the same organisms that are the causative agents of early-onset sepsis. These 
organisms first colonize the infant at the time of birth and later invade the blood stream.4 
Staphylococcus aureus and coagulase negative staphylococci are usually associated with 
late-onset sepsis.6 
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Treatment 
The threshold to initiate antibiotic therapy in neonates is low, since sepsis has a high morbid-
ity and mortality in this age group, and empirical antibiotic treatment is started while awaiting 
the blood culture results and sensitivity tests.2 The choice of empirically administered antibi-
otics depends on the type of infection (early-onset versus late-onset), since other bacterial 
species may be responsible for late-onset compared with early-onset sepsis. The choice also 
depends on the current local antibiotic susceptibility of Staphylococcus species and of Gram-
negative rods.2 In early-onset infections, initial antibiotic therapy must include coverage of 
Gram-positive cocci, particularly Group B streptococci, and Gram-negative enteric bacilli.6 
Therefore, it consists of a penicillin, such as amoxicillin, plus an aminoglycoside, such as 
gentamicin.3,6 In late-onset infections, initial antibiotic therapy includes additional coverage of 
Staphylococcus aureus, Staphylococcus epidermidis, and other coagulase negative staphy-
lococci, which are sometimes hospital acquired.6 Initial antibiotic therapy of late-onset infec-
tions should include a penicillinase-resistant penicillin derivative, such as flucloxacillin, or 
vancomycin if a substantial prevalence of methicillin resistance has been documented for 
staphylococci.6 The choice of antibiotic therapy is always reviewed as soon as results of 
blood cultures and susceptibility tests become available.6 
 
Pharmacokinetics in the Newborn Infant 
Pharmacokinetics describes how drugs are absorbed, distributed, metabolized, and excreted 
by the body. The route along which drugs pass through the body is presented in Figure 1.7 
Pharmacokinetics of drugs in newborn infants cannot be extrapolated from data obtained in 
older infants and adults, since physiological processes that influence absorption, distribution, 
metabolism, and excretion are immature in the newborn infant.6 With postnatal development, 
growth and functional maturation of the physiological processes may alter the pharmacoki-
netic processes. Therefore, absorption, distribution, metabolism, and excretion are constantly 
changing during the neonatal period.6,8 In the following paragraphs, the pharmacokinetic 
processes of absorption, distribution, metabolism, and excretion of drugs in the newborn in-
fant are outlined and differences between neonates and adults are discussed. In the last 
paragraph, the pharmacokinetic parameters used to describe these pharmacokinetic proc-
esses are presented. 
Absorption 
Absorption refers to the transfer of drugs from the site of administration into the circulation.9 
There are several routes of drug administration, but intravenous drug administration is rec-
ommended for the treatment of sick newborns to ensure effective circulating drug concentra-
tions.9,10 
GENERAL INTRODUCTION 
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Figure 1. The route along which drugs pass through the body.7  
 
Distribution 
After absorption, the drug is distributed from the circulation into various body fluids, organs  
and tissues. The distribution of drugs within the body is mostly influenced by body composi-
tion and drug binding to plasma proteins.8,11 In newborn infants, the high relative proportion 
of total body water and low proportion of fat results in higher distribution volumes for water-
soluble compounds and lower distribution volumes for fat-soluble drugs relative to adults.8,11 
Changes in body composition correlate with both gestational age and postnatal age.8 Total 
body water, expressed as a percentage of total body weight, is 85% in preterm neonates and 
70% in term neonates. Preterm neonates have much less fat than term neonates. Total body 
fat in preterm neonates is about 1% of total body weight, compared with 15% in term neo-
nates.12 With postnatal development, total body water decreases, while total body fat in-
creases.8  
The binding of drugs to plasma proteins, especially albumin, is reduced in newborn infants in 
comparison to adults. Age-related differences in plasma protein binding affinity, plasma pro-
tein concentrations, and availability of competing endogenous compounds largely explain the 
differences in the extent of plasma protein binding between neonates and adults.8 Because 
of the reduced plasma protein binding in neonates, the concentration of free (unbound) drug 
in plasma is increased. High unbound fractions may result in enhanced distribution and en-
hanced renal clearance by glomerular filtration and hepatic clearance in the newborn.8  
Metabolism 
The metabolism of most drugs occurs in the liver. Many drugs require biotransformation to 
more polar forms before they can be eliminated from the body. Biotransformation involves 
phase I reactions, which make the drug more polar through oxidation, reduction, or hydroxy-
lation, and phase II conjugation reactions, such as glucuronidation, sulfation, and acetyla-
tion.9 The drug-metabolizing activities of phase I enzymes (cytochromes P450) as well as 
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phase II enzymes (conjugating enzymes) are not yet fully developed during the neonatal pe-
riod.11,12 Their activities increase with gestational and postnatal age.11  
Excretion 
Excretion involves elimination of drug from the body by several routes, including the biliary 
tract, lungs, and kidneys. Both unchanged and metabolized forms of drug may be excreted.9 
Renal function, whether or not normalized to body weight, is reduced at birth compared with 
that in the adult.9,10 Renal function includes glomerular filtration, tubular secretion, and tubu-
lar reabsorption.8 At birth, glomerular function is more advanced than tubular function, be-
cause of the relatively small renal tubules in relation to their corresponding glomeruli.10,11 
Moreover, glomerular maturation seems to proceed faster than tubular maturation after 
birth.9,10 Postnatal functional maturation of the kidney is associated with enhancements in 
renal blood flow, as a result of increased cardiac output and reduced renal vascular resis-
tance, with improvements in glomerular filtration efficiency, and with the growth and matura-
tion of renal tubules and tubular processes.8,10      
First-Order One-Compartment Pharmacokinetic Model 
Pharmacokinetics describes the changes in drug concentration within the body with time. 
Most drugs are cleared from the body with first-order exponential rates. Exponential clear-
ance indicates that a constant fraction or constant proportion of drug is removed per unit 
time. This means that the higher the concentration, the greater the amount of drug removed 
from the body.9 The first-order elimination rate constant (Kel) refers to the fraction of drug 
eliminated per unit time and is related to the drug concentration in plasma (C) by the follow-
ing equation: C = C0 · e-Kel·t, where C is the concentration at a particular time t and C0 is the 
starting concentration.9,13 In the following studies, a one-compartment model was used. The 
one-compartment model depicts the body as a single, kinetically homogeneous unit. It is as-
sumed that the rate of change of drug concentration in plasma reflects quantitatively the 
change in drug concentration throughout the body.14 Iterative two-stage Bayesian fitting was 
used for population modeling. Individual concentration-time profiles were analysed and the 
individual pharmacokinetic parameters were estimated using pharmacokinetic parameters 
from literature as priors for Bayesian fitting. This process was iterated using the population 
mean and covariance as Bayesian priors.  
Pharmacokinetic Parameters 
To quantify the distribution of drugs within the body, the pharmacokinetic parameter volume 
of distribution (V), also known as apparent volume of distribution, is used. Volume of distribu-
tion relates the amount of drug in the body (central compartment) (A) to the concentration in 
plasma (C) (V = A/C).15 Total body clearance (CL) quantifies the volume of plasma that can 
be completely cleared from drug per unit time.15 The elimination half-life (t½) of a drug is de-
fined as the amount of time necessary to decrease plasma drug concentration by 50%.15 The 
elimination half-life depends on the pharmacokinetic parameters volume of distribution and 
total body clearance (t½ = 0.693 · V/CL) and is inversely related to the first-order elimination 
rate constant (t½ = 0.693/Kel).15   
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Aim and Outline of the Thesis 
Because of the differences in pharmacokinetics between neonates and adults, a simple re-
duction of the adult dose may not be adequate to determine a safe and effective neonatal 
dose. For safe and effective neonatal antibiotic therapy, knowledge of the pharmacokinetic 
characteristics of the antibiotic in the neonate is required. However, the pharmacokinetics of 
many antibiotics, including amoxicillin, flucloxacillin, and rifampicin, have been studied insuf-
ficiently in neonates. The aim of this thesis is to establish the population pharmacokinetic 
parameters of these three antibiotic drugs in neonates, in order to improve the safety and 
efficacy of these antibiotics in the neonatal period.  
 
Chapter 2 describes the reversed-phase high-performance liquid chromatographic assays 
used in the following studies for the determination of amoxicillin, flucloxacillin, and rifampicin 
in neonatal plasma.  
 
In chapter 3, the population pharmacokinetic parameters of amoxicillin in as much as 150 
preterm and term neonates are presented. The prediction of the pharmacokinetic parame-
ters, especially amoxicillin clearance, using demographic, anthropometric, and clinical co-
variates, is discussed. Recommendations regarding amoxicillin dosing in these neonates are 
made. Chapter 4 focuses on the pharmacokinetics and dosing of amoxicillin in older infants, 
since amoxicillin is not only used for the treatment of early-onset neonatal sepsis, but also for 
infectious diseases in older infants.  
 
Chapter 5 presents the population pharmacokinetic parameters of flucloxacillin in 55 preterm 
and term neonates treated with flucloxacillin for (suspected) late-onset sepsis. Dose sugges-
tions are made to optimize flucloxacillin dosing in neonates. For optimal flucloxacillin dosing, 
knowledge of the plasma protein binding is essential, since only the free (non-protein-bound) 
fraction of this highly protein-bound penicillin is pharmacologically active. Therefore, chapter 
6 explores the binding of flucloxacillin to plasma proteins in aggregated samples from 56 
individual neonates. The influence of several covariates, including plasma albumin concen-
tration, on the plasma protein binding of flucloxacillin is described. Moreover, the conse-
quences of the magnitude and variability of the protein binding for the dosing of flucloxacillin 
in newborn infants are discussed. 
 
In chapter 7, the first study of rifampicin pharmacokinetics in neonates is introduced. The 
pharmacokinetic parameters of rifampicin, determined in 21 neonates, are presented. Since 
rifampicin seems to induce its own metabolism, the pharmacokinetic parameters after two 
weeks of rifampicin therapy are also presented.  
 
Chapter 8 describes a preliminary study of the application of artificial neural network model-
ing to predict gentamicin clearance in neonates. Predictive performance was compared with 
that of multiple linear regression analysis.  
 
Chapter 9 summarizes and discusses the main findings of the preceding studies and gives 
ideas for future research.  
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Abstract  
Simple and rapid reversed-phase high-performance liquid chromatographic assays with ul-
traviolet detection have been developed and validated for the determination of amoxicillin, 
flucloxacillin, and rifampicin in neonatal plasma. Plasma samples were either precipitated 
with perchloric acid (amoxicillin) or methanol (rifampicin) or extracted with methylene chloride 
(flucloxacillin). Precision coefficients of variation and inaccuracy were less than 15% for all 
three assays. Only small sample volumes (20 μL to 40 μL) were required, making the assays 
suitable for therapeutic drug monitoring and pharmacokinetic studies in preterm and term 
neonates. The assays have successfully been applied to analysis of amoxicillin, flucloxacillin, 
and rifampicin in previously published pharmacokinetic studies in neonates. 
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Introduction 
Routine therapeutic drug monitoring (TDM) of antibiotics like gentamicin and vancomycin in 
preterm and term neonates is widely accepted. Other antibiotics like amoxicillin, flucloxacillin, 
and rifampicin are also widely used in neonates. TDM of these antibiotics is not routinely 
performed, but could be useful in special occasions.1-3 In literature, information about analyti-
cal assays of these antibiotics in neonates is either very concisely described in pharmacoki-
netic papers or lacking.1-5 Abundant information is available about these assays for adults. 
However, TDM in neonates is complicated by the very small sample volume available. Phle-
botomy has been reported as cause of anemia and transfusion in neonates.6 In this paper, 
we describe simple and rapid microanalytical assays for the determination of amoxicillin, flu-
cloxacillin, and rifampicin in neonatal plasma, based on reversed-phase high-performance 
liquid chromatography (RP-HPLC).  
 
Assay of Amoxicillin in Neonatal Plasma  
Introduction 
Various HPLC assays with UV detection have been developed to determine amoxicillin in 
adult human plasma.7,8,9 However, these assays are not suitable for determination of amox-
icillin in neonatal plasma, because they require a relatively large plasma volume. Therefore, 
we developed a RP-HPLC assay with UV detection for the determination of amoxicillin in 
small volume neonatal plasma samples, based on a RP-HPLC-UV method for the analysis of 
amoxicillin in adult plasma samples described earlier in the literature.7 The assay was vali-
dated for linearity, precision, accuracy, and stability. Lindegårdh et al9 evaluated long-term 
stability of amoxicillin in plasma at 8°C, -17°C, and -80°C over one month. Amoxicillin was 
found unstable in plasma stored both at 8°C and -17°C.9 Amoxicillin was stable in plasma 
stored at -80°C for at least one month.9 Mascher et al10 also found that amoxicillin in human 
plasma was stable over a time period of at least 50 days at approximately -70°C, but not at -
20°C. 
Materials and Methods 
Chemicals 
The following chemicals were used: amoxicillin (C16H19N3O5S) (Fluka, Buchs, Switzerland), 
sotalol hydrochloride (C12H20N2O3S HCl) (Bristol-Myers Squibb, New York, NY), potassium 
dihydrogen phosphate (KH2PO4), dipotassium hydrogen phosphate (K2HPO4), perchloric acid 
(HClO4), and methanol (CH4O) (Merck, Darmstadt, Germany).  
Chromatography 
The RP-HPLC system consisted of an automatic sample injector (model 717, Waters, USA), 
a pump (model 1050, Hewlett Packard, USA), a column, combined with a guard column, and 
an UV spectrophotometer detector (model 486, Waters, USA). The same chromatographic 
equipment was used for the determination of flucloxacillin and rifampicin in neonatal plasma. 
The mobile phase, consisting of 0.067 mol/L KH2PO4 (adjusted to pH 3.5 with phosphoric 
acid 25%), methanol, and water (450:50:100), was pumped through a C8 column (250 x 4.6 
mm, 5 μm) (Beckman, USA) after being degassed with helium. With a flow rate of 2.0 
2
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mL/min, amoxicillin and sotalol hydrochloride (internal standard) were detected at a wave-
length of 225 nm.  
Preparation of Calibration Standards and Quality Controls 
Two independent stock solutions of amoxicillin (1000 mg/L) were prepared on the day of 
analysis by dissolving 23.1 mg amoxicillin in 20 mL water (factor of weight 1.155 for H2O 
bound to amoxicillin). One was used for the preparation of the calibration standards and the 
other was used for the preparation of the quality controls (50 mg/L). The working solution of 
amoxicillin (200 mg/L) was prepared by adding 600 μL stock solution to 2400 μL blank hu-
man plasma. Calibration standards were prepared by adding the required amount of working 
solution to blank human plasma to obtain concentrations of 10, 50, 100, 150, and 200 mg/L 
of amoxicillin. The stock solution of the internal standard sotalol hydrochloride (1000 mg/L) 
was prepared by dissolving 22.7 mg sotalol hydrochloride (HCL) in 20 mL ethanol (factor of 
weight 1.134 for HCL). The internal standard working solution (100 mg/L) was prepared by 
diluting the stock solution 10 times with water. The stock and working solutions of sotalol 
hydrochloride were stored at 4°C. The quality controls were stored in separate containers at -
70°C until analysis.  
Sample Preparation 
Aliquots (40 μL) of patient plasma, calibrations standards, and quality controls were trans-
ferred into Eppendorf tubes and mixed with the internal standard working solution (40 μL) 
and perchloric acid 3% (80 μL) for protein precipitation. Following centrifugation at 10,500 x g 
for 5 minutes, the clear supernatant (100 μL) was transferred into an Eppendorf tube, mixed 
with 1.2 mol/L K2HPO4 (40 μL), and centrifuged again. The clear supernatant (10 μL) was 
injected. 
Validation 
The RP-HPLC assay was validated for linearity, precision, accuracy, and stability. To evalu-
ate linearity of the calibration curves, six calibration curves were independently prepared and 
analyzed. The calibration curves with zero intercept were considered linear when the correla-
tion coefficient (r) was higher than 0.99 as calculated by linear regression. Plasma samples 
at six concentration levels of amoxicillin (8, 20, 40, 60, 80, and 160 mg/L) were prepared and 
analyzed on six separate days to determine precision and accuracy of the RP-HPLC assay. 
The precision coefficient of variation (CV) determined at each concentration level should not 
exceed 15% except for the lower limit of quantification (LLOQ), where it should not exceed 
20%.11 Accuracy should be within 15% of the actual value except at LLOQ, where it should 
not deviate by more than 20%.11 Long-term stability of amoxicillin in neonatal plasma during 
storage at -70°C was determined by analyzing three plasma controls of amoxicillin (25, 100, 
and 200 mg/L) stored at -70°C in routine assay runs for a period of one month. Desktop sta-
bility of amoxicillin in neonatal plasma at room temperature (light/dark) was evaluated by 
analyzing the three controls maintained at room temperature (light/dark) for three and six 
hours. Post-preparative stability of amoxicillin in processed neonatal plasma samples during 
the run was checked by analyzing the three controls at the beginning of the run and at the 
end of the run after approximately three hours.  
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Results 
The calibration curves were linear. The correlation coefficients of the calibration curves were 
all higher than 0.99 (r = 0.9985, n = 6). The precision CV and inaccuracy determined at each 
concentration level of amoxicillin were less than 5%. The precision and accuracy of the 
amoxicillin RP-HPLC assay are presented in Table 1. The results of the quality control sam-
ples (50 mg/L), included in 48 routine assay runs during 3 months, were 53.7 ± 2.0 mg/L 
(precision CV 3.7%).  
 
 
Table 1. Precision and Accuracy (n = 6) of the Amoxicillin RP-HPLC Assay  
True Concentration 
(mg/L) 
Measured Concentration 
(mg/L) 
SD  
(mg/L) 
Precision CV  
(%) 
Accuracy  
(%) 
8 8.13 0.24 3.0 +1.6 
20 20.66 0.32 1.5 +3.3 
40 38.25 0.44 1.2 -4.4 
60 61.08 0.74 1.2 +1.8 
80 79.04 1.89 2.4 -1.2 
160 158.50 5.71 3.6 -0.9 
CV, coefficient of variation; SD, standard deviation. 
 
 
To determine the error pattern of the RP-HPLC assay, the relationship between the plasma 
concentration and the standard deviation (SD) with which it was determined, was fitted with a 
polynomial of second order (Figure 1).12 The error pattern of the assay was: SD = 0.1647 + 
0.0009 C + 0.0002 C² (r2 = 0.992). This polynomial equation can be used to calculate the SD 
corresponding with each plasma concentration. The LLOQ of the assay, the concentration 
that could just be determined with a precision of 20%, was 0.8 mg/L.  
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Figure 1. Error pattern of the amoxicillin RP-HPLC assay (n = 6). 
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Amoxicillin was stable in neonatal plasma during storage at -70°C. Mean (± SD) amoxicillin 
plasma concentrations of the three controls (25, 100, and 200 mg/L), included in 28 routine 
assay runs during one month, were 24.2 (± 0.9), 97.7 (± 4.8), and 195.9 (± 8.5) mg/L, respec-
tively. The desktop and post-preparative stability results are summarized in Table 2.  
 
 
Table 2. Desktop and Post-Preparative Stability of Amoxicillin in Neonatal Plasma 
Quality Control 
(mg/L) 
Desktop Stability 
(Light) 
Desktop Stability 
(Dark) 
Post-Preparative Stability 
 3 hours 6 hours 3 hours 6 hours 3 hours 
25 95.8% 85.0% 105.8% 95.0% 98.1% 
100 97.7% 97.5% 98.7% 97.5% 107.8% 
200 101.2% 98.9% 106.1% 97.1% 99.8% 
 
 
Assay of Flucloxacillin in Neonatal Plasma 
Introduction 
Microbiological methods13,14 were used for the analysis of flucloxacillin in adult human 
plasma before more specific HPLC assays15-17 became available. Herngren et al18 used a 
microbiological method, based on agar diffusion and bacterial growth, to determine fluclox-
acillin concentrations in neonatal plasma in a study of the pharmacokinetics of flucloxacillin in 
newborn infants. An important reason for them to use a microbiological method instead of a 
more specific HPLC assay was the small plasma volume available for analysis from newborn 
infants.19 For this microbiological assay, a plasma volume of 10 μL to 20 μL was sufficient. 
We developed a RP-HPLC assay for the determination of flucloxacillin using only small 
plasma volumes (20 μL). This assay was based on a RP-HPLC method developed by Thi-
jssen16 for flucloxacillin analysis in adults. The assay was validated for linearity, precision, 
accuracy, stability, and recovery.  
Materials and Methods 
Chemicals 
The following chemicals were used: flucloxacillin (C19H16ClFN3NaO5S·H2O) (Synopharm, 
Barsbüttel, Germany), cloxacillin (C19H18ClN3O5S) (SmithKline Beecham Pharmaceutical, 
Middlesex, United Kingdom), acetonitrile (CH3CN), citric acid monohydrate (C6H8O7·H2O), 
methylene chloride (CH2Cl2), hydrochloric acid (HCl), and sodium perchlorate (NaClO4·H2O) 
(Merck, Darmstadt, Germany).  
Chromatography 
Flucloxacillin and the internal standard cloxacillin were separated in a C8 column (250 x 4.6 
mm, 5 μm) (Beckman, USA) at a flow rate of 2.0 mL/min. A mixture of 0.02 mol/L sodium 
perchlorate and acetonitrile (750:250) was used as mobile phase. Flucloxacillin and cloxacil-
lin were detected at a wavelength of 220 nm.  
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Preparation of Calibration Standards and Quality Controls 
For flucloxacillin, a stock solution (1000 mg/L) was freshly prepared by dissolving 11 mg so-
dium flucloxacillin in 10 mL water (factor of weight 1.1 for sodium) and a working solution 
(100 mg/L) was freshly prepared by adding 200 μL stock solution to 1800 μL blank human 
plasma. The working solution was used to prepare the calibration standards by adding the 
required amount of working solution to blank human plasma to obtain concentrations of 10, 
25, 50, 75, and 100 mg/L of flucloxacillin. An independent stock solution was prepared and 
used for the preparation of the quality controls (25 mg/L), which were stored in separate con-
tainers at -70°C until analysis. The stock solution of the internal standard cloxacillin (1000 
mg/L) was prepared by dissolving 10 mg cloxacillin in 10 mL water. This stock solution was 
diluted 25 times with water to obtain the internal standard working solution (40 mg/L). Both 
cloxacillin stock and working solutions were stored at 4°C.  
Sample Preparation 
In glass tubes, 20 μL sample volume was mixed with the internal standard working solution 
(20 μL), 0.5 mol/L citric acid monohydrate (40 μL), and 0.5 mol/L HCL (10 μL), extracted with 
methylene chloride (1 mL) for 2 minutes, and centrifuged at 1780 x g for 5 minutes. After 
removal of the top water layer with vacuum, the organic phase was transferred into a glass 
tube and centrifuged again. After centrifugation, the organic phase was transferred into a 
glass tube and evaporated to dryness under a flow of nitrogen. The residue was dissolved in 
the mobile phase (100 μL) and injected (25 μL).  
Validation 
The RP-HPLC assay was validated for linearity, precision, accuracy, stability, and recovery. 
To evaluate precision and accuracy, plasma samples at six concentration levels of fluclox-
acillin (5, 10, 20, 40, 60, and 100 mg/L) were prepared and analyzed on six separate days. 
Long-term stability of flucloxacillin in neonatal plasma during storage at room temperature 
(light/dark), 4°C, -20°C, and -70°C was determined by analyzing the quality controls over a 
period of 30 days at day 3, 7, and 30 (n = 2). The recovery of flucloxacillin was determined by 
comparing the analytical results for extracted samples at two flucloxacillin concentrations (50 
and 100 mg/L) with unextracted standards that represent 100% recovery.  
Results 
All calibration curves were linear (r = 0.9964, n = 6). The precision CV and inaccuracy at all 
six concentration levels of flucloxacillin were < 10% and < 15%, respectively. The precision 
and accuracy of the flucloxacillin RP-HPLC assay are shown in Table 3. The results of the 
quality control samples (25 mg/L), included in 30 routine assay runs during 2 months, were 
24.6 ± 1.2 mg/L (precision CV 4.7%). 
The quadratic relationship between the measured plasma concentration and the SD is pre-
sented in Figure 2. The error pattern of the assay can be described by the following polyno-
mial equation: SD = 0.5117 + 0.0108 C + 0.0002 C² (r² = 0.907). The LLOQ of the assay, as 
calculated from this polynomial equation, was 2.7 mg/L. 
 
 
2
CHAPTER 2 
 24 
Table 3. Precision and Accuracy (n = 6) of the Flucloxacillin RP-HPLC Assay  
True Concentration 
(mg/L) 
Measured Concentration 
(mg/L) 
SD  
(mg/L) 
Precision CV  
(%) 
Accuracy  
(%) 
5 5.61 0.38 6.8 +12.2 
10 10.70 0.77 7.2 +7.0 
20 20.37 0.76 3.7 +1.9 
40 39.82 1.87 4.7 -0.5 
60 58.00 1.29 2.2 -3.3 
100 101.08 3.82 3.8 +1.1 
CV, coefficient of variation; SD, standard deviation. 
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Figure 2. Error pattern of the flucloxacillin RP-HPLC assay (n = 6). 
 
 
The long-term stability of flucloxacillin in neonatal plasma after storage at room temperature 
(light/dark), 4°C, -20°C, and -70°C for 3, 7, and 30 days is presented in Table 4. Flucloxacillin 
appeared to be stable in neonatal plasma at -20°C and -70°C for at least one month. 
Mean recoveries of flucloxacillin at the two concentrations (50 and 100 mg/L) were 101.4% 
and 100.6% (n = 2), respectively. 
 
 
Table 4. Long-Term Stability of Flucloxacillin in Neonatal Plasma (25 mg/L) (n = 2) 
 3 Days 7 Days 30 Days 
Room temperature (light) 90.8% 80.8% 15.5% 
Room temperature (dark)  92.3% 95.4% 2.7% 
4°C 100.4% 104.0% 82.6% 
-20°C 101.3% 122.3% 100.0% 
-70°C 104.0% 101.2% 105.0% 
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Simultaneous Assay of Rifampicin and 25-O-Desacetylrifampicin in 
Neonatal Plasma 
Introduction 
Many HPLC assays have been developed for the simultaneous determination of rifampicin 
and its main metabolite(s) in human plasma.20-23 However, none of these assays was specifi-
cally developed for neonates. We developed a RP-HPLC assay suitable for the simultaneous 
determination of rifampicin and 25-O-desacetylrifampicin in small volumes (40 μL) of neona-
tal plasma. The assay was based on a method for adult patients described by Chandi et al.20 
The assay was validated for linearity, precision, accuracy, and stability. Rifampicin was found 
to be stable in human plasma samples frozen at ≤ -70°C, but unstable at room temperature 
and -20°C.24,25   
Materials and Methods 
Chemicals 
The following chemicals were used: rifampicin (C43H58N4O12) (Yamanouchi Pharma, Leider-
dorp, The Netherlands), 25-O-desacetylrifampicin (C41H56N4O11) (Novartis Pharma, Arnhem, 
The Netherlands), ammonium sulphate ((NH4)2SO4), methanol (CH4O), and Titriplex® III 
(C10H14N2Na2O8·2H2O) (Merck, Darmstadt, Germany).  
Chromatography 
The mobile phase consisted of 0.005 mol/L disodium EDTA (0.93 g Titriplex® III in 500 mL 
water) and methanol (200:300). This mobile phase was pumped with a flow rate of 1.0 
mL/min through a C18 symmetry column (150 x 4.6 mm, 5 μm) (Waters, USA). The detection 
was performed at a wavelength of 340 nm. 
Preparation of Calibration Standards and Quality Controls 
Stock solutions of rifampicin and 25-O-desacetylrifampicin (1000 mg/L) were prepared on the 
day of analysis by dissolving 20 mg rifampicin in 15 mL methanol and 5 mL water and by 
dissolving 20 mg 25-O-desacetylrifampicin in 6 mL methanol and 14 mL water. A solution 
containing both rifampicin and 25-O-desacetylrifampicin (100 mg/L) was prepared by adding 
100 μL stock solution of rifampicin and 100 μL stock solution of 25-O-desacetylrifampicin to 
800 μL blank human plasma. This solution was diluted 10 times with blank human plasma to 
obtain the working solution (10 mg/L). Calibration standards were prepared by adding the 
required amount of working solution to blank human plasma to obtain concentrations of 2, 4, 
6, 8, and 10 mg/L of rifampicin and 25-O-desacetylrifampicin. Independent stock solutions of 
rifampicin and 25-O-desacetylrifampicin were made and used for the preparation of the qual-
ity controls, containing both rifampicin and 25-O-desacetylrifampicin (5 mg/L), which were 
stored in separate containers at -70°C until analysis. 
Sample Preparation 
Small plasma volumes (40 μL) of patient samples, calibration standards, and quality controls 
were transferred into Eppendorf tubes and mixed with ammonium sulphate 5% (10 μL) and 
methanol (80 μL) for protein precipitation. The mixture was centrifuged at 10,500 x g for 5 
minutes and the clear supernatant (30 μL) was injected.  
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Validation 
The RP-HPLC assay was validated for linearity, precision, accuracy, and stability. For rifam-
picin and 25-O-desacetylrifampicin, precision and accuracy were evaluated by measuring 
plasma samples at five concentration levels (2, 4, 6, 8, and 10 mg/L) on six separate days. 
Plasma samples at twelve concentrations levels of rifampicin and 25-O-desacetylrifampicin 
(0.1, 0.2, 0.3, 0.4, 1, 2, 4, 6, 8, 10, 25, and 50 mg/L) were measured on six separate days to 
determine the assay error patterns of rifampicin and 25-O-desacetylrifampicin. Rifampicin 
stability in neonatal plasma at room temperature (dark) was evaluated by analyzing plasma 
samples, containing 6 mg/L of rifampicin, stored at room temperature (dark) for 1, 2, 3, and 4 
hours. Post-preparative stability of rifampicin in processed neonatal plasma during the run 
was checked by analyzing plasma samples (6 mg/L) 1, 1.5, and 2 hours after sample prepa-
ration.  
Results 
The calibration curves of rifampicin and 25-O-desacetylrifampicin were considered linear (r = 
0.995, n = 6 and r = 0.994, n = 6, respectively). Precision CV and inaccuracy, measured at 
the five concentration levels, were < 10% and < 5%, respectively, for both rifampicin and 25-
O-desacetylrifampicin (Table 5). The results of the quality control samples (5 mg/L), included 
in 30 routine assay runs during 2 months, were 4.7 ± 0.3 mg/L (precision CV 6.6%). 
 
 
Table 5. Precision and Accuracy (n = 6) of the RP-HPLC Assay of Rifampicin and 25-O-Desacetylrifampicin 
True Concentration 
(mg/L) 
Measured Concentration (SD) 
(mg/L) 
Precision CV  
(%) 
Accuracy  
(%) 
 RIF DES RIF DES RIF DES 
2 2.05 (0.17) 2.04 (0.20) 8.3 9.8 +2.5 +2.0 
4 3.95 (0.26) 3.98 (0.24) 6.6 6.0 -1.3 -0.5 
6 6.10 (0.21) 6.09 (0.25) 3.4 4.1 +1.7 +1.5 
8 7.97 (0.14) 7.99 (0.16) 1.8 2.0 -0.4 -0.1 
10 9.98 (0.26) 9.96 (0.31) 2.6 3.1 -0.2 -0.4 
CV, coefficient of variation; DES, 25-O-desacetylrifampicin; RIF, rifampicin; SD, standard deviation. 
 
 
The plasma concentrations of rifampicin and 25-O-desacetylrifampicin and the corresponding 
standard deviations, used for the determination of the assay error patterns, are presented in 
Table 6. In Figure 3, the standard deviations are plotted against the measured plasma con-
centrations of rifampicin and 25-O-desacetylrifampicin and fitted with a polynomial of second 
order. The corresponding error patterns were: SD = 0.0173 + 0.0455 C + 0.0002 C² (r² = 
0.993) for rifampicin and SD = 0.0561 + 0.0323 C + 0.0005 C² (r² = 0.996) for 25-O-
desacetylrifampicin. The LLOQ was determined by analyzing plasma samples at low concen-
tration levels (0.1, 0.2, 0.3, and 0.4 mg/L). The response at the LLOQ was at least 5 times 
the response compared to blank response and was identifiable, discrete, and reproducible 
with a precision of < 20% and accuracy of 80% to 120%. The LOQ was 0.1 mg/L for rifam-
picin and 0.4 mg/L for 25-O-desacetylrifampicin (Table 6). 
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No decrease of rifampicin concentration in neonatal plasma stored at -70°C was observed 
during the entire period of two months. Rifampicin was stable in neonatal plasma at room 
temperature (dark) for 1 (103.8%), 2 (104.5%), 3 (105.5%), and 4 hours (102.4%). After 
sample preparation, rifampicin was stable for 1 (96.7%), 1.5 (97.4%), and 2 hours (96.1%).  
 
 
Table 6. Assay Error Patterns of Rifampicin and 25-O-Desacetylrifampicin (n = 6) 
True Concentration 
(mg/L) 
Measured Concentration 
(mg/L) 
SD  
(mg/L) 
Precision CV 
(%) 
Accuracy  
(%) 
 RIF DES RIF DES RIF DES RIF DES 
0.1 0.10 0.12 0.01 0.02 10.8 20.8 +3.7 +15.0 
0.2 0.18 0.25 0.03 0.07 17.6 27.4 -8.6 +23.5 
0.3 0.29 0.36 0.04 0.08 12.6 22.1 -4.3 +20.7 
0.4 0.39 0.45 0.03 0.07 7.5 15.0 -2.2 +11.9 
1 0.99 1.05 0.08 0.10 8.4 10.0 -0.6 +5.0 
2 1.99 2.07 0.11 0.12 5.6 5.9 -0.6 +3.6 
4 3.83 3.93 0.32 0.31 8.2 7.8 -4.2 -1.8 
6 5.85 5.95 0.31 0.27 5.2 4.6 -2.4 -0.8 
8 8.00 8.02 0.29 0.29 3.7 3.6 -0.0 +0.3 
10 10.2 10.0 0.36 0.32 3.5 3.2 +1.6 +0.3 
25 25.8 25.4 1.40 1.24 5.4 4.9 +3.3 +1.4 
50 52.8 51.9 2.87 2.99 5.4 5.8 +5.7 +3.8 
CV, coefficient of variation; DES, 25-O-desacetylrifampicin; RIF, rifampicin; SD, standard deviation. 
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Figure 3. Assay error patterns of rifampicin (A) and 25-O-desacetylrifampicin (B) (n = 6). 
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Discussion and Conclusions 
Simple and rapid RP-HPLC assays with UV detection for the determination of amoxicillin, 
flucloxacillin, and rifampicin in small volume neonatal plasma samples with satisfactory pre-
cision, accuracy, and sensitivity have been developed. Considering the high precision and 
accuracy, the plasma volume required for amoxicillin and rifampicin analysis could be re-
duced from 40 μL to 20 μL or even 10 μL. It had been well documented that in vitro β-lactam 
antibiotics and aminoglycosides interact with each other resulting in the formation of two bio-
logical inactive compounds.26,27 Daly et al28 studied the effect of varying concentrations of 
ampicillin on gentamicin concentration in vitro in pooled plasma obtained from umbilical cord 
blood representing a medium analogous to neonatal plasma. Although inactivation of gen-
tamicin by ampicillin did occur in this study, the degree of inactivation was small, especially 
at therapeutic concentrations of ampicillin. In vivo inactivation seems to occur only when high 
nontherapeutic concentrations of the β-lactam antibiotic are present in plasma for prolonged 
periods. Nevertheless, we recommend plasma samples to be stored at -70°C as soon as 
possible after collection until analysis to avoid possible in vitro inactivation of amoxicillin and 
flucloxacillin, since the interaction between β-lactam antibiotics and aminoglycosides is de-
pendent on temperature.26-28 Storage at -70°C is also recommended to avoid degradation of 
the antibiotics. The assays described are suitable for TDM and pharmacokinetic studies in 
neonates.  
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Abstract 
Amoxicillin plasma concentrations, pharmacokinetic parameters, and the influence of demo-
graphic, anthropometric, and clinical covariates were investigated in 150 neonates. Gesta-
tional age (GA) ranged from 25 to 42 weeks and mean postnatal age (PNA) was 0.8 days. 
Amoxicillin concentrations were measured with reversed-phase HPLC in surplus plasma 
from routine assays of coadministered gentamicin. Mean total body clearance corrected for 
body weight (CL/W) was 0.096 ± 0.036 Lkg-1h-1, mean elimination half-life (t½) was 5.2 ± 1.9 
h, and mean volume of distribution corrected for body weight (V/W) was 0.65 ± 0.13 L/kg. 
Multiple regression equations were calculated for the prediction of CL/W amoxicillin. CL/W 
gentamicin, V/W gentamicin, and GA were significant predictors of CL/W amoxicillin. Amox-
icillin peak and trough concentrations after the second dose and the time the concentration 
exceeds the minimum inhibitory concentration (T>MIC), reached with the current dosage 
regimen, were evaluated. Toxic plasma concentrations were reached in several patients. 
Therefore, the authors have proposed a lower dosage regimen, based on GA, population 
pharmacokinetic parameters, bacterial susceptibility (T>MIC), and possible toxicity: 15 mg/kg 
per 8 hours and 20 mg/kg per 8 hours for neonates with GA ≤ 34 and GA > 34 weeks, re-
spectively. Simulation with this new dosage regimen indicated that satisfactory plasma con-
centrations were reached in all 150 neonates. Therefore, use of therapeutic drug monitoring 
and pharmacokinetic calculations for dosage adjustment is generally not necessary. 
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Introduction 
Amoxicillin, an aminopenicillin, in combination with gentamicin, an aminoglycoside, is fre-
quently used for the treatment of early-onset neonatal sepsis.1 In contrast to gentamicin, 
therapeutic drug monitoring (TDM) of amoxicillin is not performed on a routine basis, be-
cause amoxicillin is considered to have a wide therapeutic window.  
Despite the widespread use of amoxicillin in neonates, data on population pharmacokinetics 
in the literature are limited. The 4 studies available describe only a relatively small number of 
patients.2-5 Charles et al2 and Huisman-de Boer et al3 limited their study population to neo-
nates with gestational age less than 32 weeks. In the study by Autret et al4 only term neo-
nates were included.  
The administration of excessive doses of amoxicillin is associated with a variety of adverse 
effects, such as rashes, urticaria, diarrhea, eosinophilia, elevated liver and muscle enzymes, 
seizures, and renal dysfunction.6-9 Renal impairment and alterations in the blood-brain barrier 
are the two major risk factors for amoxicillin-induced neurotoxicity in preterm neonates.6 The 
efficacy of penicillins, including amoxicillin, depends on the time the concentration exceeds 
the minimum inhibitory concentration (T>MIC).10 A dosage regimen is suitable if it results in 
effective, nontoxic plasma concentrations.  
The objectives of our study were to investigate whether the current dosage regimen of amox-
icillin leads to satisfactory plasma concentrations and to devise a better dosage regimen if 
necessary. To accomplish these goals, our co-objectives were the establishment of the 
population pharmacokinetic parameters of amoxicillin and the identification of demographic, 
anthropometric, and clinical covariates that may significantly influence the individual pharma-
cokinetic parameters. 
 
Materials and Methods 
Patients 
The local Ethical Board approved the study. The population consisted of 150 (pre)term neo-
nates at risk for or with (suspected) early-onset sepsis. The neonates were admitted to the 
neonatal ward at the University Hospital of Maastricht from July 2002 through February 2005. 
Inclusion criteria were: coadministration of amoxicillin and gentamicin, postnatal age (PNA) ≤ 
9 days, availability of at least one plasma sample taken just before the administration of 
amoxicillin and gentamicin (trough concentrations) and one plasma sample taken one hour 
after the administration (peak concentrations), and availability of reliable patient data with 
respect to gestational age (GA), PNA, dosing, and sampling times.  
For each patient, the following demographic, anthropometric, and clinical characteristics 
were recorded: GA, PNA, body weight (W), gender, multiple pregnancy (P), length, head 
circumference (HC), arterial cord pH (ApH), 5-minute Apgar score (AP5), divided into two 
groups (< 7 and ≥ 7),11 1/plasma creatinine (1/Cr), plasma urea concentration (Ur), blood 
culture result (BC), C-reactive protein (CRP), total body clearance of gentamicin (CL gen-
tamicin), total body clearance of gentamicin corrected for body weight (CL/W gentamicin), 
elimination half-life of gentamicin (t½ gentamicin), and volume of distribution of gentamicin 
corrected for body weight (V/W gentamicin). 
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Gentamicin and Amoxicillin Administration and Plasma Sampling 
The gentamicin dosage regimen was derived from results of our earlier study12: 5 mg/kg per 
48 hours, 4.5 mg/kg per 36 hours, and 4 mg/kg per 24 hours for neonates with GA < 30, 30 ≤ 
GA ≤ 34, and GA > 34 weeks, respectively. Gentamicin was administered intravenously by 
syringe pump during 30 minutes. Amoxicillin was administered by intravenous slow push 
according to dosing guidelines in literature13: 100 mg/kg per dose for (suspected) meningitis 
and 50 mg/kg per dose in other situations. Dosing interval was 12 hours in the first week of 
life, 8 hours in neonates 1 to 3 weeks old, and 6 hours in neonates ≥ 4 weeks old.13 Eleven 
neonates were treated with co-amoxiclav (Augmentin®), 133 neonates with amoxicillin, and 6 
neonates with amoxicillin and co-amoxiclav. Amoxicillin and gentamicin were administered 
shortly after each other. Unless the mother was treated with indomethacin as a tocolytic, all 
neonates with GA < 32 weeks or birth weight < 1250 g were treated prophylactically with 
indomethacin during the first 3 days of life.14  
Plasma samples were taken just before and one hour after the administration of amoxicillin 
and gentamicin. Surplus plasma samples from routine gentamicin assays were stored at -
70°C. Dosing and sampling times were recorded by nursing staff. 
Chemicals 
Potassium dihydrogen phosphate (KH2PO4, CAS 7778-77-0), dipotassium hydrogen phos-
phate (K2HPO4, CAS 7758-11-4), perchloric acid (HClO4, CAS 7601-90-3), and methanol 
(CH4O, CAS 67-56-1) were obtained from Merck (Darmstadt, Germany). Amoxicillin 
(C16H19N3O5S, CAS 26787-78-0) was provided by Fluka (Buchs, Switzerland), and the inter-
nal standard sotalol hydrochloride (C12H20N2O3S HCl, CAS 959-24-0) was obtained from 
Bristol-Myers Squibb (New York, NY). Ultrapure water was used in all preparations. All 
chemicals were of analytical grade. Human EDTA plasma for standard and control samples 
was provided by the Red Cross Blood Bank (Maastricht, The Netherlands). 
Amoxicillin HPLC Assay 
Gentamicin plasma concentrations were measured with the COBAS INTEGRA 700 analyzer 
(Roche, Mannheim, Germany), using the principle of fluorescence polarization. The error 
pattern of the gentamicin assay was: SD = 0.0129 + 0.0029 C + 0.0034 C2. The assay error 
pattern was determined according to a method described in literature.15 The lower limit of 
determination was 0.1 mg/L. Amoxicillin plasma concentrations were determined with re-
versed-phase HPLC. An automatic sample injector (model 717, Waters, USA), a pump 
(model 1050, Hewlett Packard, USA), a C8 column, 250 x 4.6 mm, 5 μm (Beckman, USA), 
combined with a C8 guard column, and an UV spectrophotometer detector (model 486, Wa-
ters, USA) were used. The eluent was composed of 0.067 mol/L potassium dihydrogen 
phosphate (pH 3.5), methanol, and distilled water (450:50:100). The separations were per-
formed at room temperature and at a flow rate of 2 mL/min. The detection occurred at a 
wavelength of 225 nm. The error pattern of the assay was: SD = 0.1647 + 0.0009 C + 0.0002 
C2. The lower limit of determination was 1 mg/L.  
To 40 μL surplus plasma, 40 μL of 100 mg/L sotalol hydrochloride (internal standard) was 
added. While mixing the solution with the vortex, 80 μL of perchloric acid 3% was added. The 
solution was centrifuged at 10,500 x g and 100 μL of the clear top layer was mixed with 40 
μL of 1.2 mol/L dipotassium hydrogen phosphate. The solution was centrifuged again at 
10,500 x g and 10 μL of the clear top layer was injected. The standard samples, containing 
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10, 50, 100, 150, and 200 mg/L amoxicillin in plasma, were processed in the same way as 
the surplus plasma samples. A calibration curve was constructed and amoxicillin concentra-
tions in surplus plasma samples were calculated. Two control samples, each containing 50 
mg/L of amoxicillin in plasma, were measured in each run. Measurements were performed in 
duplicate, if sufficient surplus plasma was available. 
Data Analysis 
Population pharmacokinetic parameters of amoxicillin and gentamicin were calculated with 
an iterative two-stage Bayesian fitting procedure (IT2B) (MW\PHARM 3.50, Mediware, The 
Netherlands). The Bayesian fitting procedure uses measured drug concentrations, popula-
tion-based pharmacokinetic parameters, and the expected variability associated with each 
measurement to determine individualized pharmacokinetic parameters of a patient.16 We 
used a one-compartment open model. The initial pharmacokinetic parameters of amoxicillin 
were derived from other studies: Kel 0.1 ± 0.03 h-1 and V/W 0.67 ± 0.12 L/kg for neonates 
with GA < 32 weeks3 and Kel 0.16 ± 0.09 h-1 and V/W 0.62 ± 0.23 L/kg for neonates with GA 
≥ 32 weeks.4 The initial pharmacokinetic parameters of gentamicin were derived from the 
study of Stolk et al.12 
Statistical analysis was started by checking CL/W and V/W of amoxicillin for normal distribu-
tion with the Kolmogorov-Smirnov test. One-way analysis of variance (ANOVA) was used to 
test whether the factor variables (gender, P, AP5, and BC) had a significant effect on CL/W 
and V/W of amoxicillin. Pearson product-moment correlation coefficients (r) between phar-
macokinetic parameters of amoxicillin and covariates were calculated. Multiple regression 
analysis with forward selection and backward elimination techniques was performed, using 
CL/W and V/W of amoxicillin as dependent variables. The significant (factor) variables, de-
tected with one-way ANOVA and correlation analysis, were used as possible predictors. The 
significant predictors of the dependent variable were used to establish a direct-effects model. 
First-order interaction effects between the significant predictors were tested for significance 
by forced entering within a hierarchically constructed regression model. Residual analysis 
was performed to check the studentized residuals of the dependent variable for normality 
and outliers. Discrete factors were entered as dummy variables. Listwise deletion of missing 
cases was used during the entire regression analysis procedure. Statistical analysis was 
performed by using SPSS® 12.0 (Chicago, IL). P < 0.05 was considered to be statistically 
significant. 
Evaluation of Current and Proposed Dosage Regimen 
The efficacy of penicillins, including amoxicillin, depends on the time the concentration ex-
ceeds the minimum inhibitory concentration (T>MIC).10 In neonates, T>MIC should at least 
be 40% to 50%.10 For the different species, identified as causative agents of bacteremia, the 
breakpoint MIC value of an antibiotic defines the highest MIC value still to be interpreted as 
indicating susceptibility to that antibiotic. This breakpoint MIC value of amoxicillin is 0.25 
mg/L for Streptococcus agalactiae and 8 mg/L for Enterococcus species and species belong-
ing to the Enterobacteriaceae.17 Therefore, amoxicillin plasma concentrations will have to 
exceed 8 mg/L during 40% to 50% of the time. To evaluate the efficacy of the current dosage 
regimen, we calculated T>MIC for each patient, using their individual pharmacokinetic pa-
rameters. Shaffer et al6 reported that ampicillin concentrations higher than 140 mg/L may 
cause seizures in adults. To evaluate possible toxicity of the current dosage regimen, we 
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calculated amoxicillin peak concentrations after the second dose of each patient, using their 
individual pharmacokinetic parameters.  
Amoxicillin plasma concentrations, reached with the proposed dosage regimen, were simu-
lated for all neonates in MW\PHARM 3.50 (Mediware, The Netherlands), using the individual 
pharmacokinetic parameters of amoxicillin. 
 
Results 
Demographic, Anthropometric, and Clinical Characteristics 
Demographic, anthropometric, and clinical characteristics of the study patients are presented 
in Table 1. The population consisted of 78 (52%) girls and 72 (48%) boys; 123 (82%) neo-
nates were products of singleton pregnancies and 27 (18%) neonates of twin pregnancies. 
AP5 was ≥ 7 in 122 of 148 (82.4%) neonates (2 missing data). Seven of 113 (6.2%) blood 
cultures (37 missing) were positive. There were 674 amoxicillin and gentamicin plasma con-
centrations with a mean of 4.5 ± 1.3. 
 
 
Table 1. Demographic, Anthropometric, and Clinical Characteristics of the Study Patients 
 Unit N Mean (SD) Range 
GA weeks 150 34.6 (4.9) 24.9-42.4 
PNA days 150 0.76 (1.57) 0-9 
W kg 150 2.29 (1.08) 0.57-4.7 
Length cm 104 43.7 (6.2) 30-56 
HC cm 108 30.8 (4.7) 21-55 
ApH pH 93 7.19 (0.14) 6.7-7.48 
AP5 points 148 9 (median) 1-10 
1/Cr L/μmol 101 0.012 (0.004) 0.006-0.036 
Ur mmol/L 100 5.05 (2.62) 0.8-13.5 
CRP mg/L 141 14.7 (23.2) 1-117 
CL gentamicin L/h 150 0.11 (0.065) 0.02-0.28 
CL/W gentamicin Lkg-1h-1 150 0.043 (0.012) 0.023-0.082 
t½ gentamicin h 150 10 (3.2) 5-19.7 
V/W gentamicin L/kg 150 0.59 (0.13) 0.37-1.09 
AP5, 5-minute Apgar score; ApH, arterial cord pH; CL, total body clearance; Cr, plasma creatinine level; CRP, C-
reactive protein; GA, gestational age; HC, head circumference; PNA, postnatal age; SD, standard deviation; t½, 
elimination half-life; Ur, plasma urea concentration; V, volume of distribution; W, body weight. 
 
Population Pharmacokinetic Parameters 
Mean total body clearance of amoxicillin corrected for body weight (CL/W) was 0.096 ± 0.036 
Lkg-1h-1, mean amoxicillin elimination half-life (t½) was 5.2 ± 1.9 h, and mean volume of dis-
tribution of amoxicillin corrected for body weight (V/W) was 0.65 ± 0.13 L/kg. Population 
pharmacokinetic parameters of gentamicin were: CL/W 0.043 ± 0.012 Lkg-1h-1, t½ 10 ± 3.2 h, 
and V/W 0.59 ± 0.13 L/kg. 
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Statistical Analysis: Prediction of CL/W Amoxicillin 
The factor variables (gender, P, AP5, and BC) had no significant effect on CL/W amoxicillin. 
Significant Pearson correlations between the elimination parameters of amoxicillin (CL/W, 
CL, and t½) and the demographic, anthropometric, and clinical variables are presented in 
Table 2. Correlation between CL/W amoxicillin and GA is shown in Figure 1. Multiple regres-
sion analysis was performed by using CL/W amoxicillin (normally distributed) as dependent 
variable and GA, CL/W gentamicin, V/W gentamicin, and PNA as possible predictors. The 
variables 1/Cr and Ur were not used as possible predictors, because they had many missing 
data (49 and 50, respectively). The regression equation to predict CL/W amoxicillin was: 
CL/W amoxicillin (Lkg-1h-1) = 0.014 + 1.825 CL/W gentamicin (Lkg-1h-1) - 0.083 V/W gen-
tamicin (L/kg) + 0.001 GA (weeks) (r2 = 0.615, n = 150). The standardized beta coefficients, 
which represent the relative contribution of CL/W gentamicin, V/W gentamicin, and GA in the 
prediction of CL/W amoxicillin, were 0.580, -0.297, and 0.201, respectively. Because data on 
pharmacokinetics of gentamicin are usually not available at the start of the therapy, regres-
sion analysis also was performed without the pharmacokinetic parameters of gentamicin. 
The regression equation was: CL/W amoxicillin (Lkg-1h-1) = -0.067 + 0.005 GA (weeks) + 
0.005 PNA (days) (r2 = 0.479, n = 150). The standardized beta coefficients of GA and PNA 
were 0.623 and 0.223, respectively. The standardized studentized residuals of all models 
seemed to be normally distributed. 
Statistical Analysis: Prediction of V/W Amoxicillin 
V/W amoxicillin differed significantly between singleton and twin pregnancies, F(1,148) 7.14 (P 
= 0.008) and between neonates with AP5 < 7 and AP5 ≥ 7, F(1,146) 6.41 (P = 0.012). There-
fore, the factor variables P and AP5 were admitted as possible predictors of V/W amoxicillin 
to subsequent multiple regression analysis. Significant Pearson correlations were found be-
tween V/W amoxicillin and the variables CL/W gentamicin (r = 0.216, P = 0.008) and V/W 
gentamicin (r = 0.183, P = 0.025). However, these correlations are very low and, therefore, 
not relevant for use in clinical practice. The correlation between V amoxicillin and W was very 
strong (r = 0.92), leading to the assumption that V is mainly predicted by W. 
Evaluation of Current and Proposed Dosage Regimen 
Amoxicillin peak and trough concentrations after the second dose and T>MIC of each patient 
are presented in Table 3. With the current dosage regimen, T>MIC was much greater than 
50% in all neonates. Peak concentrations were greater than 140 mg/L in 28 neonates. These 
results indicate that the current dosage regimen may result in toxic plasma concentrations. 
We recommend a reduction of the dose and dosing interval. Because of the high correlation 
between CL/W amoxicillin and GA and for practical reasons, neonates will be subdivided into 
the same 3 dosage GA subgroups as already used for gentamicin dosing. We recommend 
15 mg/kg per 8 hours for neonates with GA < 30 and 30 ≤ GA ≤ 34 weeks and 20 mg/kg per 
8 hours for neonates with GA > 34 weeks. With this new dosage regimen, simulated peak 
concentrations were < 140 mg/L in all neonates: 41.9 ± 8.4 mg/L (mean ± SD) with a range 
of 23 to 72.4 mg/L. Simulated T>MIC was greater than 50% in all neonates: 96.5% ± 8.7% 
(mean ± SD) with a range of 51.5% to 100%. 
 
 
 
3
CHAPTER 3 
 38 
Table 2. Significant Correlations of Demographic, Anthropometric, and Clinical Variables with CL/W, CL, and t½ 
of Amoxicillin 
 CL/W Amoxicillin CL Amoxicillin t½ Amoxicillin 
GA 0.656** 0.857** -0.655** 
CL/W, CL, and t½ of gentamicin  0.651** 0.906** 0.777** 
W 0.611** 0.889** -0.599** 
1/Cr 0.521** 0.352** -0.394** 
Ur -0.42** -0.277** 0.446** 
V/W gentamicin -0.356** -0.503** 0.51** 
PNA 0.314** 0.208* -0.19* 
CL, total body clearance; Cr, plasma creatinine level; GA, gestational age; PNA, postnatal age; t½, elimination 
half-life; Ur, plasma urea concentration; V, volume of distribution; W, body weight; *correlation is significant at the 
0.05 level (2-tailed); **correlation is significant at the 0.01 level (2-tailed).  
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Figure 1. Correlation between total body clearance of amoxicillin  
corrected for body weight (CL/W amoxicillin) and gestational age (GA). 
 
 
Table 3. Amoxicillin Peak and Trough Concentrations after the Second Dose and T>MIC 
Dose 
(mg/kg) 
Interval 
(h) 
N* Trough Concentration 
(SD) (mg/L) 
Peak Concentration 
(SD) (mg/L) 
N Peak > 
140 mg/L 
T>MIC 
(SD) (%) 
25 6 1 15.9 53 0 100 
50 8 2 15.3 (1.5) 92.3 (12.6) 0 100 (0) 
50 12 112 21.4 (13.1) 101 (19.3) 3 97.9 (6.8) 
75 12 6 24.2 (25.4) 147.7 (28.2) 5 95 (12.2) 
100 6 1 85.1 216.4 1 100 
100 8 1 115.8 323.8 1 100 
100 12 18 42.6 (24.3) 212.2 (42.1) 18 99.4 (2.4) 
T>MIC, the time the concentration exceeds the minimum inhibitory concentration; SD, standard deviation; *nine of 
150 patients did not receive a dose of 25, 50, 75, or 100 mg/kg. 
PHARMACOKINETICS AND DOSING OF AMOXICILLIN 
 39 
Discussion 
Population Pharmacokinetic Parameters 
CL/W amoxicillin was approximately two times higher than CL/W gentamicin. This suggests 
the presence of other elimination pathways in addition to glomerular filtration, such as tubular 
secretion and/or metabolism, because gentamicin is completely cleared by glomerular filtra-
tion.18 However, literature indicates that tubular secretion is very inefficient19 and glomerular 
filtration is the major pathway for amoxicillin elimination3 in (pre)term neonates. 
The population pharmacokinetic parameters of amoxicillin found in the present study are 
similar to the results of Autret et al,4 CL/W 0.10 Lkg-1h-1 and V/W 0.62 L/kg. Huisman-de Boer 
et al3 found a comparable V/W (0.67 L/kg), but a lower CL/W (0.07 Lkg-1h-1), which may be 
partially explained by the lower GA of the neonates. Peskine et al5 found a much higher 
CL/W amoxicillin (0.21 Lkg-1h-1) and V/W amoxicillin (1.38 L/kg). These differences may be 
attributable to the relatively small study population and the use of the method of disk diffusion 
in nutrient agar instead of a more specific HPLC method. 
Prediction of CL/W Amoxicillin 
According to literature, plasma creatinine in the first week of life does not reflect glomerular 
filtration rate (GFR) of the neonate.20 Immediately after birth, plasma creatinine levels of the 
neonate represent maternal levels. Shortly thereafter, the tubular reabsorption of creatinine 
seems to be responsible for continuous high plasma creatinine levels in the neonate.20 
Therefore, we also included data of concomitant gentamicin monitoring for our prediction 
model. Gentamicin clearance as a predictor of GFR has been suggested earlier.18 However, 
CL/W gentamicin as well as 1/Cr correlated significantly with CL/W amoxicillin. Our finding 
that CL/W gentamicin is a good predictor of CL/W amoxicillin might be useful in clinical prac-
tice as an alternative for 1/Cr. The study by Huisman-de Boer et al3 indicated that inulin 
clearance, another marker of GFR, was highly correlated with amoxicillin clearance. Another 
important predictor of CL/W amoxicillin was GA. Amoxicillin clearance increases with gesta-
tional age, which probably reflects the development of renal function (both filtration and se-
cretion). Other investigators found a positive correlation of CL amoxicillin with GA and/or 
W.2,3,5 
Dosage Regimen 
Simulation with the proposed dosage regimen indicated that satisfactory plasma concentra-
tions were reached for all 150 neonates. Therefore, we think therapeutic drug monitoring is 
generally not necessary. We recommend a reduction of the amoxicillin dose and dosing in-
terval. Reduction of the amoxicillin dose in neonates has been recommended previously by 
other investigators. Charles et al2 recommended 20 mg/kg per 12 hours or 50 mg/kg per day 
instead of 50 mg/kg per 12 hours for neonates with GA ≤ 32 weeks in the first week of life. 
Huisman-de Boer et al3 recommended 25 mg/kg per 12 hours for neonates with GA < 32 
weeks in the first week of life. Dose reduction reduces the risk of amoxicillin toxicity, but also 
lowers the costs and prevents unnecessary use of the antibiotic, which promotes bacterial 
overgrowth and resistance.  
The proposed dosage regimen will result in amoxicillin plasma concentrations sufficiently 
high for the treatment of infections that are easily reached by antibiotics, such as bacteremia, 
urinary tract infection, and intravascular catheter-related infection. However, in patients who 
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are suspected of infections that are not easily reached by antibiotics, such as meningitis, we 
recommend doses higher than our proposed dosage regimen. Some experts recommend 
100 mg/kg per dose for treating meningitis.21 However, our results indicate that a dose of 100 
mg/kg will probably result in plasma concentrations > 140 mg/L, which may cause seizures. 
Moreover, literature indicates that inflammation of the meninges results in increased cere-
brospinal fluid amoxicillin concentrations caused by the increased permeability of the blood-
brain barrier and a decrease in drug clearance, jeopardizing the infant to amoxicillin neuro-
toxicity.6 We suggest a maximum amoxicillin dose of 40 mg/kg per 12 hours for neonates 
with GA < 30 weeks and 45 mg/kg per 12 hours for neonates with 30 ≤ GA ≤ 34 and GA > 34 
weeks, still resulting in plasma concentrations < 140 mg/L in all 150 neonates. However, the 
exact dosage regimen for treating meningitis still needs to be investigated. 
 
Conclusions 
We recommend 15 mg/kg per 8 hours for neonates with GA ≤ 34 weeks and 20 mg/kg per 8 
hours for neonates with GA > 34 weeks. Simulation with this dosage regimen indicated that 
satisfactory plasma concentrations were reached for all 150 neonates. Therefore, use of 
therapeutic drug monitoring of amoxicillin and pharmacokinetic calculations for dosage ad-
justment is generally not necessary. 
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Addendum to Chapter 3 
Gentamicin Clearance versus Plasma Creatinine Level as Predictor of Amoxicillin 
Clearance  
The use of plasma creatinine level as a traditional measure of glomerular filtration rate (GFR) 
has been reported to be inaccurate in the first week(s) of life. Immediately after birth, the high 
plasma creatinine levels of the neonate represent maternal levels. Shortly thereafter, the 
tubular reabsorption of creatinine seems to be responsible for continuous high plasma 
creatinine levels in the neonate.1 Gentamicin clearance has been suggested as an alterna-
tive method for measuring GFR.2 Gentamicin is eliminated almost entirely by the kidney and 
its rate of elimination parallels the GFR.2 Plasma creatinine level and gentamicin clearance 
both correlated significantly with amoxicillin clearance in 150 neonates aged ≤ 9 days as 
shown in Chapter 3. Most often, amoxicillin treatment for early-onset neonatal sepsis is initi-
ated immediately on the first or second day after birth (postnatal age ≤ 1 day). However, in 
these first two days the correlation between amoxicillin clearance and plasma creatinine level 
proved to be much lower than the correlation between amoxicillin clearance and gentamicin 
clearance (Table 1). This strongly suggests that gentamicin clearance should be preferable 
to plasma creatinine level as a predictor of amoxicillin clearance and/or GFR during this pe-
riod. Since plasma concentrations of gentamicin are routinely measured in clinical practice, 
the use of gentamicin clearance as a predictor of amoxicillin clearance and/or GFR does not 
involve additional interventions or expenses.2  
 
 
Table 1. Correlation of Amoxicillin Clearance with Plasma Creatinine Level and Gentamicin Clearance in 
Neonates  
 Plasma Creatinine Level (1/Cr) 
Correlation with Amoxicillin  
Clearance (r) 
Gentamicin Clearance 
Correlation with Amoxicillin  
Clearance (r) 
PNA ≤ 1 day (n = 82) 0.233* 0.642** 
PNA > 1 day (n = 19) 0.602** 0.628** 
Total (PNA ≤ 9 days) (n = 101) 0.521** 0.720** 
Cr, plasma creatinine level; PNA, postnatal age; r, correlation coefficient; *correlation is significant at the 0.05 
level (2-tailed); **correlation is significant at the 0.01 level (2-tailed).  
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Addendum to Chapter 3 
To the Editor 
neonates using population pharmacokinetic methods. This is the first report in such a large 
number of newborn infants. There are, however, several issues mentioned in the paper that 
need further clarification. The authors state in their paragraph ‘Evaluation of current and pro-
posed dosage regimen’ that in neonates T>MIC needs to be at least 40% to 50%, and they 
refer to the paper by de Hoog et al.2 By doing so they have missed two issues reported in 
that paper that are important for our readers. First, it needs to be clear that the efficacy of 
amoxicillin, one of the β-lactam antibiotics, is dependent on the time the free, non-protein-
bound concentration remains above the MIC of the microorganism. Therefore, in daily prac-
tice, several times the MIC is taken as the cutoff point to correct for this free drug exposure 
requirement. Second, T>MIC of 40% to 50% is probably insufficient for neonates, because 
this vulnerable group of patients might be regarded as immunocompromised and therefore, a 
T>MIC of 70% is more desirable. I would love to see the simulations of Pullen et al taking 
these two issues into account.  
I would love to challenge the authors on another issue. I am always very worried that by hav-
ing many different dosing regimens (15 mg/kg for young infants [GA < 34 weeks] and 20 
mg/kg for older ones [GA > 34 weeks]) we increase the chance of creating medication errors. 
Looking at the excellent data presented by Pullen et al it looks like the younger kids just need 
more time to clear amoxicillin. Did the authors consider giving all neonates the same amount 
per dose (i.e., 20 mg/kg), while adjusting the dosing interval?  
In the past, studies have been performed that have shown the impact of antenatal exposure 
to indomethacin and betamethasone on the renal clearing capacity of the neonate.3 I there-
fore wonder if the authors have information on antenatal exposure to these medicines and if 
they have investigated their potential impact. 
The mean postnatal age of the studied neonates was 0.8 days and recognizing the rapid 
postnatal changes in renal maturation I would like to hear from the authors as to whether 
they are confident that their dosing regimens will result in appropriate killing of the bacteria 
after the first week of postnatal life.4 
Finally, I would like to ask the authors to conduct a prospective validation of their simulated 
dosing regimens to be sure that their simulation works in real life and to report their findings 
of that prospective study again in this Journal. 
 
Prof. dr. J.N. van den Anker 
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Response to van den Anker 
We would like to reply to the comments made by professor John N. van den Anker. He states 
that we have missed two issues reported in the paper by de Hoog, Mouton, and van den 
Anker.1 First, he states that the efficacy of amoxicillin, one of the β-lactam antibiotics, is de-
pendent on the time the free, non-protein-bound concentration remains above the MIC of the 
microorganism. Indeed, we have taken the protein binding of amoxicillin into account. We 
determined amoxicillin protein binding by ultrafiltration in 10 neonates. Protein binding was 
low, about 10%. Ehrnebo et al reported similar results for ampicillin protein binding in neo-
nates.2 With our proposed dosage regimen the total as well as the free, non-protein-bound 
concentration will exceed the MIC at least 40% of the time. The second remark is that T>MIC 
of 40% to 50% is probably insufficient for neonates, because this vulnerable group of pa-
tients might be regarded as immunocompromised and therefore a T>MIC of 70% is more 
desirable. However, in the paper by de Hoog et al, it is stated that, ‘although the therapeutic 
goal for penicillins in general is related to a T>MIC of 30% to 40%, neonates have to be con-
sidered as immunocompromised and should at least be in the order of 40% to 50%.’1 We are 
curious to know on which evidence van den Anker based the 70% T>MIC target. 
We agree with van den Anker that many different dosage regimens may increase the chance 
of creating medication errors. We do not agree with his suggestion to give all neonates a 
fixed dose and adjust the dosing interval, because medication errors may be the result of an 
erroneous change of both the dose and the dosing interval. Therefore, we simulated plasma 
concentrations reached with a fixed 20 mg/kg dose and a fixed 8-hour dosing interval for all 
neonates. With this dosage regimen, simulated peak concentrations were < 140 mg/L in all 
neonates: 48.8 ± 11.0 mg/L (mean ± SD) with a range of 25.6 to 80.9 mg/L. Simulated 
T>MIC was greater than 50% in all neonates: 97.0% ± 8.1% (mean ± SD) with a range of 
51.5% to 100%. Therefore, this dosage regimen could be a suitable alternative. 
We fully agree with van den Anker that our dosage regimens need prospective validation. 
We did not investigate the potential impact of antenatal exposure to indomethacin and be-
tamethasone on the renal clearing capacity of our neonates. Administration of corticoster-
oids, like betamethasone, is standard procedure in our hospital in case of imminent preterm 
delivery (< 33 to 34 weeks gestational age). Indomethacin is rarely used. Our information on 
antenatal exposure to these medicines is incomplete. However, we demonstrated that our 
proposed dosage regimens resulted in satisfactory plasma concentrations in all 150 neo-
nates. Therefore, we presume that antenatal exposure to these medicines has limited impact 
on amoxicillin dosing for our neonates. 
In our study we observed a positive correlation between amoxicillin clearance and postnatal 
age. Therefore, we are currently investigating the pharmacokinetics and dosing of amoxicillin 
in neonates older than one week. So far we have found a higher amoxicillin clearance after 
the first week. Therefore, the proposed dose of 20 mg/kg per 8 hours for neonates in the first 
week of life might result in ineffective plasma concentration in neonates older than one week. 
We hope to report our results soon in this Journal. 
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Abstract 
The pharmacokinetic parameters of amoxicillin were determined in 32 newborn infants aged 
10 to 52 days (mean postnatal age 24.7 ± 12.4 days) in order to improve amoxicillin dosing in 
this age group. Amoxicillin plasma concentrations were determined using reversed-phase 
HPLC in surplus plasma samples from routine gentamicin assays. Amoxicillin pharmacoki-
netic parameters were (mean ± SD): first-order elimination constant (Kel) = 0.27 ± 0.10 h-1, 
volume of distribution corrected for body weight (V/W) = 0.66 ± 0.27 L/kg, total body clear-
ance corrected for body weight (CL/W) = 0.18 ± 0.10 Lkg-1h-1, and elimination half-life (t½) = 
3.0 ± 1.3 h. Amoxicillin body clearance was approximately two-fold greater in our patients 
compared to published values in younger neonates (mean postnatal age 0.76 ± 1.57 days). 
Simulation studies using the observed amoxicillin pharmacokinetic data suggest an amoxicil-
lin dose of 40 mg/kg administered every 8 hours in infants > 9 days PNA, independent of GA 
and PCA, to achieve satisfactory target plasma amoxicillin concentrations < 140 mg/L and 
T>MIC at least 40%. Prospective evaluation of this suggested new dosage regimen is nec-
essary before implementation in the care of ill neonates. 
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Introduction 
Amoxicillin is an aminopenicillin frequently used for the treatment of early-onset neonatal 
sepsis.1 In an earlier study, we investigated amoxicillin pharmacokinetics, amoxicillin dosing, 
and the influence of covariates on the individual pharmacokinetic parameters in 150 
(pre)term neonates aged ≤ 9 days (mean postnatal age 0.76 ± 1.57 days).2 Amoxicillin phar-
macokinetics in neonates have also been investigated in 4 smaller studies.3-6 In these stud-
ies, the pharmacokinetic parameters were established in the first week of neonatal life, un-
derscoring the need for such data in older infants. 
Postnatal development of renal function in (pre)term infants has been well documented.7-11 
The progressive postnatal increase in glomerular filtration rate (GFR) results mainly from an 
increase in glomerular perfusion pressure.12 Because of this postnatal increase in GFR, it is 
expected that postnatal age (PNA) will exert a major effect on the pharmacokinetics of drugs 
which are mainly eliminated by glomerular filtration. In our previous study, we found a high 
correlation between amoxicillin clearance and plasma creatinine and gentamicin body clear-
ance, demonstrating the important role of glomerular filtration in the clearance of amoxicillin 
in neonates.2 In previous studies, the effect of postnatal age on the pharmacokinetics of gen-
tamicin,13 ceftazidime,14 and piperacillin15 in neonates has been investigated. However, we 
were unable to identify any published data describing the pharmacokinetics of amoxicillin in 
neonates aged > 9 days and the effect of postnatal age on amoxicillin pharmacokinetic char-
acteristics (MEDLINE search terms: amoxicillin, amoxycillin, pharmacokinetic(s), pharmacol-
ogy, postnatal (age), infant(s), newborn(s), neonate(s), and neonatal). Thus, the main objec-
tive of the present study was to define an amoxicillin dosage regimen appropriate for 
(pre)term infants aged > 9 days.  
  
Materials and Methods 
Patients, Drug Administration, and Plasma Sampling 
The present study was approved by the local Medical Ethical Committee. Thirty-two newborn 
infants aged > 9 days, admitted to the neonatal intensive care unit at the University Hospital 
of Maastricht from June 2002 to March 2006, were identified for inclusion in this study. All 
infants were treated with amoxicillin in combination with gentamicin for (suspected) infection. 
Amoxicillin was administered by intravenous slow push according to published dosing guide-
lines: 100 mg/kg per dose for (suspected) meningitis and 50 mg/kg per dose in other situa-
tions.16 Dosing interval was 12 hours in the first week of life, 8 hours in neonates 1 to 3 
weeks old, and 6 hours in neonates ≥ 4 weeks old.16 Gentamicin (4 mg/kg) was administered 
intravenously by syringe pump during 30 minutes every 24 hours. Amoxicillin and gentamicin 
were administered shortly after each other. Most infants (53%) were treated with a combina-
tion of amoxicillin, gentamicin, and metronidazol for (suspected) NEC. Other indications for 
amoxicillin use were Gram-positive cocci in liquor (group B Streptococcus meningitis), in-
creased C-reactive protein (CRP), and (suspected) urinary tract infection.  
Therapeutic drug monitoring of gentamicin was performed on a routine basis. Plasma sam-
ples were obtained just before and one hour after the start of the infusion of gentamicin. Sur-
plus plasma samples from routine gentamicin assays were collected and stored at -70°C until 
amoxicillin analysis. We collected 5.2 ± 2.1 plasma samples per infant during 3.5 ± 1.4 days 
(mean ± SD). 
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Amoxicillin Assay 
The determination of amoxicillin in plasma was performed using reversed-phase high-
performance liquid chromatography (RP-HPLC) with UV detection as described previously.2 
With this RP-HPLC assay, total (free + protein-bound) plasma concentrations of amoxicillin 
are determined. In five infants, aged 10 to 73 days, we determined the extent of amoxicillin 
binding to plasma proteins.17 To determine the free amoxicillin concentration in these 5 in-
fants, we collected and combined several plasma samples of each infant to obtain a suffi-
ciently large sample for analysis (150 μL to 1000 μL). Free amoxicillin was separated from 
protein-bound amoxicillin using ultrafiltration by a Centrifree® micropartition device (Millipore 
Corporation, Bedford, MA, USA). Fibrin was removed by centrifuging the sample at 4000 rpm 
for 25 minutes at room temperature before loading into the reservoir. For optimum solvent 
flow, a 33° fixed-angle centrifuge rotor was used. 
Data Analysis 
Amoxicillin pharmacokinetic parameters were estimated from the analysis of the measured 
amoxicillin plasma concentrations using a one-compartment open model with iterative two-
stage Bayesian fitting (MW\PHARM 3.60, Mediware, The Netherlands), incorporating previ-
ously determined pharmacokinetic parameters2 as initial parameters. In our previous study, 
we found a high correlation between amoxicillin clearance and gentamicin clearance. Since 
plasma creatinine may reflect GFR poorly in the first week(s) of life18, gentamicin clearance 
was also included as a measure of GFR.19 Therefore, gentamicin pharmacokinetic parame-
ters were also calculated, using parameters published by Stolk et al.20 The influence of co-
variates on the individual pharmacokinetic parameters was studied by calculating the Pear-
son correlation coefficients (r) with SPSS® 12.0 (Chicago, IL). The covariates were: gesta-
tional age (GA), PNA, postconceptional age (PCA), body weight (W), gender, multiple preg-
nancy (P), 1-minute Apgar score (AP1), 5-minute Apgar score (AP5), 1/plasma creatinine 
(1/Cr), plasma urea concentration (Ur), CRP, blood culture result (BC), and the pharmacoki-
netic parameters of gentamicin. One-way analysis of variance (ANOVA) was used to test 
whether the factor variables (gender, P, and BC) had a significant effect on the pharmacoki-
netic parameters of amoxicillin.   
Dosage Regimen 
The projected bacteriologic efficacy and safety of the amoxicillin dosage regimen used in our 
32 infants was assessed. Projected bacteriologic efficacy was determined using standard 
antimicrobial pharmacokinetic-pharmacodynamic modeling21 and safety was projected by 
calculating the amoxicillin peak plasma concentrations after the second dose, which should 
not exceed 140 mg/L.22,23 For bacteriologic efficacy the amount of time (T) the free amoxicillin 
plasma concentration must remain above the minimum inhibitory concentration (T>MIC) of 
important neonatal pathogens (e.g., target MIC = 0.25 mg/L for Streptococcus agalactiae and 
8 mg/L for Enterococcus species and species belonging to the Enterobacteriaceae24) should 
be at least 40-50% of the dosing interval for neonates.25 Considering that amoxicillin plasma 
protein binding in adults is rather low (< 20%)26 and ampicillin protein binding in neonates 
averages 9.9% ± 1.5% (range 8.3% to 11.5%, n = 4)27 and our own data (see Results) sug-
gest 11.7%, we elected to assume amoxicillin protein binding for our simulation studies to be 
10%. Our target, optimal dosage regimen, would result in free amoxicillin plasma concentra-
tions that remain above the MIC for a minimum of at least 40% of the time and total plasma 
concentrations had to be below 140 mg/L. 
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Results 
The clinical characteristics of the infants included in the present study (8 girls and 24 boys; 7 
infants were twins) and for comparative purposes the data obtained in neonates aged ≤ 9 
days from our previous study2 are presented in Table 1. The characteristics of both popula-
tions were very much alike, except for CRP and the expected differences in PNA, PCA, and 
1/Cr. The lower mean plasma creatinine concentration (45.0 versus 90.7 μmol/L) probably 
reflects a higher GFR and the higher mean CRP (128.0 versus 14.7 mg/L) may indicate a 
higher incidence of bacterial infection (see Table 1). Seven of 24 blood cultures (29%) were 
positive; coagulase negative staphylococci (CoNS) n = 4, Escherichia coli n = 2, and Strep-
tococcus mitis n = 1. 
 
 
Table 1. Characteristics of the Infants in the Present Study and in Our Previous Study2 
  Present Study Previous Study 
 Unit N Mean (SD) Range N Mean (SD) Range 
GA weeks 32 33.7 (4.6) 26.3-41.4 150 34.6 (4.9) 24.9-42.4 
PNA days 32 24.7 (12.4) 10-52 150 0.76 (1.57) 0-9 
PCA weeks 32 37.2 (4.9) 28-46.1 150 34.7 (4.9) 24.9-42.6 
W kg 32 2.27 (1.02) 0.78-4.25 150 2.29 (1.08) 0.57-4.7 
AP5 points 30 8 (median) 4-10 148 9 (median) 1-10 
1/Cr L/μmol 30 0.025 (0.009) 0.011-0.050 101 0.012 (0.004) 0.006-0.036 
Ur mmol/L 30 3.70 (2.06) 0.6-11.5 100 5.05 (2.62) 0.8-13.5 
CRP mg/L 31 128.0 (100.2) 3.6-343.0 141 14.7 (23.2) 1-117 
AP5, 5-minute Apgar score; Cr, plasma creatinine level; CRP, C-reactive protein; GA, gestational age; PCA, post-
conceptional age; PNA, postnatal age; SD, standard deviation; Ur, plasma urea concentration; W, body weight. 
 
 
Amoxicillin pharmacokinetic parameters were (mean ± SD): first-order elimination constant 
(Kel) = 0.27 ± 0.10 h-1, volume of distribution corrected for body weight (V/W) = 0.66 ± 0.27 
L/kg, total body clearance corrected for body weight (CL/W) = 0.18 ± 0.10 Lkg-1h-1, and elimi-
nation half-life (t½) = 3.0 ± 1.3 h. Gentamicin pharmacokinetic parameters were (mean ± 
SD): Kel = 0.11 ± 0.02 h-1, V/W = 0.59 ± 0.13 L/kg, CL/W = 0.06 ± 0.02 Lkg-1h-1, and t½ = 6.8 
± 1.9 h. The mean (± SD) amoxicillin protein binding in the 5 infants aged 10 to 73 was 
11.7% ± 2.7% (range 8.0% to 14.1%). 
The highest Pearson correlation coefficient was found between amoxicillin clearance and 
PCA (r = 0.718, P < 0.001), which showed a logarithmic rise with PCA (r = 0.717). The corre-
lation between amoxicillin clearance and PCA, on linear and semi-logarithmic scales, is 
shown in Figure 1. Amoxicillin clearance was also significantly related to GA (r = 0.655, P < 
0.001), 1/Cr (r = 0.552, P = 0.002), and gentamicin clearance (r = 0.490, P = 0.004). How-
ever, no significant relationship was observed between amoxicillin clearance and PNA (r = 
0.318, P = 0.076). V/W amoxicillin was significantly correlated with GA (r = 0.455, P = 0.009), 
PCA (r = 0.463, P = 0.008), and CL/W gentamicin (r = 0.444, P = 0.011). We could not find a 
relationship between infection and amoxicillin pharmacokinetics. Further, no relationship or 
differences were observed between amoxicillin pharmacokinetics and infants suffering from 
an infectious disease (defined by a positive blood culture) and infants having negative blood 
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cultures. Moreover, no relationship between CRP and amoxicillin pharmacokinetic parame-
ters was observed. 
The amoxicillin T>MIC (8 mg/L) was > 40% in all 32 infants: T>MIC = 85.4% ± 18.3% (mean 
± SD), range 41% to 100%. The average (± SD) peak amoxicillin plasma concentration was 
80.1 (± 37.9) mg/L with a range of 20.1 to 167.8 mg/L and the average (± SD) trough amox-
icillin plasma concentration was 10.2 (± 8.4) mg/L (range 0.6 to 34.8 mg/L). In 3 of the 32 
infants amoxicillin peak plasma concentrations were higher than 140 mg/L (140.6, 158.3, and 
167.8 mg/L). Simulation studies using the determined amoxicillin pharmacokinetic parame-
ters to determine the dose to achieve a target T>MIC of at least 40% of the dosing interval 
and peak amoxicillin concentrations < 140 mg/L suggest a new dosage regimen of 40 mg 
amoxicillin per kg every 8 hours, independent of GA, PNA, and PCA, for infants aged > 9 
days. Based upon these simulations this dosage regimen yielded satisfactory amoxicillin 
plasma concentrations in all infants with the T>MIC greater than 40% in all 32 infants (mean 
T>MIC = 87.3% ± 19.1%, range 43% to 100%) and greater than 50% in 31 of the 32 infants. 
Furthermore, the peak amoxicillin plasma concentrations were below 140 mg/L in all 32 in-
fants: 70.0 ± 27.4 mg/L (range 29.7 to 134.5 mg/L); average trough plasma concentration 
was 10.8 (± 7.6) mg/L with a range of 1.0 to 32.6 mg/L. 
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Figure 1. Correlation between total body clearance of amoxicillin corrected for body weight (CL/W amoxicillin) 
and postconceptional age (PCA) on linear scale (A) and semi-logarithmic scale (B). 
 
 
Discussion 
The amoxicillin body clearance in infants aged > 9 days (mean PNA 24.7 ± 12.4 days) de-
termined in the present study (0.18 Lkg-1h-1) is approximately two-fold greater that the amox-
icillin body clearance observed in younger neonates (0.10 Lkg-1h-1) aged ≤ 9 days (mean 
PNA 0.76 ± 1.57 days). In addition, the amoxicillin t½ was much shorter (3.0 h versus 5.2 h), 
whereas the V/W was approximately the same (0.66 L/kg versus 0.65 L/kg) in the older and 
younger infants, respectively.2 These results confirm our expectations about the effect of 
postnatal age on amoxicillin pharmacokinetics. Glomerular filtration and tubular secretion are 
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less mature during the first week of life.28 Therefore, amoxicillin clearance is considerably 
reduced in the newborn infant compared with that in older infants.  
Amoxicillin clearance showed a logarithmic rise with PCA (Figure 1). For infants aged > 9 
days, amoxicillin clearance hardly seems to increase until the infant reaches a PCA of 34 
weeks. After that, there is a rapid linear increase in amoxicillin clearance with PCA (r = 
0.863). This finding is consistent with results in the literature.11,29 Coulthard reported a loga-
rithmic rise of absolute GFR with PCA, which was independent of postnatal age, based on 
his own study in 39 infants (GA 27 to 40 weeks and PNA 2 to 63 days) and based on 14 
other studies.11 Arant reported a slight increase in GFR prior to the time an infant reaches a 
PCA of 34 weeks and a more rapid increase thereafter. A PCA of 34 weeks seems to be the 
point in renal development from which the absolute GFR increases gradually to mature val-
ues.29 So, GFR and thus amoxicillin clearance, are dependent upon the infant’s PCA, which 
differs between our first study (34.7 weeks) and the present study (37.2 weeks). This may 
help to explain the difference in amoxicillin clearance observed between the two studies. 
Amoxicillin clearance was also highly related to GA (r = 0.655). In our previous study, we 
found the same relationship between amoxicillin clearance and GA (r = 0.656), which proba-
bly reflects the development of renal function.2 In the present study too, we found a relation-
ship between amoxicillin clearance and the predictors of GFR, plasma creatinine concentra-
tion (1/Cr) (r = 0.552 versus r = 0.521) and gentamicin clearance (r = 0.490 versus r = 0.651), 
indicating the important role of glomerular filtration in the clearance of amoxicillin in (pre)term 
infants.2  
The amoxicillin body clearance observed in our 32 infants was, on average, three times 
higher than the observed gentamicin clearance. This observation indicates the additive role 
of tubular secretion in amoxicillin clearance, because gentamicin is completely cleared by 
glomerular filtration.19 In younger infants, amoxicillin body clearance exceeded the gen-
tamicin clearance by about two-fold2 reflecting the dependence upon age for the maturation 
of the proximal renal tubular weak acid transport system.   
Dose simulation assessments incorporating the amoxicillin pharmacokinetic data determined 
in the present study to achieve specific targets, i.e., T>MIC of at least 40% (MIC = 8 mg/L) 
and peak amoxicillin concentrations < 140 mg/L, suggest an amoxicillin dose of 40 mg/kg 
administered every 8 hours in neonates > 9 days of age independent of GA and PCA. It 
should be noted that this dosage regimen will result in plasma concentrations sufficiently high 
only for the treatment of infections which are easily reached by beta-lactam antibiotics, such 
as bacteremia, urinary tract infection, and intravascular catheter-related infection, but not for 
meningitis. Lastly, when performing simulation assessments with expected free amoxicillin 
concentrations, as we did in this study, it might be possible that higher T>MIC values (e.g., 
T>MIC 60%) are necessary for optimal treatment of neonates, who suffer from age-
dependent deficiencies in immunological functions. However, prospective validation of this 
new dosage regimen is necessary.  
 
Conclusions 
Postnatal alterations in amoxicillin pharmacokinetics, particularly an increase in amoxicillin 
body clearance, require adjustment of the dosage regimen after the first week of life. We 
suggest an amoxicillin dose of 40 mg/kg every 8 hours for infants aged > 9 days. The validity 
of this projected dose regimen must be evaluated before routine implementation in the care 
of older neonates.  
4
CHAPTER 4 
 54 
References 
1. Fanos V, Dall’Agnola A. Antibiotics in neonatal infections: a review. Drugs. 1999;58:405-427. 
2. Pullen J, Stolk LML, Nieman FHM, et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term 
neonates. Ther Drug Monit. 2006;28:226-231. 
3. Huisman-de Boer JJ, Anker van den JN, Vogel M, et al. Amoxicillin pharmacokinetics in preterm infants with 
gestational ages of less than 32 weeks. Antimicrob Agents Chemother. 1995;39:431-434. 
4. Peskine F, Despaux E, Rodiere M, et al. Étude pharmacocinétique et clinique de l’amoxicilline intra-veineuse 
chez le nouveau-né. Pathol Biol (Paris). 1982;30:476-480. 
5. Charles BG, Preechagoon Y, Lee TC, et al. Population pharmacokinetics of intravenous amoxicillin in very 
low birth weight infants. J Pharm Sci. 1997;86:1288-1292. 
6. Autret E, Laugier J, Marimbu J, et al. Comparaison des concentrations plasmatiques d’amoxicilline par voie 
orale et intraveineuse dans les colonisations bactériennes néonatales. Arch Fr Pediatr. 1988;45:679-682. 
7. Aperia A, Borberger O, Elinder G, et al. Postnatal development of renal function in pre-term and full-term 
infants. Acta Paediatr Scand. 1981;70:183-187. 
8. Heijden van der AJ, Grose WF, Ambagtsheer JJ, et al. Glomerular filtration rate in the preterm infant: the 
relation to gestational and postnatal age. Eur J Pediatr. 1988;148:24-28. 
9. Fawer CL, Torrado A, Guignard JP. Maturation of renal function in full-term and premature neonates. Helv 
Paediatr Acta. 1979;34:11-21. 
10. Arant BS. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 
1978;92:705-712. 
11. Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. Early Hum Dev. 
1985;11:281-292. 
12. Jose PA, Fildes RD, Gomez RA, et al. Neonatal renal function and physiology. Curr Opin Pediatr. 
1994;6:172-177. 
13. Knight JA, Davis EM, Manouilov K, et al. The effect of postnatal age on gentamicin pharmacokinetics in 
neonates. Pharmacotherapy. 2003;23:992-996. 
14. Anker van den JN, Hop WC, Schoemaker RC, et al. Ceftazidime pharmacokinetics in preterm infants: effect 
of postnatal age and postnatal exposure to indomethacin. Br J Clin Pharmacol. 1995;40:439-443. 
15. Kacet N, Roussel-Delvallez M, Gremillet C, et al. Pharmacokinetic study of piperacillin in newborns relating 
to gestational and postnatal age. Pediatr Infect Dis J. 1992;11:365-369. 
16. Hey E, Hall C. Neonatal Formulary. 4th ed. London: Blackwell BMJ Books; 2003. 
17. Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet. 
1990;18:20-36. 
18. Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics. 1999;103:E49. 
19. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin 
pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther. 1985;38:680-685. 
20. Stolk LML, Degraeuwe PLJ, Nieman FHM, et al. Population pharmacokinetics and relationship between 
demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit. 
2002;24:527-531. 
21. Andes D, Anon J, Jacobs MR, et al. Application of pharmacokinetics and pharmacodynamics to antimicrobial 
therapy of respiratory tract infections. Clin Lab Med. 2004;24:477-502. 
22. Shaffer CL, Davey AM, Ransom JL, et al. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. 
Ann Pharmacother. 1998;32:482-484. 
23. Hodgman T, Dasta JF, Armstrong DK, et al. Ampicillin-associated seizures. South Med J. 1984;77:1323-
1325. 
24. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibil-
ity Testing; Twelfth Informational Standard M100-S12. Wayne, PA: NCCLS; 2002. 
25. Hoog de M, Mouton JW, Anker van den JN. New dosing strategies for antibacterial agents in the neonate. 
Semin Fetal Neonatal Med. 2005;10:185-194. 
26. Working Party of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antim-
icrob Chemother. 1991;27 (Suppl. D):1-50. 
27. Ehrnebo M, Agurell S, Jalling B, et al. Age differences in drug binding by plasma proteins: studies on human 
foetuses, neonates and adults. Europ J Clin Pharmacol. 1971;3:189-193. 
28. Heimann G. Drug disposition during the perinatal period. Int J Biol Res Pregnancy. 1981;2:1-14. 
29. Arant BS. Postnatal development of renal function during the first year of life. Pediatr Nephrol. 1987;1:308-
313. 
 55 
 
 
 
Chapter 5 
Population Pharmacokinetics and Dosing of 
Flucloxacillin in Preterm and Term Neonates 
 
 
Joyce Pullen, Lindsay de Rozario, Leo M.L. Stolk, Pieter L.J. Degraeuwe, Frank H. van Tiel, 
and Luc J.I. Zimmermann 
 
Ther Drug Monit 2006;28(3):351-358 
5
CHAPTER 5 
 56 
Abstract 
In total 235 flucloxacillin total (free + protein-bound) plasma concentrations were determined 
in 55 neonates (gestational age 26 to 42 weeks, postnatal age 0 to 44 days) with reversed-
phase HPLC in surplus plasma samples from routine gentamicin assays. Population phar-
macokinetic parameters were calculated according to a one-compartment open model with 
iterative two-stage Bayesian fitting (MW\PHARM 3.50, Mediware, The Netherlands). Mean 
clearance corrected for weight was 0.18 ± 0.10 Lkg-1h-1 and volume of distribution corrected 
for weight was 0.54 ± 0.17 L/kg. Pearson correlations between the individual pharmacoki-
netic parameters and covariates, like gestational age, plasma creatinine, and gentamicin 
clearance, were low and therefore not relevant for use in clinical practice. Total plasma con-
centrations above 200 mg/L were considered toxic and T>MIC (time above minimum inhibi-
tory free plasma concentration) of more than 40% was considered effective. Protein binding 
was assumed to be 86.3% in all neonates, based on literature. The current dosage regimen, 
25 or 50 mg/kg every 8 or 12 hours, did not result in effective plasma concentrations for the 
treatment of Staphylococcus aureus in 17 (31%) of the 55 neonates. Therefore, the authors 
suggest an initial dose of 25 mg/kg/4 h for all neonates, irrespective of their age, based on 
the breakpoint MIC value of flucloxacillin for Staphylococcus aureus (2.0 mg/L). After isola-
tion of the causative agent of infection, flucloxacillin administration ought to be reconsidered 
based on the expected susceptibility pattern of the isolate. When oxacillin sensitive coagu-
lase negative staphylococci are isolated, the initial dose should be reduced to 10 mg/kg/6 h, 
based on the breakpoint MIC value of 0.25 mg/L. Simulation with these new dosage regi-
mens indicated that satisfactory plasma concentrations were reached in 52 of the 55 neo-
nates. However, the regimens need prospective verification. Moreover, the exact role of neo-
natal protein binding needs to be further investigated. 
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Introduction 
Late-onset neonatal sepsis is relatively common in hospitalized neonates, especially in those 
who are extremely premature. Preterm infants frequently need invasive interventions, such 
as prolonged ventilation and vascular access, which may increase the risk of infection.1 Most 
late-onset infections are caused by Gram-positive organisms. Coagulase negative staphylo-
cocci (CoNS) account for half of all late-onset infections.1 It is not clear which antibiotic regi-
men is most suitable for initial treatment of suspected late-onset sepsis.2 Flucloxacillin, a 
narrow spectrum penicillin, in combination with gentamicin, an aminoglycoside, is the drug of 
choice in the vast majority in Dutch hospitals.3,4 In contrast to gentamicin, therapeutic drug 
monitoring (TDM) of flucloxacillin is not performed on a routine basis. 
Data concerning population pharmacokinetics of flucloxacillin in adults are limited to a few 
studies.5-8 Considering the large differences in body composition and metabolic functions 
between neonates and adults, pharmacokinetic data from studies in adults cannot be applied 
to newborn infants. In a small study flucloxacillin pharmacokinetics in nine newborn infants of 
various gestational (mean 36.6 weeks) and chronological (mean 7.2 days) ages were inves-
tigated.9 Flucloxacillin pharmacokinetics were also investigated in another study with eleven 
neonates aged between 3 and 60 days undergoing cardiopulmonary bypass surgery.10 The 
elimination half-life was considerably longer, the total body clearance was much lower, and 
the apparent volumes of distribution in the central and peripheral compartments were much 
larger than in healthy adults. 
The present study was designed to investigate the efficacy of the current dosage regimen of 
flucloxacillin and to develop a better dosage regimen if necessary. Therefore, flucloxacillin 
plasma concentrations of a large population of 55 neonates were determined with a specific 
HPLC method, the population pharmacokinetic parameters of flucloxacillin were calculated, 
and demographic, anthropometric, and clinical covariates, that may influence the individual 
pharmacokinetic parameters of flucloxacillin, were investigated for significance. 
 
Materials and Methods 
Patients 
The study was approved by the local Ethical Board. Fifty-five (pre)term neonates, admitted to 
the neonatal ward at the University Hospital of Maastricht from May 2002 through March 
2005, participated in the study. Inclusion criteria were: coadministration of flucloxacillin and 
gentamicin, postnatal age (PNA) ≤ 2 months, availability of reliable patient data with respect 
to gestational age (GA), PNA, dosing and sampling times, and availability of at least one 
plasma sample taken shortly before the administration of gentamicin and flucloxacillin (trough 
concentration) and one plasma sample taken one hour after the administration (peak con-
centration). 
For each patient, the following demographic, anthropometric, and clinical characteristics 
were recorded: GA, PNA, postconceptional age (PCA), birth weight (BW), body weight (W), 
gender, multiple pregnancy (P), arterial cord pH (ApH), 1-min Apgar score (AP1), 5-min Ap-
gar score (AP5), divided into two groups (< 7 and ≥ 7), 1/plasma creatinine (1/Cr), plasma 
urea concentration (Ur), blood culture result (BC), and C-reactive protein (CRP). Because 
literature11 indicates that plasma creatinine in the first week of life does not reflect glomerular 
filtration rate (GFR) of the neonate, data on gentamicin clearance were also collected. Gen-
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tamicin clearance as an estimate of GFR in neonates has been suggested previously.12 The 
following pharmacokinetic parameters of gentamicin were calculated: total body clearance 
corrected for body weight (CL/W gentamicin), elimination half-life (t½ gentamicin), and vol-
ume of distribution corrected for body weight (V/W gentamicin). 
Drug Administration and Plasma Sampling 
Gentamicin dosage regimen was 5.0 mg/kg/48 h, 4.5 mg/kg/36 h, and 4.0 mg/kg/24 h for 
neonates in the first week of life with GA < 30, 30 ≤ GA ≤ 34, and GA > 34 weeks, respec-
tively.13 Neonates older than one week received 4 mg/kg/24 h.14 Gentamicin was adminis-
tered intravenously by syringe pump over 30 min. The flucloxacillin dosage regimen, 25 to 50 
mg/kg every 8 or 12 hours, depending on GA and PNA, was based on dosing guidelines in 
literature.4,15 Flucloxacillin was administered by intravenous slow push (0.1 h). Usually, flu-
cloxacillin and gentamicin were administered shortly after each other. 
Plasma samples were taken just before and one hour after the infusion of gentamicin. Dosing 
and sampling times were recorded by nursing staff. Surplus plasma samples from routine 
gentamicin assays were stored at -70°C. 
Chemicals 
Acetonitrile (CH3CN, CAS 75-05-8), citric acid monohydrate (C6H8O7·H2O, CAS 5949-29-1), 
methylene chloride (CH2Cl2, CAS 75-09-2), hydrochloric acid (HCl, CAS 7647-01-0), and 
sodium perchlorate (NaClO4·H2O, CAS 7601-89-0) were obtained from Merck (Darmstadt, 
Germany). Flucloxacillin (C19H16ClFN3NaO5S·H2O, CAS 1847-24-1) was provided by Syno-
pharm (Barsbüttel, Germany) and the internal standard cloxacillin (C19H18ClN3O5S, CAS 61-
72-3) was obtained from SmithKline Beecham Pharmaceutical (Middlesex, United Kingdom). 
Ultrapure water was used in all preparations. All chemicals were of analytical grade. Human 
EDTA plasma for standard and control samples was provided by the Red Cross Blood Bank 
(Maastricht, The Netherlands). 
Analytical Techniques 
Gentamicin plasma concentrations were measured with the COBAS INTEGRA 700 analyzer 
(Roche, Mannheim, Germany), using the principle of fluorescence polarization. The error 
pattern of the gentamicin assay was: SD = 0.0129 + 0.0029 C + 0.0034 C2. The assay error 
pattern was determined according to a method described in literature.16 The lower limit of 
determination was 0.1 mg/L. Total (free + protein-bound) flucloxacillin concentrations were 
determined with reversed-phase HPLC in surplus plasma from routine gentamicin assays. 
The HPLC assay method was based on a method described by Thijssen.17 An automatic 
sample injector (model 717, Waters, USA), a pump (model 1050, Hewlett Packard, USA), a 
C8 column, 250 x 4.6 mm, 5 μm (Beckman, USA), combined with a C8 guard column, and an 
UV spectrophotometer detector (model 486, Waters, USA) were used. The eluent was com-
posed of 0.02 mol/L sodium perchlorate in water and acetonitrile (750:250). The separations 
were carried out at room temperature and at a flow rate of 2.0 mL/min. The detection oc-
curred at a wavelength of 220 nm. The error pattern of the assay was: SD = 0.5117 + 0.0108 
C + 0.0002 C2. The lower limit of determination was 3 mg/L. 
To 20 μL surplus plasma, consecutively 20 μL 40 mg/L cloxacillin internal standard solution, 
40 μL 0.5 mol/L citric acid monohydrate, 10 μL 0.5 mol/L HCl, and 1mL methylene chloride 
were added. The solution was extracted for 2 minutes and centrifuged at 1780 x g for 5 min-
PHARMACOKINETICS AND DOSING OF FLUCLOXACILLIN 
 59 
utes. The top water layer was removed with vacuum and the organic layer containing fluclox-
acillin was centrifuged at 1780 x g for 5 minutes. The organic layer was evaporated with ni-
trogen at room temperature. After evaporation, 100 μL eluent was added and the solution 
was mixed for 60 s. This solution (25 μL) was injected into the HPLC. Standard solutions, 
containing 10, 25, 50, 75, and 100 mg/L flucloxacillin, were freshly prepared on the day of 
analysis. The standard plasma samples were processed in the same way as the surplus 
plasma samples. A calibration curve was constructed and total flucloxacillin concentrations in 
surplus plasma samples were calculated. Plasma samples containing more than 100 mg/L 
flucloxacillin were diluted two times with blank plasma. Control plasma samples, containing 
25 mg/L flucloxacillin, were prepared and stored in separate containers at -70°C until analy-
sis. Two control plasma samples were measured in each run. 
Validation 
The HPLC assay method was validated on linearity, precision, accuracy, and extraction re-
covery. The correlation coefficient of the calibration curves (n = 6) was > 0.99. Inter-day pre-
cision and accuracy, measured at 10, 25, 50, 75, and 100 mg/L (n = 6), were < 10% and < 
5%, respectively. Extraction recovery, measured at 50 and 100 mg/L, was 100%. 
Flucloxacillin stability in plasma samples during storage at -70°C was determined by analyz-
ing the control plasma samples stored at -70°C over a period of 30 days at day 3, 7, and 30. 
We did not observe decrease of flucloxacillin concentration. In each run, six standard plasma 
samples, two control plasma samples, and six surplus plasma samples, if possible in dupli-
cate, were included. The duration of each run was about three hours. Flucloxacillin is re-
ported to be stable at 4°C and at room temperature for up to 24 hours.18 
Data Analysis 
Population pharmacokinetic parameters of flucloxacillin and gentamicin were calculated ac-
cording to a one-compartment open model with an iterative two-stage Bayesian fitting proce-
dure (IT2B) (MW\PHARM 3.50, Mediware, The Netherlands). Individual pharmacokinetic 
parameters were calculated by maximum a posteriori Bayesian fitting (MW\PHARM 3.50). 
The Bayesian fitting procedure uses measured drug concentrations, population-based phar-
macokinetic parameters, and the expected variability associated with each measurement to 
determine individualized pharmacokinetic parameters of a patient.19 The initial pharmacoki-
netic parameters of flucloxacillin were derived from Herngren et al9: Kel 0.15 ± 0.05 h-1 and 
V/W 0.28 ± 0.05 L/kg. The initial pharmacokinetic parameters of gentamicin were derived 
from the study of Stolk et al.13 The population pharmacokinetic model was validated with 
Monte Carlo analysis. 20,21 With the MW\PHARM program, 100 sets of 55 simulated patients 
were generated, based on our own original 55 patients. The individual and population phar-
macokinetic parameters of these 5500 simulated patients were calculated with iterative two-
stage Bayesian fitting. The calculated individual pharmacokinetic parameters were compared 
with the ‘‘real’’ (generated) individual pharmacokinetic parameters and the bias (mean error) 
and the root mean square error (RMSE) were determined. The smaller the bias and the 
RMSE, the better the performance of the model. Also, the calculated population pharmacoki-
netic parameters of the 5500 simulated patients were compared with the original population 
pharmacokinetic parameters. 
Statistical analysis was started by checking CL/W and V/W of flucloxacillin for normal distri-
bution with the Kolmogorov-Smirnov test. One-way analysis of variance was used to test if 
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the factor variables (gender, P, AP5, and BC) had a significant effect on CL/W and V/W of 
flucloxacillin. Pearson product-moment correlation coefficients (r) between pharmacokinetic 
parameters of flucloxacillin and covariates were calculated. Multiple regression analysis with 
forward selection and backward elimination techniques was done with CL/W and V/W of flu-
cloxacillin as dependent variables. The significant variables, detected with correlation analy-
sis, were used as possible predictors. The significant predictors of the dependent variable 
were used to establish a direct-effects model. First-order interaction effects between the sig-
nificant predictors were tested for significance by forced entering within a hierarchically con-
structed regression model. Residual analysis was performed to check the studentized re-
siduals of the dependent variable for normality and outliers. Discrete factors were entered as 
dummy variables. Listwise deletion of missing cases was used during the entire regression 
analysis procedure. Statistical analysis was performed using SPSS® 12.0 (Chicago, IL). A P 
value of < 0.05 was considered to be statistically significant. 
Evaluation of Current and Proposed Dosage Regimen 
The efficacy of penicillins, including flucloxacillin, depends on the time the free (not protein-
bound) plasma concentration exceeds the minimum inhibitory concentration (T>MIC).22 In 
neonates, T>MIC should be at least 40%.22 The breakpoint MIC value of an antibiotic defines 
the highest MIC value still to be interpreted as indicating susceptibility to that antibiotic. In 
neonates, flucloxacillin is frequently used for the treatment of infections caused by CoNS, 
including Staphylococcus epidermidis, and less frequently by Staphylococcus aureus. For 
these two bacterial species, the breakpoint MIC values of flucloxacillin are 0.25 and 2.0 
mg/L, respectively.23 Therefore, when treating staphylococcal infections, plasma concentra-
tions of free flucloxacillin should exceed 0.25 or 2.0 mg/L, depending on the species deter-
mination of the blood isolate, during at least 40% of the time. To evaluate the efficacy of the 
current dosage regimen, we calculated T>MIC2.0 and T>MIC0.25 for all patients, using their 
individual pharmacokinetic parameters. The expected level of free flucloxacillin activity was 
calculated, assuming that our neonates had levels of protein binding of 86.3%, according to 
Herngren et al.9 
High intravenous doses of isoxazolyl penicillins have been considered to increase the risk of 
kernicterus in neonates due to displacement of bilirubin at plasma levels above 200 mg/L.9,24 
According to Rolinson et al,25 saturation of albumin with penicillins in adults occurs at plasma 
concentrations of approximately 200 mg/L, when a substantial proportion of available sites 
on the albumin molecules become occupied by antibiotic molecules. This situation may result 
in displacement of bilirubin. Therefore, total flucloxacillin plasma concentrations should not 
exceed the possibly toxic limit of 200 mg/L. To evaluate possible toxicity of the current dos-
age regimen, we calculated flucloxacillin peak concentrations after the second dose of all 
patients, using their individual pharmacokinetic parameters. 
Flucloxacillin plasma concentrations, reached with the proposed dosage regimen, were simu-
lated in MW\PHARM 3.50 for all neonates, using their individual pharmacokinetic parame-
ters. 
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Results 
Patients 
Demographic, anthropometric, and clinical characteristics of the population are presented in 
Table 1. The population consisted of 21 (38.2%) girls and 34 (61.8%) boys. Forty-four (80%) 
neonates were products of singleton pregnancies and 11 (20%) neonates of twin pregnan-
cies. Eighteen (33.3%) out of 54 blood cultures (1 missing) were positive. Only Staphylococ-
cus species were isolated: CoNS (88.9%), including S. epidermidis (25%), and S. aureus 
(11.1%). 
 
 
Table 1. Demographic, Anthropometric, and Clinical Characteristics of the Study Patients 
 Unit N Mean (SD) Range 
GA weeks 55 31.2 (4.1) 26.0-42.0 
PNA days 55 11.1 (9.3) 0-44 
PCA weeks 55 32.7 (4.2) 27.1-42.9 
BW kg 55 1.39 (8.60) 0.37-4.06 
W kg 55 1.49 (0.82) 0.43-4.11 
ApH pH 36 7.19 (0.15) 6.74-7.46 
AP1 points 55 7 (median) 0-10 
AP5 points 55 9 (median) 0-10 
Cr μmol/L 43 64.5 (23.9) 21-115 
Ur mmol/L 40 4.01 (2.45) 0.10-10.00 
CRP mg/L 55 40.0 (49.0) 1.0-234.0 
CL/W gentamicin Lkg-1h-1 55 0.057 (0.016) 0.029-0.096 
t½ gentamicin h 55 9.1 (3.5) 5.0-19.8 
V/W gentamicin L/kg 55 0.69 (0.16) 0.43-1.18 
AP1, 1-min Apgar score; AP5, 5-min Apgar score; ApH, arterial cord pH; BW, birth weight; CL, total body clear-
ance; Cr, plasma creatinine level; CRP, C-reactive protein; GA, gestational age; PCA, postconceptional age; 
PNA, postnatal age; SD, standard deviation; t½, elimination half-life; Ur, plasma urea concentration; V, volume of 
distribution; W, body weight. 
 
Population Pharmacokinetic Parameters 
In total 235 flucloxacillin plasma concentrations (mean 4.3 ± 1.4 per patient) and 267 gen-
tamicin plasma concentrations (4.9 ± 1.4 per patient) were measured. An example of a mod-
elled concentration-time profile of a patient with iterative two-stage Bayesian fitting is shown 
in Figure 1. A plot of the actual measured concentrations versus the estimated concentra-
tions with iterative two-stage Bayesian fitting is presented in Figure 2. 
Mean total body clearance of flucloxacillin corrected for body weight (CL/W) was 0.18 ± 0.10 
Lkg-1h-1, mean flucloxacillin elimination half-life (t½) was 2.6 ± 1.6 h, and mean volume of 
distribution of flucloxacillin corrected for body weight (V/W) was 0.54 ± 0.17 L/kg. Mean 
population pharmacokinetic parameters of gentamicin were: CL/W 0.057 ± 0.016 Lkg-1h-1, t½ 
9.1 ± 3.5 h, and V/W 0.69 ± 0.16 L/kg. 
The population pharmacokinetic parameters of flucloxacillin estimated with Monte Carlo 
analysis (Kel 0.3417 ± 0.1559 h-1 and V/W 0.5486 ± 0.1735 L/kg) were almost identical to the 
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population pharmacokinetic parameters of our original population (Kel 0.3486 ± 0.1662 h-1 and 
V/W 0.5392 ± 0.1698 L/kg). The bias and the RMSE of the Monte Carlo analysis were low, 
respectively, -2.2% and 3.1% for Kel flucloxacillin and 0.9% and 1.5% for V/W flucloxacillin. 
 
 
 
Figure 1. Example of a modelled concentration-time profile of a patient with  
iterative two-stage Bayesian fitting (MW\PHARM 3.50, Mediware, The Netherlands). 
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Figure 2. Correlation between actual measured concentration  
(mg/L) and estimated concentration (mg/L) with iterative two-stage 
Bayesian fitting (MW\PHARM 3.50, Mediware, The Netherlands). 
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Statistical Analysis 
Few statistically significant Pearson correlations were found between covariates and phar-
macokinetic parameters. CL/W flucloxacillin correlated significantly with the covariates GA (r 
= 0.340, P = 0.011) and PCA (r = 0.319, P = 0.018). The correlation between CL/W fluclox-
acillin and GA is shown in Figure 3. V/W flucloxacillin correlated significantly with the covari-
ates V/W gentamicin (r = 0.397, P = 0.003) and AP1 (r = -0.266, P = 0.049). Multiple regres-
sion analysis was done with CL/W flucloxacillin (normally distributed) as dependent variable 
and GA and PCA as possible predictors and with V/W flucloxacillin as dependent variable 
and V/W gentamicin and AP1 as possible predictors. GA was a significant predictor of CL/W 
flucloxacillin (r2 = 0.116, n = 55), and V/W gentamicin was a significant predictor of V/W flu-
cloxacillin (r2 = 0.158, n = 55). The standardized studentized residuals of all models seemed 
to be normally distributed. 
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Figure 3. Correlation between total body clearance of flucloxacillin  
corrected for body weight (CL/W) (Lkg-1h-1) and gestational age (GA) (weeks). 
 
Evaluation of Current and Proposed Dosage Regimen 
Flucloxacillin peak and trough concentrations after the second dose and T>MIC0.25 and 
T>MIC2.0 of each patient are shown in Table 2. With the current dosage regimen, T>MIC0.25 
was much higher than 40% in all neonates, except one (36%). T>MIC2.0 was lower than 40% 
in 17 (31%) of the 55 neonates. None of the neonates had peak concentrations above 200 
mg/L. Thus, the current dosage regimen resulted in ineffective plasma concentrations in sev-
eral patients, especially for the treatment of S. aureus. S. aureus is a less common, but viru-
lent pathogen isolated in late-onset infections. Therefore, the initial flucloxacillin dose should 
result in free plasma concentrations exceeding 2.0 mg/L during at least 40% of the time. We 
suggest an initial dose of 25 mg/kg/4 h. After isolation of the causative agent of infection, the 
initial dose should be either reduced to 10 mg/kg/6 h, when CoNS are isolated, or main-
tained, when S. aureus is isolated. 
5
CHAPTER 5 
 64 
With the suggested initial dose of 25 mg/kg/4 h, simulated peak concentrations did not ex-
ceed 200 mg/L: 76.4 ± 31.1 mg/L (mean ± SD) with a range of 31.8 to 161.2 mg/L (Fig. 4). 
Simulated T>MIC2.0 was at least 40% in 52 neonates with a mean of 86.3% ± 19.5% (mean ± 
SD) with a range of 29% to 100% (Fig. 4). With the dose of 10 mg/kg/6 h, simulated peak 
concentrations were all < 200 mg/L with a mean of 25.2 ± 8.8 mg/L (range 11.8 to 48.8 
mg/L). Simulated T>MIC0.25 was satisfactory (> 40%) in all neonates with a mean of 94.1% ± 
12.7% (range 52% to 100%).  
 
 
Table 2. Flucloxacillin Peak and Trough Concentrations after the Second Dose and the Time the Free Concentra-
tion Exceeds the Minimum Inhibitory Concentration of 0.25 (T>MIC0.25) and 2.0 mg/L (T>MIC2.0) 
SD, standard deviation; *median (percentile 25/75). 
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Figure 4. Histogram at the time above the minimum inhibitory concentration (T>MIC) of 2.0 mg/L (%) (A) and 
histogram at the peak concentration (mg/L) (B) with the proposed dosage regimen (25 mg/kg/4 h). 
 
Dose 
(mg/kg) 
Interval  
(h) 
N Trough (SD) 
(mg/L) 
Peak (SD) 
(mg/L)  
T>MIC0.25 (SD) 
(%) 
T>MIC2.0 (SD) 
(%) 
25  12 4 1.4 (2.2) 
0.4 (0.1/3.6)* 
38.4 (5.5) 66.0 (26.7) 24.5 (16.2) 
35 8 1 0.3 82.0 70 33 
35 12 2 0.8 (0.1) 70.9 (19.2) 76.5 (2.1) 34.0 (5.7) 
50 8 9 10.8 (16.9) 
3.8 (1.5/14.6)* 
114.4 (38.8) 94.9 (12.6) 64.1 (28.6) 
50 12 39 8.0 (11.2) 
2.2 (0.9/13.3)* 
106.3 (31.0) 91.4 (12.8) 59.3 (26.0) 
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Discussion 
Population Pharmacokinetic Parameters 
We found a high inter-individual variability in the pharmacokinetic parameters. CL/W fluclox-
acillin was about three times higher than CL/W gentamicin in our neonates. This suggests 
the presence of other elimination pathways in addition to glomerular filtration, such as tubular 
secretion and nonrenal clearance (metabolism), because gentamicin is completely cleared 
by glomerular filtration.12 However, tubular secretion is believed to be very inefficient in neo-
nates.26 For isoxazolyl penicillins, including flucloxacillin, about 30% to 40% of their total 
plasma clearance in healthy adults is by a nonrenal route.27,28 The formation of inactive peni-
cilloic acids seems to be the main route by which these penicillins are metabolized.29 In addi-
tion, as the result of other metabolic pathways, active metabolites are formed.30 Because the 
formation of active metabolites is small (about 10% in adults) and their antibacterial activities 
are of the same order of magnitude as the parent compounds, it is not to be expected that 
their formation will have any influence on the outcome of therapy.30 
The population pharmacokinetic parameters of flucloxacillin in the present study differ from 
the population pharmacokinetic parameters found by Herngren et al.9 CL/W (0.04 Lkg-1h-1) 
and V/W (0.28 L/kg) were low and t½ (4.6 h) was high compared with our results. These dif-
ferences may be attributable to their relatively small study population (n = 9) and the use of 
the method of disk diffusion in nutrient agar instead of the more specific HPLC method. The 
population pharmacokinetic parameters found by Adrianzén Vargas et al10 were: CL/W 0.12 
Lkg-1h-1, t½ 2.6 h, and V/W 0.45 L/kg. They studied older neonates (n = 11), as a result of 
which we would expect a higher CL/W, a shorter t½, and a lower V/W. However, cardiopul-
monary bypass has an effect on drug pharmacokinetics and leads to a decreased CL/W, a 
prolonged t½, and an increased V/W.10 
Predictors of Individual Pharmacokinetic Parameters 
The investigated covariates had no or very low predictive power for the pharmacokinetic pa-
rameters of flucloxacillin. The age parameters GA and PNA had low predictability for CL/W 
flucloxacillin in contrast with our earlier study of amoxicillin.31 Herngren et al9 found a signifi-
cant negative correlation between elimination half-life of flucloxacillin and gestational age in 9 
neonates (r = -0.661, P < 0.05). The correlation between elimination half-life of flucloxacillin 
and gestational age in our population was not statistically significant (r = -0.257, P = 0.058). 
This difference may be associated with the size of the study population, 9 versus 55 neo-
nates, and with the range of gestational age of the population, 33 to 41 versus 26 to 42 
weeks. 
In our previous study we found that CL/W gentamicin and 1/Cr were very good predictors of 
CL/W amoxicillin in (pre)term neonates.31 In the present study we did not find a significant 
correlation between CL/W flucloxacillin and the covariates CL/W gentamicin and 1/Cr. There-
fore, we think that the relative contribution of glomerular filtration to the elimination of fluclox-
acillin is small compared with that of gentamicin and amoxicillin. Glomerular filtration of flu-
cloxacillin may be lowered by its high protein binding.32 
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Dosage Regimen 
The efficacy of the current and proposed dosage regimen was investigated by calculating the 
time the free plasma concentration of flucloxacillin exceeds the MIC. The free plasma con-
centration was assumed as constant in all neonates. However, there are a lot of factors, such 
as circulating substances (albumin, bilirubin, free fatty acids), disease, albumin structure, 
plasma volume, and GA, that may influence protein binding and cause inter-patient variability 
in protein binding.33 Herngren et al9 found a significant positive correlation between protein 
binding (mean 86.3%) and GA (mean 36.6 weeks, range 33 to 41 weeks). Therefore, we 
expect part of our neonates (mean GA 31.2 weeks, range 26 to 42 weeks) to have protein 
binding below 86.3% and a favourably higher T>MIC. Knowledge of the free fraction would 
be beneficial in estimating the required dose. However, there are ethical and practical prob-
lems in obtaining a sufficiently large sample for analysis from neonates and the assay is 
time-consuming and complicated.  
We suggest one dose for all neonates, irrespective of their age, because of the low correla-
tion between CL/W flucloxacillin and the covariates GA and PNA. This is in contrast with the 
existing dosing schemes. For initial therapy, we suggest a higher dose and a more frequent 
administration than is customary now to reach sufficiently high plasma concentrations. Con-
tinuous infusion could be considered as an alternative for frequent intermittent administration, 
because flucloxacillin is reported to be stable at room temperature for 24 hours.18 We sug-
gest an initial dose of 25 mg/kg/4 h. This initial dose should be reduced to 10 mg/kg/6 h 
when CoNS are isolated. Dose reduction lowers the costs and prevents unnecessary use of 
the antibiotic, which promotes bacterial overgrowth and resistance. These new dosage regi-
mens need prospective verification, because they have been tested only by the original data 
from which the regimens derived. 
Simulation with the new dosage regimens indicated that satisfactory plasma concentrations 
were reached in 52 of the 55 neonates. A large inter-individual variability of T>MIC and peak 
concentrations was observed with these dosage regimens. With the suggested initial dose of 
25 mg/kg/4 h, simulated T>MIC2.0 did not exceed 40% in three neonates (29%, 35%, and 
35%). With a higher initial dose, e.g. 30 mg/kg/4 h, simulated T>MIC2.0 did exceed 40% in all 
55 neonates, but simulated peak concentrations came very close to the toxic limit of 200 
mg/L in several patients. We think it is safer to have T>MIC2.0 somewhat below the desired 
40% in a few patients instead of risking toxic levels in several patients. Flucloxacillin is al-
ways administered in combination with gentamicin for the initial treatment of suspected late-
onset sepsis. Moreover, the toxic limit of 200 mg/L found in adults might even be lower in 
neonates, because of the lower binding capacity of albumin in neonates.34 
The suggested dosage regimens will result in plasma concentrations sufficiently high for the 
treatment of infections which are easily reached by antibiotics, such as bacteremia, urinary 
tract infection, and intravascular catheter-related infection. However, in patients who are 
suspected of infections which are not easily reached by antibiotics, such as meningitis, 
higher doses should be necessary. In these patients, flucloxacillin administration ought to be 
reconsidered, because doses higher than our proposed dosage regimens may result in 
plasma concentrations exceeding 200 mg/L. 
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Conclusions 
We suggest an initial flucloxacillin dose of 25 mg/kg/4 h for all neonates, irrespective of their 
GA and PNA. This dose is higher than the customary dose. After isolation of the causative 
agent of infection, the initial dose should be either reduced to 10 mg/kg/6 h, when oxacillin 
sensitive CoNS are isolated, or maintained, when S. aureus is isolated. Simulation with these 
new dosage regimens showed that satisfactory plasma concentrations were reached in 52 of 
the 55 neonates. However, the regimens need prospective verification. Moreover, the exact 
role of neonatal protein binding needs to be further investigated. 
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Abstract 
The isoxazolyl penicillins, including flucloxacillin, have the highest levels of plasma protein 
binding among the semisynthetic penicillins. Since only the free fraction of the penicillin is 
pharmacologically active, it would be useful to measure both protein-bound and free fluclox-
acillin to determine its protein binding. Until now, flucloxacillin protein binding in newborn 
infants has been investigated in only two studies with relatively small populations. In the pre-
sent study, flucloxacillin protein binding was investigated in 56 (preterm) infants aged 3 to 87 
days (gestational age 25 to 41 weeks). Surplus plasma samples from routine gentamicin 
assays of each infant were collected and combined to obtain a sufficiently large sample for 
analysis. Free flucloxacillin was separated from protein-bound flucloxacillin using ultrafiltra-
tion. Reversed-phase HPLC with UV detection was used to measure free flucloxacillin con-
centrations in ultrafiltrate and total flucloxacillin concentrations in pooled plasma. Flucloxacil-
lin protein binding was 74.5% ± 13.1% (mean ± SD) with a high variability among the infants 
(34.3% to 89.7%). High Pearson correlations were found between protein binding and the 
covariates - plasma albumin concentration (r = 0.804, P < 0.001, n = 18) and plasma 
creatinine concentration (r = -0.601, P < 0.001, n = 45). Statistically significant but less strik-
ing correlations were found between protein binding and gestational age, postconceptional 
age, body weight, and triglyceride concentration. Because of the high variability of protein 
binding among infants, it is difficult to devise a flucloxacillin dosage regimen effective for all 
infants. Individualized dosing, based on free flucloxacillin concentrations, might help to opti-
mize treatment of late-onset neonatal sepsis, but practical obstacles will probably prevent 
analysis of free flucloxacillin concentrations in newborn infants on a routine basis.   
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Introduction 
Flucloxacillin is used frequently for the initial treatment of late-onset neonatal sepsis in Dutch 
hospitals, in spite of limited information about protein binding.1 In an earlier study, we investi-
gated flucloxacillin population pharmacokinetics, flucloxacillin dosing, and the influence of 
covariates on the individual pharmacokinetic parameters in 55 (pre)term neonates.2 To 
evaluate the efficacy of the dosage regimen, the time the free (non-protein-bound) plasma 
concentration exceeded the minimum inhibitory concentration (T>MIC) was calculated.2 A 
dosage regimen, based on a T>MIC of at least 40%, as advised in the literature3, was de-
vised. Based on previous studies it was assumed that all neonates had a protein binding 
level of 86.3%.4 However, there are many covariates that affect protein binding, including 
circulating substances (albumin, bilirubin, free fatty acids), disease, presence of other drugs, 
plasma volume, and gestational age (GA).5  
The isoxazolyl penicillins, including flucloxacillin, have the highest levels of plasma protein 
binding among the semisynthetic penicillins.6 Plasma protein binding is the major factor de-
termining extravascular penetration of antimicrobial agents into tissues.7 Zeitlinger et al8 
showed a significant decrease in bacterial killing by penicillins after the addition of albumin, 
suggesting that only the free fraction of the penicillin is available for bacterial killing. There-
fore, knowledge of the plasma protein binding of flucloxacillin and the covariates affecting its 
protein binding is essential for estimating the flucloxacillin dose required for effective treat-
ment of late-onset neonatal sepsis.  
Plasma protein binding of flucloxacillin has already been studied in healthy adults9-11, patients 
with pacemakers12, postpartum mothers13, and patients with impaired kidney function10. Pro-
tein binding values ranged from 91% in pacemaker patients12 to 95.7% in healthy adults9. In 
neonates, plasma protein binding of drugs is generally lower than in adults.5 In two studies, 
flucloxacillin protein binding was investigated in relatively small populations of newborn in-
fants. Herngren et al4 found a mean protein binding value of 86.3% (range 82.7% to 89.7%) 
in nine newborn infants aged 7.2 days (mean GA 36.6 weeks). In another study, plasma pro-
tein binding of flucloxacillin was determined in vitro by equilibrium dialysis in newborn infants 
at delivery and during their first postnatal week.13 Median protein binding values of 93.4% 
(range 90.5% to 95.8%) and 88.6% (range 86.5% to 90.6%) were reported in 22 infants im-
mediately after delivery (mean GA 40.1 weeks) and in two infants during the first week (5th to 
7th day) after delivery (mean GA 40.7 weeks), respectively.13 Free flucloxacillin was sepa-
rated from protein-bound flucloxacillin using an ultrafiltration method9,11 or equilibrium dialy-
sis4,10,12,13. Protein binding values of flucloxacillin, as determined by equilibrium dialysis and 
ultrafiltration, are comparable.14 Flucloxacillin concentrations were measured with a microbi-
ological assay4,9,11-13 or a more specific high-performance liquid chromatography (HPLC) 
method10. 
In this study, plasma protein binding of flucloxacillin was investigated in a large population of 
(preterm) infants, who were treated with flucloxacillin for (suspected) late-onset sepsis. Sev-
eral covariates possibly affecting flucloxacillin protein binding were tested for significance 
and the implications for flucloxacillin dosing of variation in free-fraction were explored. 
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Materials and Methods 
Patients 
The study was approved by the local Medical Ethical Committee. Plasma of fifty-six (pre)term 
infants was investigated. All infants had been admitted to the neonatal ward at the University 
Hospital of Maastricht and received flucloxacillin in combination with gentamicin for (sus-
pected) late-onset sepsis.  
Sample Preparation of Non-Protein-Bound Flucloxacillin 
Free flucloxacillin was separated from protein-bound flucloxacillin in samples from 56 infants 
(Table 1) by ultrafiltration, using a Centrifree® micropartition device (Millipore Corporation, 
Bedford, MA).15 This system required a minimum plasma volume of 150 μL for analysis.15 
Unused portions of plasma samples from routine gentamicin assays were collected and 
combined for each infant to obtain a sufficiently large sample. 5.5 ± 2.1 plasma samples 
were collected per infant that had been obtained over a period of 3.4 ± 1.3 days (mean ± 
SD). For more efficient flow rates, fibrin was first removed by centrifugation at 1780 x g for 5 
minutes at room temperature. Micropartition devices were then centrifuged at 4000 rpm for 
25 minutes at room temperature using a 33° fixed-angle centrifuge rotor for optimum solvent 
flow.  
Assay of Free Flucloxacillin 
Flucloxacillin was provided by Synopharm (Barsbüttel, Germany). A stock solution of fluclox-
acillin (1000 mg/L) was freshly prepared on the day of analysis by dissolving 11 mg sodium 
flucloxacillin in 10 mL water. This stock solution was diluted 10 fold with 0.9% saline solution 
to obtain the working solution (100 mg/L). Calibration standards were prepared by adding the 
required amount of working solution to 0.9% saline solution to obtain concentrations of 10, 
25, 50, 75, and 100 mg/L of flucloxacillin. A quality control sample, containing 100 mg/L of 
flucloxacillin in plasma, was prepared and ultrafiltrated. The calibration standards, the ultrafil-
trate of the quality control, and the ultrafiltrates of the infants, were directly injected (25 μL) 
into a RP-HPLC with UV detection.2 Mean concentration of free flucloxacillin in the ultrafil-
trates of the quality controls was 8.1 ± 0.6 mg/L (n = 11) (mean ± SD). Thus, mean protein 
binding of flucloxacillin in quality control adult plasma was 91.9%. Coefficient of variation was 
7.8%. The RP-HPLC assay was validated for linearity, precision, and accuracy. The correla-
tion coefficients of the calibration curves (n = 6) were > 0.99. To determine inter-day preci-
sion and accuracy, three concentrations of flucloxacillin (0.5, 1, and 25 mg/L) were prepared 
in blank neonatal ultrafiltrate and each of them was analyzed six times. Coefficients of varia-
tion were 14.0%, 9.3%, and 3.3%, respectively. Inaccuracy, measured at the three concen-
trations, was < 15% (+13.0%, -1.5%, and +3.2%, respectively). The lowest free flucloxacillin 
concentration measured in the ultrafiltrates from infants was 0.6 mg/L. 
Total Flucloxacillin Concentrations 
Analysis of total flucloxacillin concentrations in pooled plasma was performed as described 
previously.2 RP-HPLC with UV detection was used. The mobile phase consisted of perchlo-
rate buffer and acetonitrile. Cloxacillin was used as internal standard and methylene chloride 
was used for extraction.  
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Protein Binding 
The binding of flucloxacillin to plasma proteins was determined using the following equation: 
(Cp-Cu)/Cp · 100%, where Cp and Cu are the concentrations in plasma (total) and ultrafiltrate 
(free), respectively.   
Covariates Affecting Protein Binding 
Pearson correlation coefficients (r) between flucloxacillin protein binding and covariates pos-
sibly affecting this protein binding were calculated with SPSS® 12.0 (Chicago, IL), considering 
a P value of < 0.05 as being statistically significant. Covariates possibly affecting flucloxacillin 
protein binding were: plasma albumin concentration, unconjugated plasma bilirubin concen-
tration, plasma concentration of free fatty acids, and plasma creatinine concentration.5,16 Un-
fortunately, the plasma concentration of free fatty acids was measured in only one infant. 
However, plasma triglyceride concentrations were measured in 38 infants. Pearson correla-
tion coefficients were also calculated between protein binding and GA, postnatal age (PNA), 
postconceptional age (PCA), and body weight. Co-administered drugs with a high protein 
binding might also affect flucloxacillin protein binding. Therefore, complete concomitant 
medication of each infant was registered. One-way analysis of variance was used to test if 
the co-administered drugs with high protein binding had a significant influence on flucloxacil-
lin protein binding. Because of the large number of missing values, mainly of plasma albumin 
concentration, regression analysis was not performed. 
 
Results 
Patients 
The main characteristics of the infants are presented in Table 1. The population consisted of 
30 boys (54%) and 26 girls (46%). In 53 infants (3 missing), blood cultures were taken. 
Twenty-six (49%) of the 53 blood cultures were positive, most frequently with coagulase 
negative staphylococci (CoNS) (77%).  
 
 
Table 1. Demographic, Anthropometric, and Clinical Characteristics of 56 Infants 
 Unit N Mean (SD) Range 
GA weeks 55 31.2 (4.7) 25.0-41.4 
PNA days 56 20.4 (18.7) 3-87 
PCA weeks 55 34.1 (4.6) 27.7-42.7 
Weight kg 56 1.63 (0.83) 0.67-3.90 
Creatinine μmol/L 45 57.3 (26.8) 20-139 
Total bilirubin μmol/L 33 95.7 (50.7) 3-193 
Unconjugated bilirubin μmol/L 13 68.1 (51.7) 7-163.6 
Albumin g/L 18 17.5 (5.1) 10.1-27.8 
GA, gestational age; PCA, postconceptional age; PNA, postnatal age; SD, standard deviation. 
 
 
6
CHAPTER 6 
 74 
Protein Binding 
Free and total flucloxacillin plasma concentrations of all infants are illustrated in Figure 1. 
Plasma protein binding of flucloxacillin was 74.5% ± 13.1% (mean ± SD) (median 79.4%) 
with a range of 34.3% to 89.7%. The distribution of the free fraction of flucloxacillin among 
the infants is illustrated in Figure 2.   
Covariates Affecting Protein Binding 
Statistically significant Pearson correlation coefficients were found between flucloxacillin pro-
tein binding and plasma albumin concentration (r = 0.804, P < 0.001, n = 18), plasma 
creatinine concentration (r = -0.601, P < 0.001, n = 45), body weight (r = 0.475, P < 0.001, n 
= 56), PCA (r = 0.450, P = 0.001, n = 55), GA (r = 0.374, P = 0.005, n = 55), and plasma 
triglyceride concentration (r = -0.326, P = 0.046, n = 38). The relationship between fluclox-
acillin protein binding and plasma albumin concentration is shown in Figure 3. The regres-
sion equation to predict flucloxacillin protein binding from plasma albumin concentration was: 
flucloxacillin protein binding (%) = 23.05 + 2.58 · plasma albumin concentration (g/L) (r2 = 
0.647, n = 18). The standard error of the estimate (SEE), which is a measure of the accuracy 
of the predictions made with the regression line, was 9.92. The correlation between fluclox-
acillin protein binding and plasma creatinine concentration is presented in Figure 4. Fifteen 
infants received co-administered drugs with a protein binding > 90% (e.g. furosemide, hydro-
chlorothiazide/triamterene, and indometacin). We did not observe a significant difference in 
protein binding between these 15 infants and the other 41 infants.  
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Figure 1. Free versus total flucloxacillin plasma concentrations of 56 infants. 
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Figure 2. Distribution of free flucloxacillin among 56 infants. 
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Figure 3. Correlation between flucloxacillin protein binding and plasma  
albumin concentration (n = 18). The equation of the regression line was  
y = 23.05 + 2.58x and the coefficient of correlation was 0.804 (P < 0.001).   
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Figure 4. Correlation between flucloxacillin protein binding  
and plasma creatinine concentration (n = 45). 
 
 
Discussion 
In the present study, flucloxacillin has been shown to be highly bound to plasma proteins in 
neonates (median 79.4%). However, even higher protein binding values were found by 
Herngren et al.4,13 The high inter-infant variability in protein binding found in the present study 
(34.3% to 89.7%) and the differences between our results and the results reported by Hern-
gren et al4,13 might be explained by difference in covariates affecting protein binding. 
A highly significant relationship was found between the plasma protein binding of flucloxacil-
lin and plasma albumin concentration (r = 0.804, P < 0.001, n = 18). Herngren et al13 found a 
correlation coefficient of 0.612 (P < 0.01) between the molar concentration of plasma albumin 
and plasma binding ratio (bound flucloxacillin/unbound flucloxacillin) in 22 newborn infants. 
Mean plasma albumin concentration (17.5 g/L) measured in 18 of our 56 infants (mean GA 
30.2 weeks, mean PNA 27.1 days) was somewhat lower than that generally seen in healthy 
infants of the same age.17 It should be noted that in our Neonatal Unit plasma albumin con-
centrations are only measured in sick infants suffering usually from oedema or liver dysfunc-
tion. Mean protein binding of these 18 infants was 68.2% and was considerably lower that 
the protein binding found by Herngren et al4,13, which may partly be explained by the differ-
ence in plasma albumin concentration, 17.5 g/L versus 33 g/L4 and 39.0 g/L13.  
We also noticed a significant relationship between flucloxacillin protein binding and plasma 
creatinine concentration (r = -0.601, P < 0.001, n = 45), as noted for phenytoin, theophylline, 
methotrexate and diazepam (r = -0.87, -0.80, -0.79, and -0.67, respectively, P < 0.001) in 
chronic renal failure.16 This relationship supports earlier findings that endogenous acidic 
ligands, which accumulate in renal failure, act as binding inhibitors. These ligands are re-
sponsible for decreased plasma protein binding in renal failure of many acidic drugs, includ-
ing the isoxazolyl penicillins.10,18-21 In addition, decreased drug binding in renal failure may be 
at least partly due to altered albumin composition.22 Moreover, the relationship between flu-
cloxacillin protein binding and plasma creatinine concentration may partly be explained by 
PROTEIN BINDING OF FLUCLOXACILLIN 
 77 
the relationship between protein binding and GA, PCA, and body weight, since plasma 
creatinine concentration is inversely related to these parameters. 
Two other endogenous compounds that may affect plasma protein binding of flucloxacillin in 
neonates are free fatty acids and unconjugated bilirubin. Unfortunately, the plasma concen-
tration of free fatty acids was measured in only one infant. However, we found a significant 
relationship between flucloxacillin protein binding and plasma triglyceride concentration. Flu-
cloxacillin protein binding decreased when the plasma concentration of triglyceride, which is 
split into glycerol and free fatty acids in the intestine, increased. Most neonates have high 
levels of unconjugated bilirubin in plasma, since bilirubin production is increased and bilirubin 
removal is decreased in the first weeks of life.5 Unconjugated bilirubin is capable of binding to 
plasma albumin. Isoxazolyl penicillins may displace bilirubin from albumin binding sites.4,23 
Bilirubin itself may also displace drugs from their binding to albumin and thereby increase the 
free fraction of the drug.24 However, we did not find any relationship between flucloxacillin 
protein binding and unconjugated plasma bilirubin concentration. In contrast, a significant 
correlation between total (conjugated + unconjugated) bilirubin/albumin molar concentration 
ratio and flucloxacillin binding ratio (bound/unbound flucloxacillin) was reported by Herngren 
et al.4 We did not observe a significant correlation between total bilirubin/albumin ratio, which 
could be calculated for only 12 of our 56 infants, and flucloxacillin binding ratio. It should be 
noted that total bilirubin concentration varies considerably in the first few days/weeks of life.5 
In most newborn infants, total plasma bilirubin concentration increases during the first week 
after birth and then decreases, because metabolic processes become more efficient in its 
removal.5 Mean total bilirubin concentration in our infants (mean PNA 16.5 days) was low 
compared to the concentration in the much younger infants (mean PNA 7.2 days) investi-
gated by Herngren et al4 (95.7 versus 131 μmol/L).  
The plasma protein binding of flucloxacillin was also significantly correlated with GA, PCA, 
and body weight. Herngren et al4 also showed a significant correlation between flucloxacillin 
protein binding and GA. This may partly be explained by the quantitative and qualitative 
changes in plasma proteins during foetal and postnatal growth.25 Plasma albumin concentra-
tion and binding affinity increases with gestational and postnatal age.5 Moreover, plasma 
volume and, therefore, the absolute number of drug binding sites increase during gestational 
and postnatal growth.5 GA, PCA, and body weight of our population are lower than those of 
the populations investigated by Herngren et al4,13, which may partly explain the lower protein 
binding found in the present study. 
In an earlier study, we investigated flucloxacillin population pharmacokinetics, flucloxacillin 
dosing, and the influence of covariates on the individual pharmacokinetic parameters in 55 
(pre)term neonates.2 An initial flucloxacillin dose of 25 mg/kg/4 h was suggested for all neo-
nates. This initial dose should be either reduced to 10 mg/kg/6 h, when oxacillin sensitive 
CoNS are isolated, or maintained, when S. aureus is isolated.2 The free flucloxacillin fraction 
was assumed to be 13.7% in all neonates, based on the literature.4 Patient characteristics 
were comparable to the characteristics in this study, except for PNA (11.1 days versus 20.4 
days). In the present study, the free flucloxacillin fraction was higher than 13.7% in most in-
fants, but in nine infants it was lower than 13.7%. To reach effective plasma concentrations 
in all infants, including those having a low free flucloxacillin fraction, the earlier suggested 
dosage regimens should probably be increased. However, higher doses may result in 
plasma concentrations exceeding the possibly toxic limit of 200 mg/L.2 Thus, because of the 
high variability of protein binding among infants, caused by many covariates, it is difficult to 
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devise a flucloxacillin dosage regimen effective for all infants. Individual measurement of the 
free flucloxacillin fraction would be beneficial in estimating the required dose, but methods for 
separating free and protein-bound drug are labour intensive and there are ethical and practi-
cal problems in obtaining a sufficiently large sample for analysis from newborn infants.5 
Moreover, the literature5 indicates that newborns display a continuingly changing plasma 
composition, which might affect protein binding. Subsequently, frequent dosage adaptation is 
required in newborn infants. Perhaps, plasma albumin measurement could be helpful in pre-
dicting protein binding or use of alternative antibiotics could be considered. 
 
Conclusions 
Predicting flucloxacillin protein binding in newborn infants, aimed at optimal dosing of this 
drug, is very difficult, because many covariates affect protein binding. A high variability of 
flucloxacillin protein binding was demonstrated among 56 infants with (suspected) late-onset 
sepsis. Effective treatment with flucloxacillin should take this variability into account. Indi-
vidualized dosing, based on free flucloxacillin concentrations, might help to optimize treat-
ment of late-onset neonatal sepsis, but practical obstacles will probably prevent their analysis 
in newborn infants on a routine basis. We suggest further studies or efforts to develop an 
inexpensive and efficient test to measure free flucloxacillin concentrations in neonates. 
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Abstract 
Few reports have addressed neonatal rifampicin plasma concentrations and data on neona-
tal rifampicin pharmacokinetics are completely lacking. Therefore, plasma concentrations of 
rifampicin and its main metabolite 25-O-desacetylrifampicin (DES) were measured in 123 
surplus plasma samples from routine vancomycin monitoring in 21 neonates using reversed-
phase HPLC. Rifampicin peak and trough plasma concentrations were 4.66 ± 1.47 mg/L and 
0.21 ± 0.20 mg/L, respectively, after a dose of 8.5 ± 2.1 (mean ± SD) mg/kg per day. A sig-
nificant linear relationship between rifampicin dose and peak plasma concentrations was 
found, but inter-patient variability was high. Pharmacokinetic parameters of rifampicin were 
calculated according to a one-compartment open model with iterative two-stage Bayesian 
fitting (MW\PHARM 3.60, Mediware, The Netherlands). First-order elimination constant, vol-
ume of distribution corrected for weight, total body clearance corrected for weight (CL/W), 
and elimination half-life were 0.16 ± 0.06 h-1, 1.84 ± 0.59 L/kg, 0.28 ± 0.11 Lkg-1h-1, and 4.9 ± 
1.7 h, respectively. A high Pearson correlation was found between CL/W rifampicin and the 
covariates plasma creatinine and CL/W gentamicin of a preceding gentamicin treatment 
course, r = 0.728 (n = 17) and r = 0.837 (n = 12), respectively. DES was detected in each 
plasma sample. Therefore, rifampicin seems to be eliminated by both renal and metabolic 
pathways in neonates. In 8 study patients, plasma concentrations of rifampicin and DES 
were measured again after two weeks of therapy. CL/W rifampicin was significantly higher 
(67% ± 50%). The authors suggest maintaining the current dose regimen of 10 mg/kg once a 
day. Because of the large inter-patient variability in rifampicin plasma concentrations and 
CL/W increase during therapy, the authors suggest monitoring rifampicin peak and trough 
plasma concentrations to avoid low plasma concentrations. More research is needed to de-
termine well-founded dosing guidelines. 
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Introduction 
The initial antibiotic choice in suspected late-onset neonatal infections depends on the local 
susceptibility patterns. In most Dutch hospitals, flucloxacillin, in combination with gentamicin, 
is used for this indication.1 After isolation of the causative agent of infection, antibiotic choice 
ought to be reconsidered based on the expected or determined susceptibility pattern of the 
isolate. Flucloxacillin is used for the treatment of infections caused by methicillin-susceptible 
staphylococci, whereas vancomycin is the drug of choice for infections caused by methicillin-
resistant coagulase negative staphylococci (CoNS), mainly Staphylococcus epidermidis.2 
However, some neonates do not respond to treatment with vancomycin.2 The addition of 
rifampicin is a safe and effective option in the treatment of these persistent staphylococcal 
infections in neonates.2-5 However, rifampicin and vancomycin have been shown to be syn-
ergistic, indifferent, or antagonistic, depending on the rifampicin concentration. Rifampicin 
and vancomycin seem to be antagonistic when the concentrations of rifampicin are high.6,7  
Rifampicin has a wide spectrum of antibacterial activity and is the most active anti-
staphylococcal agent known.4 Rifampicin is highly soluble in lipids and has the unique ability 
to penetrate phagocytic leukocytes and kill intracellular staphylococci.8 Plasma protein bind-
ing of rifampicin in adults is about 80%.9 Rifampicin cannot be used as monotherapy be-
cause resistance may develop during therapy.10  
Several studies have investigated the pharmacokinetics of IV rifampicin in children11,12 and 
adults.13-15 In neonates, rifampicin pharmacokinetics have not been studied yet. Only one 
small study investigated peak and trough plasma concentrations after IV rifampicin admini-
stration in four neonates (gestational age 30 to 40 weeks, mean 35 weeks).2 However, rifam-
picin pharmacokinetic parameters were not reported. Because very little is known about the 
pharmacokinetics of rifampicin in neonates, the current dosage regimen5 is based on phar-
macokinetic data from studies in children and adults. Knowledge about neonatal rifampicin 
pharmacokinetics is essential for optimizing rifampicin dosing in neonates. Therefore, we 
have determined plasma concentrations of rifampicin in surplus plasma samples from routine 
vancomycin monitoring in 21 neonates, who received cotreatment with IV rifampicin and 
vancomycin for persistent staphylococcal bacteremia, in order to determine the pharmacoki-
netic parameters of rifampicin. We also investigated the influence of several demographic, 
anthropometric, and clinical covariates on the individual pharmacokinetic parameters of ri-
fampicin. 
 
Materials and Methods 
Patients 
The study was approved by the local Ethical Board. Twenty-one neonates, admitted to the 
neonatal ward at the University Hospital of Maastricht from July, 2002 through November, 
2005, participated in the study. They were treated concurrently with IV rifampicin and van-
comycin for persistent staphylococcal infections. To calculate the individual pharmacokinetic 
parameters of rifampicin, at least two surplus plasma samples from routine vancomycin as-
says of each neonate had to be available. Patient information concerning gestational age 
(GA), postnatal age (PNA), postconceptional age (PCA), birth weight (BW), body weight (W), 
gender, multiple pregnancy (P), 1-minute Apgar score (AP1), 5-minute Apgar score (AP5), 
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plasma creatinine (Cr), plasma urea concentration (Ur), C-reactive protein (CRP), and blood 
culture result (BC) was obtained from patient records. 
Demographic, Anthropometric, and Clinical Characteristics 
The demographic, anthropometric, and clinical characteristics of the neonates are described 
in Table 1. Of the eight patients who were treated with rifampicin for more than two weeks, 
GA and PNA were 28.4 ± 2.3 weeks and 24.8 ± 15.9 days (at the beginning of the rifampicin 
therapy), respectively. Seven neonates (33%) were immature (GA < 28 weeks) and 12 neo-
nates (57%) were premature (28 ≤ GA < 37 weeks). These 19 preterm neonates had a low 
birth weight (< 2500 g) and 18 of them had a very low birth weight (< 1500 g). Seventeen 
neonates (81%) were male. Fourteen neonates (67%) were products of singleton pregnan-
cies and 7 neonates (33%) were products of twin pregnancies. Seventeen out of the 19 
blood cultures (89%) (2 missing) were positive. In all cases, CoNS, including Staphylococcus 
epidermidis (41%), were isolated. 
 
 
Table 1. Demographic, Anthropometric, and Clinical Characteristics of the Neonates 
 Unit N Mean (SD) Median (Percentile 25/75) Range 
GA weeks 21 29.9 (4.1) 28.6 (26.9/31.5) 26.0-41.3 
PNA days 21 24.8 (13.4) 18.0 (15.0/34.5) 11-55 
PCA weeks 21 33.5 (5.0) 31.4 (30.4/36.2) 28.3-48.0 
BW kg 21 1.24 (1.02) 0.88 (0.68/1.30) 0.37-4.30 
W kg 21 1.58 (1.14) 1.25 (0.92/1.50) 0.49-4.78 
AP1 points 21 6.6 (2.9) 8 (5/9) 0-9 
AP5 points 21 8.6 (1.8) 9 (9/9) 2-10 
Cr μmol/L 17 52.1 (13.4) 52.0 (42.5/58.0) 33.0-85.0 
Ur mmol/L 17 3.5 (2.6) 2.7 (1.9/5.3) 0.4-11.1 
CRP mg/L 20 74.7 (45.8) 62.0 (38.3/116.8) 2.9-158.0 
AP1, 1-minute Apgar score; AP5, 5-minute Apgar score; BW, birth weight; Cr, plasma creatinine level; CRP, C-
reactive protein; GA, gestational age; PCA, postconceptional age; PNA, postnatal age; SD, standard deviation; 
Ur, plasma urea concentration; W, body weight. 
 
Drug Administration and Sample Collection 
Rifampicin was dosed at 5 to 10 mg/kg intravenously on a once-a-day schedule: 5 mg/kg (n 
= 4), 7 mg/kg (n = 1), 9 mg/kg (n = 3), and 10 mg/kg (n = 12). One neonate received 5 mg/kg 
every 12 hours. Rifampicin was infused over 30 minutes using an electronic infusion pump.5 
Neonates with a PCA of < 30, 30 to 33, 34 to 37, 38 to 44, and > 44 weeks received 20, 20, 
20, 15, and 10 mg/kg vancomycin with an interval of 24, 18, 12, 8, and 6 hours, respectively. 
Vancomycin was infused over 60 minutes using an electronic infusion pump.5 Dosing times 
of vancomycin and rifampicin were different. Dosing times were recorded in the patient’s 
medical record by nursing staff each time rifampicin and vancomycin were administered.  
Twelve neonates were treated with a combination therapy of IV flucloxacillin and gentamicin 
for 4.5 ± 2.3 days (range 2 to 9 days) preceding rifampicin therapy. However, this combina-
tion therapy turned out to be unsuccessful in all 12 neonates and therapy with IV vancomycin 
was started. The other nine neonates were treated from the beginning with IV vancomycin. 
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After 3.3 ± 2.6 days (range 0 to 8 days), IV rifampicin was added. The duration of the rifam-
picin course was 16.4 ± 7.1 days (4 to 29 days). After the addition of rifampicin, 14 out of the 
17 positive blood cultures were sterile after 6.6 ± 5.0 days (1 to 16 days). The other three 
positive blood cultures also became sterile, but it was not known after how many days. 
Therapeutic drug monitoring of vancomycin was performed on a routine basis. Plasma sam-
ples were drawn by heel prick just before and two hours after the end of the vancomycin in-
fusion. Sampling times were recorded in the patient’s medical record by nursing staff each 
time a blood sample was taken for vancomycin analysis. Surplus plasma samples from rou-
tine vancomycin assays were collected and frozen at -70°C until the rifampicin assay was 
performed. Heparin was used as anticoagulant. We collected 5.9 ± 3.0 plasma samples per 
neonate during 3.7 ± 1.8 days (mean ± SD). Fourteen of the 21 neonates were treated with 
rifampicin for more than two weeks. Surplus plasma samples after 2 weeks of treatment were 
available for only 8 of these 14 neonates. In this second study period, we collected 5.9 ± 2.6 
plasma samples per neonate during 3.4 ± 1.6 days. 
Chemicals 
Ammonium sulphate ((NH4)2SO4, CAS 7783-20-2), methanol (CH4O, CAS 67-56-1), and Ti-
triplex® III (C10H14N2Na2O8·2H2O, CAS 6381-92-6) were obtained from Merck (Darmstadt, 
Germany). Rifampicin (C43H58N4O12, CAS 13292-46-1) was provided by Yamanouchi Pharma 
(Leiderdorp, The Netherlands) and its main metabolite, 25-O-desacetylrifampicin 
(C41H56N4O11), was a gift from Novartis Pharma (Arnhem, The Netherlands). Ultrapure water 
was used in all preparations. All chemicals were of HPLC grade. Human EDTA plasma for 
standard and control samples was provided by the Red Cross Blood Bank (Maastricht, The 
Netherlands). 
High-Performance Liquid Chromatography 
Rifampicin and 25-O-desacetylrifampicin plasma concentrations were measured with re-
versed-phase high-performance liquid chromatography (RP-HPLC). The RP-HPLC assay 
method was based on a method described by Chandi et al.16 The RP-HPLC system con-
sisted of an automatic sample injector (model 717, Waters, USA), a pump (model 1050, 
Hewlett Packard, USA), a C18 symmetry column, 150 x 4.6 mm, 5 μm (Waters, USA) com-
bined with a C18 guard column, and an UV spectrophotometric detector (model 486, Waters, 
USA). The effluent was composed of 0.005 mol/L disodium EDTA (0.93 g Titriplex® III in 500 
mL ultrapure water) and methanol (200:300). The separations were carried out at room tem-
perature and at a flow rate of 1.0 mL/min. The detection was performed at a wavelength of 
340 nm. The assay error pattern was determined according to a method described in the 
literature.17 To determine the error pattern, we measured plasma samples at twelve concen-
tration levels (0.1, 0.2, 0.3, 0.4, 1, 2, 4, 6, 8, 10, 25, and 50 mg/L) on six separate days. The 
relationship between the measured plasma concentration and SD was fitted with a second-
order polynomial function. The error pattern of the rifampicin assay was: SD = 0.0173 + 
0.0455 C + 0.0002 C2. The error pattern of the 25-O-desacetylrifampicin assay was: SD = 
0.0561 + 0.0323 C + 0.0005 C2. The lower limit of quantification (LLOQ) of rifampicin was 0.1 
mg/L and the LLOQ of 25-O-desacetylrifampicin was 0.4 mg/L. The rifampicin and 25-O-
desacetylrifampicin response at the LLOQ was at least 5 times the response compared to 
blank response and was identifiable, discrete, and reproducible with a precision of < 20% 
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(11% and 15%, respectively) and accuracy of 80% to 120% (104% and 112%, respectively) 
according to guidelines in the literature.18  
Ammonium sulphate (10 μL, 5%) and 80 μL methanol were added to 40 μL surplus plasma, 
and the solution was mixed for 1 minute. The solution was centrifuged at 10,500 x g for 5 
minutes. Following centrifugation, chromatography of the supernatant (30 μL) was accom-
plished. Standard solutions, containing 2, 4, 6, 8, and 10 mg/L rifampicin and 25-O-
desacetylrifampicin, were freshly prepared on the day of analysis. The standard plasma 
samples were processed in the same way as the surplus plasma samples. A calibration 
curve was constructed and concentrations of rifampicin and 25-O-desacetylrifampicin in sur-
plus plasma samples were calculated. Control plasma samples, containing 5 mg/L rifampicin 
and 25-O-desacetylrifampicin, were prepared and stored in separate containers at -70°C until 
analysis. 
Validation 
The RP-HPLC assay method was validated for linearity, precision, and accuracy. The corre-
lation coefficient of the calibration curves was > 0.99 (n = 6). Inter-day precision and inaccu-
racy, measured at 2, 4, 6, 8, and 10 mg/L (n = 6), were < 10% and < 5%, respectively, for 
both rifampicin and 25-O-desacetylrifampicin.  
Rifampicin stability in plasma samples during storage at -70°C was determined by analyzing 
the control plasma samples stored at -70°C in each run during the entire measurement pe-
riod of approximately 2 months. We did not observe any decrease of rifampicin concentra-
tion. This has been found earlier by Peloquin.19 We also measured rifampicin plasma con-
centrations after 1, 2, 3, and 4 hours at room temperature (in the dark). We observed no loss 
under these conditions although Peloquin19 found rifampicin plasma extracts began to decay 
after approximately 4 hours at room temperature (under fluorescent ceiling lights). In each 
run, six standard plasma samples, one control plasma sample, and five surplus plasma sam-
ples were included. The duration of each run was about two hours. We checked rifampicin 
stability during the run by analyzing one control plasma sample at the beginning of the run 
and one control plasma sample at the end of the run after approximately two hours. We did 
not see any difference in rifampicin concentration between the two control plasma samples. 
Data Analysis 
The individual pharmacokinetic parameters of rifampicin and vancomycin were calculated by 
maximum a posteriori Bayesian fitting (MW\PHARM 3.60, Mediware, The Netherlands). The 
population pharmacokinetic parameters were calculated with an iterative two-stage Bayesian 
fitting procedure (IT2B) (MW\PHARM 3.60). The Bayesian method uses measured drug con-
centrations, population-based parameters, and the expected variability associated with each 
measurement to determine individualized pharmacokinetic parameters of a patient.20 Analy-
sis took place according to a one-compartment open model. The initial pharmacokinetic pa-
rameters of rifampicin, Kel 0.10 ± 0.05 h-1 and V/W 1.60 ± 0.80 L/kg, were extrapolated from 
rifampicin pharmacokinetic data in adults. The initial pharmacokinetic parameters of vanco-
mycin were derived from the study by de Beer et al.21 The population pharmacokinetic model 
was validated with Monte Carlo analysis.22,23 With the MW\PHARM program, 100 sets of 21 
simulated patients were generated, based on our own original 21 patients. The individual and 
population pharmacokinetic parameters of these 2100 simulated patients were calculated 
with iterative two-stage Bayesian fitting. The calculated individual pharmacokinetic parame-
PHARMACOKINETICS OF RIFAMPICIN 
 87 
ters were compared with the ‘real’ (generated) individual pharmacokinetic parameters and 
the bias (mean error) and the root mean square error (RMSE) were determined. The smaller 
the bias and the RMSE, the better the performance of the model. Also, the calculated popu-
lation pharmacokinetic parameters of the 2100 simulated patients were compared with the 
original population pharmacokinetic parameters.  
We calculated peak (one hour after the beginning of the rifampicin infusion) and trough (just 
before the infusion) plasma concentrations of rifampicin after the second dose of each neo-
nate in MW\PHARM 3.60, using the individual pharmacokinetic parameters.  
Statistical analysis was performed using SPSS® 12.0 (Chicago, IL). P < 0.05 was considered 
to be statistically significant. The paired-samples t test was used to investigate the differ-
ences between the individual pharmacokinetic parameters at the beginning of the rifampicin 
therapy and the individual pharmacokinetic parameters after two weeks of rifampicin therapy. 
While it is known that statistical evaluation of estimates such as pharmacokinetic parameter 
values is not nearly as accurate as that of direct observations, nevertheless the paired-
samples t test was used. To investigate the influence of several demographic, anthropomet-
ric, and clinical covariates on the individual pharmacokinetic parameters of rifampicin, we 
calculated Pearson product-moment correlation coefficients. The investigated covariates 
were: GA, PNA, PCA, BW, W, gender, P, AP1, AP5, 1/Cr, Ur, CRP, BC, pharmacokinetic 
parameters of vancomycin, and pharmacokinetic parameters of gentamicin of a preceding 
gentamicin treatment course. Gentamicin clearance is an ideal exogenous marker for estima-
tion of the glomerular filtration rate in neonates, since gentamicin is eliminated almost entirely 
by the kidney and gentamicin clearance can easily be calculated during routine therapeutic 
drug monitoring.24,25 One-way ANOVA was used to test if the factor variables (gender, P, and 
BC) had a significant effect on the individual pharmacokinetic parameters of rifampicin. 
 
Results 
Plasma Concentrations 
We measured plasma concentrations of rifampicin and 25-O-desacetylrifampicin in 123 
plasma samples. These plasma concentrations are plotted against the time after rifampicin 
administration in Figure 1. Calculated rifampicin peak and trough plasma concentrations after 
the second dose were 4.66 ± 1.47 mg/L (range 2.06 to 6.87 mg/L) and 0.21 ± 0.20 mg/L 
(range 0.01 to 0.75 mg/L), respectively, after a dose of 8.5 ± 2.1 mg/kg. A significant linear 
relationship between rifampicin dose and peak plasma concentrations was found (r = 0.556, 
P = 0.009), but inter-patient variability was high (Figure 2). 
Plasma concentrations of rifampicin and 25-O-desacetylrifampicin were also measured after 
2 weeks of rifampicin therapy in 8 neonates (Figure 3). Both rifampicin and 25-O-
desacetylrifampicin concentrations were lower after two weeks of rifampicin therapy. 
 
7
CHAPTER 7 
 88 
0 5 10 15 20 25
0
2
4
6
8 RIFconcentration
DES
concentration
Time after RIF 
administration 
(hours)
Plasma 
concentration 
(mg/L)
 
Figure 1. Plasma concentrations of rifampicin (RIF) and  
25-O-desacetylrifampicin (DES) plotted against the time  
after rifampicin administration. 
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Figure 2. Rifampicin peak plasma concentrations after the  
second dose plotted against the rifampicin dose. 
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Figure 3. Plasma concentrations of rifampicin (RIF) and 25-O-desacetylrifampicin (DES) plotted against the time 
after rifampicin administration at the beginning of the rifampicin therapy (A) and after two weeks of therapy (B) in 
eight study patients. 
 
Population Pharmacokinetic Parameters 
An example of a modelled concentration-time profile of a patient with iterative two-stage 
Bayesian fitting is shown in Figure 4. A plot of the actual measured concentrations versus the 
estimated concentrations with iterative two-stage Bayesian fitting is presented in Figure 5. 
Rifampicin first-order elimination constant (Kel), volume of distribution corrected for body 
weight (V/W), total body clearance corrected for body weight (CL/W), and elimination half-life 
(t½) were 0.16 ± 0.06 h-1, 1.84 ± 0.59 L/kg, 0.28 ± 0.11 Lkg-1h-1, and 4.9 ± 1.7 h, respectively.  
The population pharmacokinetic parameters of rifampicin, estimated with Monte Carlo analy-
sis (Kel 0.1600 ± 0.0562 h-1 and V/W 1.7949 ± 0.5998 L/kg), were almost identical to the 
population pharmacokinetic parameters of our original population (Kel 0.1592 ± 0.0570 h-1 
and V/W 1.8425 ± 0.5888 L/kg). The bias and the RMSE of the Monte Carlo analysis were 
low, 0.3% and 2.3%, respectively, for Kel rifampicin and -1.6% and 4.3%, respectively, for 
V/W rifampicin.  
We also calculated the individual pharmacokinetic parameters of rifampicin after 2 weeks of 
rifampicin therapy in 8 of the 21 neonates. Mean pharmacokinetic parameters at the begin-
ning of the rifampicin therapy, mean pharmacokinetic parameters after two weeks of rifam-
picin therapy, and the results of the paired-samples t test of these eight neonates are pre-
sented in Table 2. The difference between CL/W rifampicin at the beginning and after 2 
weeks of rifampicin therapy was statistically significant (P = 0.007; n = 8). CL/W rifampicin 
increased significantly (67% ± 50%). These results suggest that CL/W rifampicin increases 
during the first two weeks of rifampicin therapy. 
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Figure 4. Example of a modelled concentration-time profile of a patient with  
iterative two-stage Bayesian fitting (MW\PHARM 3.60, Mediware, The Netherlands). 
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Figure 5. Correlation between rifampicin actual measured  
concentration and estimated concentration with iterative two-stage  
Bayesian fitting (MW\PHARM 3.60, Mediware, The Netherlands). 
 
 
Table 2. Differences between Mean Pharmacokinetic Parameters at the Beginning and after Two Weeks of  
Rifampicin (RIF) Therapy (n = 8)  
Pharmacokinetic  
Parameter 
Begin RIF Therapy After Two Weeks RIF 
Therapy 
Paired-Samples T Test 
Kel (h-1) 0.13 (± 0.06) 0.18 (± 0.06) -1.55 (P = 0.165) 
V/W (L/kg) 1.77 (± 0.31) 2.33 (± 1.19) -1.30 (P = 0.236) 
CL/W (Lkg-1h-1) 0.22 (± 0.07) 0.36 (± 0.15) -3.74 (P = 0.007) 
t½ (h) 6.1 (± 1.9) 4.4 (± 1.7) 1.91 (P = 0.099) 
CL, total body clearance; Kel, first-order elimination constant; t½, elimination half-life; V, volume of distribution; W, 
body weight. 
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Influence of Covariates on Individual Pharmacokinetic Parameters 
We found statistically significant Pearson correlations between CL/W rifampicin and the co-
variates CL/W gentamicin, 1/Cr, GA, PCA, CL/W vancomycin, BW, and W (Table 3). The 
highest correlations were found between CL/W rifampicin and the covariates CL/W gen-
tamicin and 1/Cr, r = 0.837 and r = 0.728, respectively (Figure 6). 
 
 
Table 3. Statistically Significant Pearson Correlations between the Individual Pharmacokinetic Parameters of 
Rifampicin (RIF) and the Demographic, Anthropometric, and Clinical Covariates 
 CL/W RIF V/W RIF Kel RIF t½ RIF 
CL/W / V/W / Kel / t½ gentamicin (n = 12) 0.837** NS NS NS 
1/Cr (n = 17) 0.728** NS 0.506* -0.580* 
GA (n = 21) 0.600** 0.468* NS NS 
PCA (n = 21) 0.557** 0.477* NS NS 
CL/W / V/W / Kel / t½ vancomycin (n = 21) 0.552** NS NS 0.508* 
BW (n = 21) 0.510* 0.568** NS NS 
W (n = 21) 0.449* 0.560** NS NS 
BW, birth weight; CL, total body clearance; Cr, plasma creatinine level; GA, gestational age; Kel, first-order elimi-
nation constant; PCA, postconceptional age; t½, elimination half-life; V, volume of distribution; W, body weight; 
NS, not significant; *correlation is significant at the 0.05 level (2-tailed); **correlation is significant at the 0.01 level 
(2-tailed). 
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Figure 6. Correlation between total body clearance of rifampicin corrected for body weight (CL/W) and the covari-
ates CL/W gentamicin (n = 12) (A) and 1/plasma creatinine (1/Cr) (n = 17) (B). 
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Discussion 
Plasma Concentrations 
We calculated rifampicin peak and trough plasma concentrations after the second dose of 
each neonate. Rifampicin peak and trough plasma concentrations after IV rifampicin admini-
stration have been investigated earlier in neonates. Tan et al2 investigated peak and trough 
plasma concentrations in four neonates (GA 30 to 40 weeks, mean 35 weeks), who received 
5 mg/kg rifampicin. Rifampicin peak concentration was 4.02 ± 1.22 mg/L (range 3.13 to 5.82 
mg/L). Five of our 21 neonates also received a rifampicin dose of 5 mg/kg. Rifampicin peak 
concentration of these neonates was 3.42 ± 1.15 mg/L (range 2.06 to 4.91 mg/L). The 
plasma concentrations seem to be effective in the treatment of persistent staphylococcal 
bacteremia, since all blood cultures became sterile.  
After two weeks of therapy rifampicin concentrations were lower than at the beginning of 
therapy. This might be explained by auto-induction of metabolism of the liver, which metabo-
lizes rifampicin more rapidly to 25-O-desacetylrifampicin.4 However, 25-O-desacetylrifampicin 
concentrations were also lower after two weeks of rifampicin therapy. Probably, the elimina-
tion of 25-O-desacetylrifampicin also increases during rifampicin therapy. Mouton et al26 also 
found decreasing 25-O-desacetylrifampicin concentrations during therapy in adults. We did 
not observe any change in plasma creatinine after two weeks of rifampicin therapy. This 
suggests that the increase in the elimination of rifampicin and 25-O-desacetylrifampicin dur-
ing rifampicin therapy is caused by an increase of non-renal clearance. 
Population Pharmacokinetic Parameters 
Pharmacokinetic data of rifampicin are only available of older children and adults. Koup et 
al12 and Nahata et al11 both investigated the pharmacokinetics of IV rifampicin in older pediat-
ric patients. Koup et al12 studied 12 pediatric patients aged 3 months to 12.8 years (mean 4.6 
years). Kel, V/W, CL/W, and t½ of rifampicin were 0.37 h-1, 0.63 L/kg, 0.16 Lkg-1h-1, and 1.94 
h, respectively. Nahata et al11 investigated the pharmacokinetics of IV rifampicin in 9 pediat-
ric patients aged 1 day to 18 years (mean 5.6 years), who received a single dose of rifam-
picin (20 mg/kg). Kel, V/W, CL/W, and t½ of rifampicin were 0.25 h-1, 1.1 L/kg, 0.29 Lkg-1h-1, 
and 2.8 h, respectively. In the present study, V/W was higher. This difference is possibly due 
to a larger total body water compartment in neonates compared to infants and older children. 
In the present study, t½ was longer and Kel lower. The elimination of rifampicin seems to be 
less efficient in neonates compared to infants and older children.  
We compared the pharmacokinetic parameters of rifampicin at the beginning of the rifampicin 
therapy with the pharmacokinetic parameters after two weeks of therapy. Our results suggest 
that CL/W rifampicin increases during the first two weeks of rifampicin therapy. This has 
been found earlier by other investigators in children and adults.9,12,14 Rifampicin induces its 
own metabolism (auto-induction) and, as a result, clearance increases markedly during the 
first two weeks of treatment.4 In adults, equilibrium is reached after one to two weeks of 
treatment, after which no more changes occur.27 Therefore, it seems prudent to consider 
adaptation of the rifampicin dose after two weeks of therapy in neonates. For future research, 
it would be useful to develop a one-compartment open model integrated with a correction for 
auto-induction in MW\PHARM. 
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Predictors of Individual Pharmacokinetic Parameters 
We investigated the influence of several demographic, anthropometric, and clinical covari-
ates on the individual pharmacokinetic parameters of rifampicin. The correlation between 
CL/W rifampicin and the covariates CL/W gentamicin and 1/Cr was high. About 70% of the 
inter-patient variance in CL/W rifampicin could be explained by CL/W gentamicin and more 
than 50% could be explained by 1/Cr. CL/W gentamicin and plasma creatinine are both pre-
dictors of the glomerular filtration rate in neonates.24,25 Therefore, we conclude that glomeru-
lar filtration rate plays an important role in the elimination of rifampicin in neonates. Holdi-
ness28 reported that 37% of the rifampicin dose (10 mg/kg) was recovered in urine in the first 
12 hours in neonates compared with 2.5% of the dose in older children. In each plasma 
sample, 25-O-desacetylrifampicin was found. Therefore, both non-renal clearance (metabo-
lism) and renal clearance are involved in the elimination of rifampicin in neonates. 
Rifampicin Dosing 
It is not possible to provide a definite dosing scheme for rifampicin in neonates at this stage. 
Information about effective pharmacodynamics of rifampicin, the role of protein binding, the 
free-fraction, and pharmacodynamic interaction with coadministered vancomycin or fluclox-
acillin is insufficient at this moment. For now, we suggest maintaining the current dose regi-
men of 10 mg/kg intravenously on a once-a-day schedule, until more information is available. 
The rifampicin plasma concentrations achieved with this dose seem to be effective in the 
treatment of persistent staphylococcal bacteremia, since all blood cultures became sterile. It 
may be appropriate to shorten the dosing interval from 24 to 12 hours to avoid prolonged 
intervals of low plasma concentrations. Tan et al2 and Shama et al3 both found prompt clear-
ance of persistent staphylococcal infections in neonates within only five days after the addi-
tion of rifampicin to vancomycin. In both studies, the neonates received rifampicin (5 mg/kg 
and 10 mg/kg, respectively) twice a day. More research is needed to determine well-founded 
dosing guidelines. 
 
Conclusions 
We suggest maintaining the current rifampicin dose regimen of 10 mg/kg on a once-a-day 
schedule, until information about effective pharmacodynamics of rifampicin, the role of pro-
tein binding and the free-fraction, and pharmacodynamic interaction with co-administered 
vancomycin or flucloxacillin is available. Because of the large inter-patient variability in rifam-
picin plasma concentrations and in CL/W increase during rifampicin therapy, we suggest 
monitoring of peak and trough plasma concentrations to avoid low plasma concentrations. 
More pharmacokinetic work is required to give a solid base for neonatal rifampicin dose 
guidelines. 
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Abstract 
Artificial neural networks (ANNs) are powerful tools to study complex non-linear relation-
ships. ANNs have successfully been applied to population pharmacokinetic data analysis. In 
the present study, the applicability of ANN for the prediction of gentamicin clearance in neo-
nates from covariates was compared with multiple linear regression analysis. Data of the 
potential predictors gestational age (GA), postnatal age (PNA), gender, multiple pregnancy, 
plasma creatinine concentration, and C-reactive protein were collected from 325 neonates 
treated with gentamicin. Gentamicin clearance was calculated with Bayesian fitting using 
plasma concentrations derived from routine therapeutic drug monitoring. All but five patients 
were randomized and divided into 10 groups (folds) of 32 patients. Each fold served once as 
a validation set, while the remaining 9 folds and 5 cases (293 patients) were used to estab-
lish the linear regression and neural network model. Each model was validated with the cor-
responding validation set and gentamicin clearances in 320 patients were predicted. Various 
ANNs were tested, but a single-layer perceptron with a linear transfer function appeared to 
be the most accurate. The ANN was created, trained, and validated with the software pack-
age Matlab® (MathWorks, Natick, MA). Both ANN and linear regression identified GA, PNA, 
and plasma creatinine concentration as the most important predictors of gentamicin clear-
ance and ANN. Predictive performance measures (median (squared) prediction error) were 
compared using the Wilcoxon matched paired test. Linear regression predictions were sig-
nificantly less biased and more precise than ANN predictions. The results suggest that ANNs 
may be less useful for simple linear input-output relationships. The input-output relationship 
(linear or non-linear) should be taken into account when selecting between ANNs and linear 
regression for pharmacokinetic modeling.  
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Introduction 
Artificial neural networks (ANNs) are powerful tools to study complex multivariate non-linear 
relationships and have successfully been applied to population pharmacokinetic data analy-
sis.1-4 Ritschel et al1 used ANNs to predict human pharmacokinetic parameters from a com-
bination of physicochemical properties and animal pharmacokinetic parameters. Chow et al2 
and Brier et al3 compared the predictive performance of ANNs with that of a standard popula-
tion pharmacokinetic modeling program (NONMEM) for tobramycin plasma concentrations in 
pediatric patients and for gentamicin plasma concentrations in adult patients, respectively. 
They concluded that ANNs and NONMEM provided comparable predictions of plasma drug 
concentrations. Yamamura4 reviewed the clinical application of ANNs to predict plasma con-
centrations and pharmacokinetic parameters of aminoglycosides in severely ill patients. In 
general, the predictive performance of ANNs was shown to be superior to that of multiple 
linear regression analysis.4 However, the prediction of aminoglycoside clearance using 
plasma creatinine concentration by linear regression analysis was much better than the ANN 
prediction, suggesting that aminoglycoside clearance can be evaluated without complicated 
non-linear calculations.4 
The strength of ANNs is that they do not assume a specific model. Instead, they learn to es-
tablish the input and output relationships from the data provided to them.2 ANNs do not re-
quire assumptions about the distribution of the data and inputs that are highly correlated can 
be used.3 Therefore, we investigated the applicability of ANN for the prediction of gentamicin 
clearance in 325 neonates. Predictive performance was compared with that of multiple linear 
regression analysis.  
 
Materials and Methods 
Patient Characteristics 
In this study, we included 325 neonates admitted to the neonatal ward at the University Hos-
pital of Maastricht between 1996 and 2005 and receiving gentamicin treatment. Patient gen-
tamicin clearances corrected for weight (CL/W) were derived from routine therapeutic drug 
monitoring data collected for pharmacokinetic studies.5-7 Gentamicin clearance was calcu-
lated according to a one-compartment model with Bayesian fitting (MW\PHARM 3.60, Medi-
ware, The Netherlands). The following potential predictors of gentamicin clearance were col-
lected from patient records: gestational age (GA), postnatal age (PNA), gender, multiple 
pregnancy, plasma creatinine concentration, and C-reactive protein (CRP). There were no 
missing values. 
All 325 patients were randomized and divided into 10 groups (folds) of 32 patients, leaving 5 
patients that were used only for modeling and not for validation. Each fold served once as a 
validation set, while the remaining 9 folds and 5 cases (293 patients) were used to establish 
the linear regression model and the neural network model (10-fold cross-validation). Conse-
quently, gentamicin clearances in 320 patients were predicted.  
Multiple Linear Regression Analysis 
Multiple linear regression analysis was performed using SPSS® 12.0 (Chicago, IL). CL/W 
gentamicin was checked for normal distribution with the Kolmogorov-Smirnov test. Pearson 
product-moment correlation coefficients were calculated between CL/W gentamicin and GA, 
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PNA, plasma creatinine concentration, and CRP. One-way analysis of variance (ANOVA) 
was used to test whether gender and multiple pregnancy had a significant effect on CL/W 
gentamicin. Multiple linear regression analysis with forward selection and backward elimina-
tion techniques was performed with CL/W gentamicin as dependent variable. The significant 
variables, detected with one-way ANOVA and correlation analysis, were used as possible 
predictors. The significant predictors of CL/W gentamicin were used to establish a direct-
effects model. First-order interaction effects between the significant predictors were tested 
for significance by forced entering within a hierarchically constructed regression model. Dis-
crete factors were entered as dummy variables. A P value of < 0.05 was considered to be 
statistically significant. 
Artificial Neural Network 
ANNs are inspired by biological principles of learning in neural networks. An ANN consists of 
several artificial neurons arranged in layers, i.e. input, hidden, and output layers. All neurons 
in one layer are connected to all neurons within the next layer. Each connection has a real-
valued weight that specifies its strength. Input data used to predict the outcome are pre-
sented to the input layer and values are propagated from each neuron to every neuron in the 
next layer. Eventually, a result is delivered from the output layer. Initially, all connections are 
assigned random weights. The propagated output is compared to the true value, the so-
called target output, and the difference between the two values (mean squared error) is fed 
back into the ANN (backpropagation of error), gradually changing the weights as to minimize 
the error.8-10 A high mean squared error results in higher adjustment of the ANN weights than 
a low mean squared error (error minimization). In this way, the ANN is learning the relation-
ships between the input data and results (supervised training).8 Once fully trained, the ANN 
can be applied to future cases where the outcome is unknown.  
The ANN used for the prediction of CL/W gentamicin consisted of a plain (single-layer) per-
ceptron without any hidden layers, which provided the best results compared to multilayer 
ANNs that can learn more complex input-output mappings (data not shown). The structure of 
this ANN is presented in Figure 1. The ANN was created, trained, and validated with the 
software package Matlab® (MathWorks, Natick, MA). The perceptron consisted of a linear 
transfer function that maps the values of the weighted input. It is also possible to use a non-
linear transfer function, but the linear transfer function performed better than a non-linear 
transfer function (data not shown). Before ANN training, the input variables were pre-
processed. This pre-processing was done by normalization of the input and target values to a 
range between 0 and 1. The error minimization, as described above, was combined with 
Bayesian regularization that varies the number of free parameters (weights) to prevent over-
fitting.11 Training terminated when the number of weights and error stabilized. After success-
ful completion of training, the input data of the 32 patients in the validation set were pre-
sented to the input layer of the trained ANN and transformed into a predicted value of CL/W 
gentamicin.   
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Figure 1. Artificial neural network (ANN) structure used for the prediction of gentamicin clearance in neonates. 
The circle represents the perceptron with linear transfer function and w1, w2, w3, w4, w5, and w6 represent the 
ANN input weights. 
 
Predictive Performance 
To evaluate the predictive performance of linear regression analysis and ANN, the mean 
prediction error (ME) (bias) and the mean squared prediction error (MSE) (precision) were 
used.12 The prediction error (PE) is a measure of the proximity of a predicted value to a true 
value (predicted value - true value).12 The ME and MSE should be presented as a mean 
value when (squared) PE’s are normally distributed and as a median value when (squared) 
PE’s are non-normally distributed.13 The property of distribution of (squared) PE’s was de-
termined using the Kolmogorov-Smirnov test.13 When PE’s have both positive and negative 
signs, ME might not present the real bias of a predictive method, because positive and nega-
tive PE’s can offset each other.13 Therefore, ME was divided into two parts: +ME (all positive 
PE’s) and -ME (all negative PE’s).13  
Sheiner and Beal suggested evaluating the predictive performance between two predictive 
methods by observing whether the 95% confidence intervals for the relative performance 
measures (ΔME and ΔMSE) include zero.12 However, when the number of samples is quite 
large and samples are non-normally distributed, it might be more convenient to use the Wil-
coxon matched paired test, since the amount of calculation of the confidence intervals for a 
large number of non-normally distributed samples is discouraging.13 Therefore, the statistical 
measures of the predictive performance of linear regression analysis and ANN were com-
pared using the Wilcoxon matched paired test. A P value of < 0.05 was considered to be 
statistically significant. 
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Results 
Multiple Linear Regression Analysis 
Significant predictors of CL/W gentamicin were GA, PNA, and plasma creatinine concentra-
tion. Mean standardized beta coefficients, which represent the relative contribution of GA, 
PNA, and plasma creatinine concentration in the prediction of CL/W gentamicin, were 0.300, 
0.202, and -0.496, respectively. 
Artificial Neural Network 
The advantage of using a perceptron is that the learned weights represent the influence of 
each input variable on CL/W gentamicin. The ANN weights of GA, PNA, and plasma 
creatinine concentration were 0.192, 0.267, and -0.366, respectively. The ANN weights of 
gender, multiple pregnancy, and CRP were -0.009, -0.017, and 0.072, respectively. 
Predictive Performance 
The relationship between the true values of CL/W gentamicin calculated with Bayesian fitting 
and the predicted values of CL/W gentamicin from linear regression analysis and ANN is 
illustrated in Figure 2. The statistical measures of the predictive performance of linear re-
gression analysis and ANN are summarized in Table 1. PE’s and squared PE’s of linear re-
gression analysis and ANN were not normally distributed (P < 0.05 and P < 0.001, respec-
tively). ANN resulted in significantly higher ME and MSE than linear regression analysis (P < 
0.001 and P = 0.008, respectively).  
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Figure 2. Plots of true values of gentamicin clearance (Lkg-1h-1) calculated with Bayesian fitting and predicted 
values of gentamicin clearance for multiple linear regression analysis (A) and artificial neural network modeling 
(B). 
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Table 1. Statistical Measures of Predictive Performance of Multiple Linear Regression Analysis and Artificial  
Neural Network (ANN) Modeling for Gentamicin Clearance (Lkg-1h-1) (n = 320 neonates) 
 Linear Regression Analysis ANN 
True value calculated with Bayesian fitting 0.0488* 0.0488* 
Predicted value  0.0481* 0.0501* 
Median prediction error (ME) 
+ME 
-ME  
0.00123** 
0.00564 (n = 174)** 
-0.00799 (n = 146)** 
0.00306** 
0.00759 (n = 194)** 
-0.00820 (n = 126)** 
Median squared prediction error (MSE) 0.00004** 0.00006** 
*Mean; **Median. 
 
 
Discussion 
In the present study, gentamicin clearances in neonates were predicted by multiple linear 
regression analysis and ANN from patient data. Both methods indicated that GA, PNA, and 
plasma creatinine concentration were the most important predictors of gentamicin clearance, 
as expected from earlier studies.7,14,15 ANNs are often seen as a black box.10 The advantage 
of using a perceptron is that the ANN weights represent the influence of each predictor on 
gentamicin clearance. The disadvantage is that, in contrast to their multilayer counterparts, 
single-layer perceptrons with linear transfer function can only learn a linear mapping from 
input to output.  
Multiple linear regression analysis showed better predictive performance than ANN for gen-
tamicin clearance in neonates. Linear regression predictions of gentamicin clearance were 
significantly less biased and more precise than ANN predictions. Yamamura4 concluded from 
his review that the prediction of aminoglycoside clearance using plasma creatinine concen-
tration by linear regression analysis was much better than the ANN prediction in severely ill 
patients. Our results support his idea that the clearance of aminoglycosides, including gen-
tamicin, can be evaluated without complicated non-linear calculations.4 This idea may be 
reinforced by our finding that a perceptron with linear transfer function performed better than 
a perceptron with non-linear transfer function for the prediction of gentamicin clearance in our 
neonates. Moreover, the simplest ANN structure, a single-layer perceptron without any hid-
den layers, provided the best results compared to more complicate multilayer ANNs. The 
complexity of the transformation from input to output pattern is proportional to the number of 
hidden nodes. If the number of hidden nodes is too large for the transformation required, the 
ANN will exhibit suboptimal behaviour.10 
In contrast, ANNs have successfully been used for the prediction of peak and trough plasma 
concentrations of aminoglycosides based on patient-related parameters, dosing regimens, 
time of blood drawn, and the resulting aminoglycoside plasma concentrations.2-4,16 ANNs 
may therefore be useful tools for population pharmacokinetic data analysis. However, our 
results suggest that ANNs may be less useful for simple linear input-output relationships. 
Therefore, the input-output relationship (linear or non-linear) should be taken into account 
when selecting between ANNs and multiple linear regression analysis for pharmacokinetic 
modeling.  
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Conclusions 
The relationship between gentamicin clearance and covariates, including GA, PNA, and 
plasma creatinine concentration, was linear. For modeling linear input-output relationships, 
statistical methods, such as linear regression analysis, are most suitable. Therefore, the in-
put-output relationship (linear or non-linear) should be taken into account when selecting 
between ANNs and linear regression analysis for pharmacokinetic modeling. However, when 
the nature of the input-output relationship is not clear in advance, the predictive performance 
of ANNs and linear regression analysis should be compared.  
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Pharmacokinetics of Amoxicillin, Flucloxacillin, and Rifampicin 
Knowledge of the pharmacokinetic characteristics of an antibiotic is required for effective and 
safe antibiotic therapy. For lack of pharmacokinetic data of amoxicillin, flucloxacillin, and ri-
fampicin in neonates, current dosage regimens are based on pharmacokinetic data obtained 
in relatively small numbers of neonates. Sometimes guidelines are extrapolated from data 
obtained in older children or even adults. The use of surplus plasma samples from routine 
gentamicin and vancomycin therapeutic drug monitoring made it possible to establish the 
pharmacokinetic parameters of amoxicillin, flucloxacillin, and rifampicin in newborn infants as 
described in the studies of this thesis. The pharmacokinetic results in this thesis confirm ear-
lier described differences in drug disposition between neonates and adults. In this paragraph, 
the main pharmacokinetic results are discussed. 
The distribution of amoxicillin, flucloxacillin, and rifampicin within the neonatal body appeared 
to be increased as compared to adults. This is mainly due to a relatively larger total body 
water compartment. In addition, the larger volume of distribution observed for all three antibi-
otics may partly be explained by their reduced binding to plasma proteins, as demonstrated 
in this thesis for flucloxacillin and to a limited extent for amoxicillin. Plasma protein binding is 
known to impair the antimicrobial activity of antibiotics. This is particularly relevant for highly 
protein-bound antibiotics, such as flucloxacillin and rifampicin, but not for low protein-bound 
amoxicillin. Median protein binding of flucloxacillin in neonatal plasma was nearly 80% with a 
high inter-patient variability, most of which could be explained by plasma albumin level. The 
extent and variability of rifampicin binding to plasma proteins in newborn infants should be 
subject to further investigation. The elimination of amoxicillin, flucloxacillin, and rifampicin 
from the body appeared to be reduced in the neonatal period. Glomerular filtration appeared 
to be an important elimination route for amoxicillin and rifampicin, but a minor route for flu-
cloxacillin, as indicated by the correlation between antibiotic clearance and the covariates 
plasma creatinine level and gentamicin clearance. Plasma creatinine and gentamicin clear-
ance both showed to be useful predictors of glomerular filtration rate (GFR). However, gen-
tamicin clearance should be preferable to plasma creatinine for the prediction of amoxicillin 
clearance and/or GFR in the first two days after birth, since the correlation between amoxicil-
lin clearance and plasma creatinine proved to be much lower than the correlation between 
amoxicillin clearance and gentamicin clearance during this period. Amoxicillin clearance and 
flucloxacillin clearance were both higher than gentamicin clearance, which suggests the 
presence of other elimination pathways in addition to glomerular filtration, such as tubular 
secretion. Metabolism may also play a role in flucloxacillin clearance and to a lesser extent in 
amoxicillin clearance as expected from data in adults. Amoxicillin and rifampicin clearance 
both correlated highly with gestational age (GA), which probably reflects the development of 
renal function, especially glomerular filtration. At birth, GFR is low, but the postnatal increase 
in glomerular perfusion pressure results in a progressive increase in GFR after birth. Amox-
icillin clearance appeared to be two times higher in newborn infants aged > 9 days com-
pared to younger infants, mainly because of the postnatal increase in GFR, as indicated by 
the two times lower plasma creatinine level in the older population. In addition to glomerular 
filtration, metabolism of rifampicin into its main active metabolite 25-O-desacetylrifampicin 
seemed to be responsible for rifampicin clearance in newborn infants. Rifampicin clearance 
has been shown to be increased after two weeks of therapy, probably because of induction 
of its own metabolism. 
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Amoxicillin, Flucloxacillin, and Rifampicin Dosing 
Dosing of antibiotics should be based on a balance between maximal efficacy and minimal 
toxicity. Unfortunately, there is a lack of data on efficacy and toxicity of amoxicillin, flucloxacil-
lin, and rifampicin in neonates. Until valuable data on efficacy are available, dosing of penicil-
lins, including amoxicillin and flucloxacillin, should be based on the pharmacokinetic charac-
teristics of the antibiotic in combination with the surrogate marker T>MIC, the time the free, 
non-protein-bound concentration remains above the minimum inhibitory concentration of the 
micro-organism, which should be at least 40% in neonates. Based on our acquired pharma-
cokinetic knowledge and the T>MIC, we conclude that currently used dosage regimens of 
flucloxacillin in neonates may result in ineffective therapy for Staphylococcus aureus. Despite 
the high variability in pharmacokinetics between neonates, predefined target concentrations 
seemed to be reached by increasing the dosing frequency and at the same time lowering the 
dose to ensure efficacy and safety of the flucloxacillin therapy. However, inter-patient vari-
ability in plasma protein binding turned out to be higher than initially thought, which makes 
effective and safe flucloxacillin therapy in neonates difficult. Measurement of free flucloxacil-
lin levels is probably not a realistic option because of practical obstacles. Measuring plasma 
albumin levels might provide a solution, because of the high correlation between plasma al-
bumin level and flucloxacillin protein binding. However, the predictive performance of plasma 
albumin for flucloxacillin protein binding still has to be investigated in a larger number of 
newborn infants. Also, the use of alternative antibiotics might be considered. 
In contrast to flucloxacillin, currently used amoxicillin dosage regimens may result in neuro-
toxicity. However, it should be noted that, for lack of data on amoxicillin toxicity in neonates, 
the toxic limit has been selected based on few case reports in adults. As mentioned earlier, 
amoxicillin dosage regimens for newborn infants with (suspected) early-onset sepsis should 
differ from older infants. Initially, two dosage GA subgroups were recommended for amoxicil-
lin dosing in neonates with (suspected) early-onset sepsis because of the high correlation 
between amoxicillin clearance and GA mentioned earlier. However, different dosage regi-
mens could give rise to medication errors. Therefore, as an alternative regimen, we suggest 
an amoxicillin dose of 20 mg/kg every 8 hours for the effective and safe treatment of early-
onset neonatal infections easily reached by the antibiotic. Because of the postnatal increase 
in amoxicillin clearance, the amoxicillin dose should be increased to 40 mg/kg every 8 hours 
for the treatment of infectious diseases in older infants aged > 9 days. Increasing the dosing 
frequency in stead of increasing the dose could be an alternative, but might be less practical 
in clinical practice. Prospective validation of both dosage regimens still needs to be per-
formed. 
The acquired knowledge of the pharmacokinetic characteristics of rifampicin did not result in 
a definite dosage regimen. For effective and safe rifampicin dosing in newborn infants, fur-
ther studies should focus on rifampicin pharmacodynamics and plasma protein binding. As 
expected from data in adults, plasma protein binding of rifampicin in neonates is probably 
high enough to have significant impact on bacterial killing. The currently used dosage regi-
men of rifampicin seemed to be effective in the treatment of persistent staphylococcal bac-
teremia, but our data suggest the necessity of dosage adjustment in case of prolonged ther-
apy.  
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Future Perspectives 
As already mentioned in the general discussion, the following items should be object of fur-
ther study in newborn infants: 
• Prospective validation of amoxicillin dosage regimens; 
• Predictive performance of plasma albumin level for flucloxacillin protein binding; 
• Pharmacokinetics of rifampicin in a larger population; 
• Extent and variability of rifampicin binding to plasma proteins; 
• Pharmacodynamics of amoxicillin, flucloxacillin, and rifampicin using bacterial time-
killing curves in the absence and presence of albumin. 
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Introduction 
This thesis focuses on the pharmacokinetics and dosing of amoxicillin, flucloxacillin, and ri-
fampicin in newborn infants. These antibiotics are used in the treatment of neonatal sepsis. 
Neonatal sepsis is a blood bacterial infection in neonates. Antibiotic therapy has to be started 
immediately in case of suspected neonatal sepsis, since neonatal sepsis is one of the most 
important causes of neonatal mortality. For safe and effective antibiotic therapy, knowledge 
of the pharmacokinetic characteristics of the antibiotic is required. Pharmacokinetics de-
scribes how drugs are absorbed, distributed, metabolized, and excreted by the body. Phar-
macokinetics of drugs in neonates differ from those in adults, since physiologic processes 
that influence absorption, distribution, metabolism, and excretion of drugs are immature in 
the newborn infant. Therefore, a simple reduction of the adult dose may not be adequate to 
determine a safe and effective neonatal dose. The studies described in this thesis have been 
accomplished to establish the population pharmacokinetic parameters of amoxicillin, fluclox-
acillin, and rifampicin in neonates, in order to improve the safety and efficacy of these antibi-
otics in the neonatal period.  
 
Chapter 2 
This chapter describes the development and validation of the reversed-phase high-
performance liquid chromatographic assays for the determination of amoxicillin, flucloxacillin, 
and rifampicin concentrations in neonatal plasma. These assays have been based on meth-
ods for adults and were made suitable for neonates by using smaller plasma volumes and 
smaller amounts of reagents. Because only small plasma volumes (20-40 μL) are required 
for analysis, the assays are highly suitable for therapeutic drug monitoring and pharmacoki-
netic studies in (preterm) neonates. They have successfully been applied to the studies de-
scribed in Chapters 3, 4, 5, 6, and 7.   
 
Chapter 3 and 4 
In Chapter 3 and 4, the population pharmacokinetic parameters of amoxicillin, established in 
150 neonates with (suspected) early-onset sepsis (postnatal age ≤ 9 days) and in 32 older 
infants (postnatal age > 9 days), are presented. Amoxicillin is an aminopenicillin and is fre-
quently used in combination with gentamicin in the treatment of early-onset neonatal sepsis 
and infectious diseases in older infants, for example necrotizing enterocolitis. Amoxicillin 
concentrations were determined in surplus plasma samples from routine gentamicin assays. 
These plasma concentrations were used to establish the population pharmacokinetic pa-
rameters. Mean total body clearance was 0.096 Lkg-1h-1, mean elimination half-life was 5.2 
hours, and mean volume of distribution was 0.65 L/kg in neonates aged ≤ 9 days. However, 
in newborn infants aged > 9 days mean total body clearance was higher (0.18 Lkg-1h-1) and 
mean elimination half-life was shorter (3.0 hours). Mean volume of distribution was approxi-
mately the same (0.66 L/kg). In both studies, high correlations were found between amoxicil-
lin clearance and gestational age, plasma creatinine concentration, and gentamicin clear-
ance. Moreover, in newborn infants aged > 9 days a very high correlation was found between 
amoxicillin clearance and postconceptional age (gestational age + postnatal age).  
New dosage regimens were based on the pharmacokinetic characteristics of amoxicillin in 
combination with the surrogate marker T>MIC, the time the non-protein-bound (free) concen-
tration remains above the minimum inhibitory concentration of the micro-organism. The 
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T>MIC of amoxicillin should be at least 40% in neonates. The toxic limit selected was 140 
mg/L, based on few case reports in adults. For neonates with (suspected) early-onset sepsis, 
we recommend a lower dose than currently used (20 mg/kg per 8 hours), since currently 
used dosage regimens might result in toxic plasma concentrations. Because of the higher 
amoxicillin clearance, we recommend a higher dose for older infants (40 mg/kg per 8 hours). 
  
Chapter 5 and 6 
Chapter 5 presents the population pharmacokinetic parameters of flucloxacillin, an isoxazolyl 
penicillin frequently used in combination with gentamicin in the treatment of late-onset neo-
natal sepsis. Flucloxacillin concentrations were determined in surplus plasma samples from 
routine gentamicin assays. Mean total body clearance was 0.18 Lkg-1h-1, mean elimination 
half-life was 2.6 hours, and mean volume of distribution was 0.54 L/kg in 55 neonates with 
(suspected) late-onset sepsis.  
Dosing of flucloxacillin should be based on the pharmacokinetic characteristics of flucloxacil-
lin in combination with the T>MIC of the non-protein-bound (free) flucloxacillin concentration. 
Therefore, knowledge of the plasma protein binding of flucloxacillin is essential. Since flu-
cloxacillin protein binding has been investigated in only small populations of neonates, we 
studied the protein binding in a large population of 56 neonates. Therefore, surplus plasma 
samples from routine gentamicin assays of each neonate were collected and combined to 
obtain a sufficiently large sample for analysis. Ultrafiltration was used to separate free flu-
cloxacillin from protein-bound flucloxacillin. Mean flucloxacillin protein binding was 74.5% 
with a high variability among the neonates (34.3%-89.7%). For effective treatment with flu-
cloxacillin, this variability should be taken into account. Due to this variability, a dosing 
schedule suitable for the whole population could not be formulated. Individualized dosing, 
based on free flucloxacillin concentrations, might help to optimize treatment of late-onset 
neonatal sepsis with flucloxacillin, but is probably not a realistic option because of practical 
obstacles. The high correlation between flucloxacillin protein binding and plasma albumin 
concentration suggests that plasma albumin measurement might be helpful to predict flu-
cloxacillin protein binding in neonates. 
 
Chapter 7 
In Chapter 7, plasma concentrations and pharmacokinetic parameters of rifampicin after in-
travenous administration in 21 neonates are presented. Rifampicin is frequently used in 
combination with vancomycin in the treatment of persistent staphylococcal infections in neo-
nates. Concentrations of rifampicin and its main active metabolite 25-O-desacetylrifampicin 
were determined in surplus plasma samples from routine vancomycin assays. Mean total 
body clearance was 0.28 Lkg-1h-1, mean elimination half-life was 4.9 hours, and mean vol-
ume of distribution was 1.84 L/kg. Rifampicin clearance was highly correlated with plasma 
creatinine concentration and gentamicin clearance during a preceding gentamicin treatment. 
Therefore, rifampicin seems to be eliminated by both renal and metabolic pathways in neo-
nates. Plasma concentrations of rifampicin and 25-O-desacetylrifampicin were also deter-
mined after two weeks of rifampicin therapy in 8 neonates. In all neonates, rifampicin clear-
ance was increased, probably because of induction of its own metabolism. Because of the 
relatively small population studied and lack of information about protein binding and pharma-
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codynamics of rifampicin, maintenance of conventional dosage policy is advised at this mo-
ment. 
 
Chapter 8 
Chapter 8 describes a preliminary study of the applicability of artificial neural networks (ANN) 
for the prediction of gentamicin clearance in neonates. Artificial neural networks can be used 
to model complex non-linear relationships between input and output data. In this study, a 
neural network was used to model the relationship between gentamicin clearance and sev-
eral covariates, including gestational age, postnatal age, and plasma creatinine concentra-
tion, and to predict gentamicin clearance in 320 neonates. The predictive performance of the 
neural network was compared with that of multiple linear regression analysis. Linear regres-
sion predictions were significantly less biased and more precise than ANN predictions. 
Therefore, artificial neural networks seem to be less useful for simple linear relationships 
between input and output data.  
 
Chapter 9 
In this chapter, the pharmacokinetic results and the consequences for dosing are reviewed. 
Important challenges for future studies include prospective validation of the amoxicillin dos-
age regimens, evaluation of the predictive performance of plasma albumin for flucloxacillin 
protein binding, establishment of the pharmacokinetic parameters of rifampicin in a larger 
population of neonates, investigation of the extent and variability of rifampicin protein binding 
in neonates, and in particular study of the pharmacokinetic-pharmacodynamic relationships. 
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Inleiding 
Dit proefschrift richt zich op de farmacokinetiek en dosering van amoxicilline, flucloxacilline 
en rifampicine bij pasgeboren. Deze antibiotica worden gebruikt bij de behandeling van neo-
natale sepsis. Neonatale sepsis is bloedvergiftiging (een infectie in de bloedbaan) bij neona-
ten. Aangezien neonatale sepsis één van de belangrijkste doodsoorzaken is bij neonaten, 
moet antibioticatherapie onmiddellijk gestart worden bij verdenking op neonatale sepsis. 
Voor een veilige en effectieve antibioticatherapie moet men kennis hebben van de farmaco-
kinetische karakteristieken van het antibioticum. De farmacokinetiek beschrijft de wijze waar-
op geneesmiddelen door het lichaam worden geabsorbeerd, verdeeld, gemetaboliseerd en 
uitgescheiden. De farmacokinetiek van geneesmiddelen bij neonaten verschilt van die bij 
volwassenen vanwege de onrijpheid van de fysiologische processen die de absorptie, de 
distributie, het metabolisme en de uitscheiding van geneesmiddelen beïnvloeden. Een een-
voudige verlaging van de dosis voor volwassenen is daarom niet voldoende om te komen tot 
een veilige en effectieve dosis voor neonaten. De onderzoeken in dit proefschrift zijn uitge-
voerd om de populatie farmacokinetische parameters van amoxicilline, flucloxacilline en ri-
fampicine bij neonaten vast te stellen en zo de veiligheid en effectiviteit van deze antibiotica 
in de neonatale periode te vergroten.  
 
Hoofdstuk 2 
Dit hoofdstuk beschrijft de ontwikkeling en validatie van de zogenaamde reversed-phase 
hoge druk vloeistofchromatografische bepalingen, waarmee de concentraties van amoxicilli-
ne, flucloxacilline en rifampicine in het bloedplasma (bloedvloeistof zonder de bloedcellen) 
van pasgeborenen kunnen worden gemeten. Deze bepalingen zijn gebaseerd op methoden 
voor volwassenen en zijn geschikt gemaakt voor neonaten door gebruik te maken van klei-
nere hoeveelheden plasma en reageermiddelen. De bepalingen zijn zeer geschikt voor the-
rapeutic drug monitoring (bloedspiegelbepalingen) en farmacokinetische onderzoeken bij 
(premature) pasgeborenen, aangezien slechts kleine hoeveelheden plasma (20-40 μl) nodig 
zijn. Ze zijn met succes toegepast in de onderzoeken beschreven in Hoofdstuk 3 tot en met 
7.  
 
Hoofdstuk 3 en 4 
In Hoofdstuk 3 en 4 worden de populatie farmacokinetische parameters van amoxicilline, die 
zijn vastgesteld bij 150 neonaten met (verdenking op) early-onset sepsis (postnatale leeftijd 
≤ 9 dagen) en bij 32 oudere pasgeborenen (postnatale leeftijd > 9 dagen), gepresenteerd. 
Amoxicilline is een aminopenicilline en wordt regelmatig gebruikt in combinatie met gentami-
cine bij de behandeling van early-onset neonatale sepsis en infecties bij oudere pasgebore-
nen, bijvoorbeeld necrotiserende enterocolitis. De concentraties van amoxicilline werden 
bepaald in plasma dat resteerde na routine bepalingen van gentamicine. Met behulp van 
deze plasmaconcentraties werden de populatie farmacokinetische parameters vastgesteld. 
Bij neonaten ≤ 9 dagen bedroeg de gemiddelde totale lichaamsklaring 0,096 lkg-1h-1, de ge-
middelde halfwaardetijd 5,2 uur en het gemiddeld verdelingsvolume 0,65 l/kg. Echter, bij 
pasgeborenen > 9 dagen was de gemiddelde totale lichaamsklaring hoger (0,18 lkg-1h-1) en 
de gemiddelde halfwaardetijd korter (3,0 uur). Het gemiddelde verdelingsvolume was onge-
veer hetzelfde (0,66 l/kg). In beide studies werd een sterke correlatie gevonden tussen de 
amoxicilline klaring en de zwangerschapsleeftijd, de plasmaconcentratie van creatinine en de 
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gentamicine klaring. Daarnaast werd er bij pasgeborenen > 9 dagen een heel sterke correla-
tie gevonden tussen de amoxicilline klaring en de postconceptionele leeftijd (zwangerschaps-
leeftijd + postnatale leeftijd).  
Nieuwe doseerschema’s werden gebaseerd op de farmacokinetische karakteristieken van 
amoxicillin in combinatie met de surrogaat marker T>MRC, de tijd dat de niet aan eiwit ge-
bonden (vrije) concentratie de minimaal remmende concentratie van het micro-organisme 
overschrijdt. De T>MRC van amoxicilline moet bij neonaten ten minste 40% zijn. Als toxische 
grens werd 140 mg/l gekozen, gebaseerd op enkele case reports bij volwassenen. Voor ne-
onaten met (verdenking op) early-onset sepsis adviseren wij een lagere dosis dan momen-
teel wordt gebruikt (20 mg/kg per 8 uur), aangezien de huidige doseerschema’s zouden kun-
nen leiden tot toxische plasmaconcentraties. Voor oudere pasgeborenen adviseren wij een 
hogere dosis (40 mg/kg per 8 uur) in verband met de hogere amoxicilline klaring.  
 
Hoofdstuk 5 en 6 
Hoofdstuk 5 presenteert de populatie farmacokinetische parameters van flucloxacilline, een 
isoxazolyl penicilline, dat regelmatig gebruikt wordt in combinatie met gentamicine bij de be-
handeling van late-onset neonatale sepsis. De concentraties van flucloxacilline werden be-
paald in plasma dat resteerde na routine bepalingen van gentamicine. De gemiddelde totale 
lichaamsklaring bedroeg 0,18 lkg-1h-1, de gemiddelde halfwaardetijd 2,6 uur en het gemiddel-
de verdelingsvolume 0,54 l/kg bij 55 neonaten met (verdenking op) late-onset sepsis.  
De dosering van flucloxacilline moet gebaseerd worden op de farmacokinetische karakteris-
tieken van flucloxacilline in combinatie met de T>MRC van de niet aan eiwit gebonden (vrije) 
flucloxacilline concentratie. Het is daarom van essentieel belang dat men op de hoogte is 
van de eiwitbinding van flucloxacilline in het plasma. Aangezien de eiwitbinding van flucloxa-
cilline alleen in kleine groepen neonaten is onderzocht, bestudeerden wij de eiwitbinding in 
een grote populatie van 56 neonaten. Daartoe werd van elke neonaat al het plasma dat res-
teerde na routine bepalingen van gentamicine verzameld en samengevoegd om zo voldoen-
de plasma te verkrijgen voor de analyse. Met behulp van ultrafiltratie werd de vrije flucloxacil-
line concentratie gescheiden van de aan eiwit gebonden flucloxacilline concentratie. De ge-
middelde eiwitbinding van flucloxacilline was 74,5% met een grote variabiliteit tussen de ne-
onaten (34,3%-89,7%). Voor een effectieve behandeling met flucloxacilline moet men reke-
ning houden met deze variabiliteit. Vanwege deze variabiliteit was het niet mogelijk een ge-
schikt doseerschema te vinden voor de gehele populatie. Individuele dosering, gebaseerd op 
de vrije flucloxacilline concentraties, zou kunnen bijdragen aan het optimaliseren van de be-
handeling van late-onset neonatale sepsis met flucloxacilline, maar is waarschijnlijk geen 
realistische optie aangezien er praktische belemmeringen zijn. De sterke correlatie tussen de 
eiwitbinding van flucloxacilline en de plasmaconcentratie van albumine wijst erop dat het 
meten van het plasma albumine nuttig zou kunnen zijn bij het voorspellen van de eiwitbin-
ding van flucloxacilline bij neonaten. 
 
Hoofdstuk 7 
In Hoofdstuk 7 worden de plasmaconcentraties en de farmacokinetische parameters van 
rifampicine na intraveneuze toediening bij 21 neonaten gepresenteerd. Rifampicine wordt bij 
neonaten regelmatig gebruikt in combinatie met vancomycine bij de behandeling van aan-
houdende stafylokokken infecties. De concentraties van rifampicine en de belangrijkste ac-
S
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tieve metaboliet 25-O-desacetylrifampicine werden bepaald in plasma dat resteerde na routi-
ne bepalingen van vancomycine. De gemiddelde totale lichaamsklaring bedroeg 0,28 lkg-1h-1, 
de gemiddelde halfwaardetijd 4,9 uur en het gemiddelde verdelingsvolume 1,84 l/kg. De ri-
fampicine klaring was sterk gecorreleerd met de plasmaconcentratie van creatinine en met 
de gentamicine klaring tijdens een voorafgaande gentamicine behandeling. Rifampicine 
schijnt bij neonaten dus zowel renaal als metabool te worden geëlimineerd. De plasmacon-
centraties van rifampicine en 25-O-desacetylrifampicine werden bij 8 neonaten ook bepaald 
na twee weken therapie met rifampicin. Bij al deze neonaten was de rifampicine klaring toe-
genomen, waarschijnlijk doordat rifampicine het eigen metabolisme induceert. Op dit mo-
ment adviseren wij het huidige doseerbeleid te handhaven, aangezien wij slechts een relatief 
kleine populatie hebben onderzocht en omdat er tot nu toe weinig bekend is over de eiwit-
binding en de farmacodynamiek van rifampicine.  
 
Hoofdstuk 8 
Hoofdstuk 8 beschrijft een inleidend onderzoek naar de toepasbaarheid van kunstmatige 
neurale netwerken bij de voorspelling van de gentamicine klaring bij neonaten. Kunstmatige 
neurale netwerken kunnen worden gebruikt om complexe, niet-lineaire verbanden tussen 
input en output gegevens te modelleren. In dit onderzoek werd gebruik gemaakt van een 
neuraal netwerk om het verband tussen de gentamicine klaring en enkele co-variabelen, 
waaronder de zwangerschapsleeftijd, de postnatale leeftijd en de plasmaconcentratie van 
creatinine, te modelleren en de gentamicine klaring bij 320 neonaten te voorspellen. De 
voorspelbaarheid van het neurale netwerk werd vergeleken met die van meervoudige lineai-
re regressie analyse. De voorspellingen van lineaire regressie hadden een kleinere systema-
tische fout en een grotere precisie dan de voorspellingen van het neurale netwerk. Kunstma-
tige neurale netwerken schijnen dus minder bruikbaar te zijn voor eenvoudige lineaire ver-
banden tussen input en output gegevens. 
 
Hoofdstuk 9 
In dit hoofdstuk worden de farmacokinetische resultaten en de gevolgen voor de dosering 
bediscussieerd. Belangrijke uitdagingen voor toekomstig onderzoek zijn: prospectieve valida-
tie van de doseerschema’s van amoxicilline, evaluatie van de voorspelbaarheid van plasma 
albumine voor de eiwitbinding van flucloxacilline, vaststelling van de farmacokinetische pa-
rameters van rifampicine bij een grotere populatie van neonaten, onderzoek naar de grootte 
en variabiliteit van de eiwitbinding van rifampicine bij neonaten en in het bijzonder bestude-
ring van de farmacokinetische-farmacodynamische relaties.  
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klaar stond met advies rondom het promoveren en het drukken van mijn proefschrift. Beste 
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aan kan. Ik hou van je.  
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